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Air pollution 
Ambient environmental air pollutants include gaseous (carbon monoxide, nitrogen 
oxides, sulfur dioxide, ozone) and particulate components. The particulate 
component, particulate matter (PM), consists of a heterogeneous mixture of solid and 
liquid particles suspended in air, and is subdivided based on size ranges into 'thoracic 
particles' (PM10, with a mean aerodynamic diameter <10 µm), 'coarse particles' (>2.5 
µm and <10 µm), 'fine particles' (PM2.5, <2.5 µm), and ultrafine particles (UFP, <0.1 
µm) (Fig. 1). Although exposure to some gaseous components has been linked to 
cardiovascular events, the larger body of evidence points towards the deleterious 
effects of the particulates in polluted air. 
Primary particles are emitted directly into the atmosphere, such as diesel soot, 
whereas secondary particles are created through physicochemical transformation of 
gases, such as nitrate and sulfate formation from gaseous nitric acid and sulfur 
dioxide (SO2), respectively. 
 
Figure 1. Size distribution of PM air pollution (from (1), with permission) 
 
The numerous natural and anthropogenic sources of PM include motor vehicle 
emissions, tire fragmentation and resuspension of road dust, electric power generation 
and other industrial combustion, agriculture, construction and demolition activities, 
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residential wood burning, windblown soil, pollen and molds, forest fires, volcanic 
emissions and sea spray. 
In general, PM2.5 originates mostly from combustion sources, whereas the coarse 
fraction derives predominantly from natural sources, especially crustal material 
(including windblown soil) and grinding processes. Important bioaerosols (eg. 
endotoxin, pollen grains and fungal spores) are found mostly in the coarse fraction 
(and larger particles). 
 
Generally, larger particles demonstrate a greater fractional deposition in the 
extrathoracic and upper tracheobronchial regions, whereas smaller particles (eg. 
PM2.5) show greater deposition in the deep lung. More recently, considerable research 
attention has been devoted to the UFP, which, by virtue of their small size (<0.1 µm) 
penetrate deeply into the lungs and deposit in the alveoli. UFPs tend to be short-lived, 
because they agglomerate and coalesce into larger particles. They account for a major 
portion of the actual numbers of particles within PM, and have a high surface area-to-
mass ratio, potentially leading to enhanced biological toxicity, in spite of their limited 
mass (1). 
 
 
Air pollution and cardiovascular disease 
Introduction 
The human cardiovascular system consists of a functional vascular network for blood 
distribution, subdivided in a systemic and pulmonary circulatory system. The 
systemic circulation transports oxygenated blood through the arteries from the left 
heart to the organs and returns oxygen-depleted blood through the veins to the lungs. 
The pulmonary circulation subsequently transports the oxygen-depleted blood from 
the heart to the lungs, where it is oxygenated and returned to the heart. 
Vascular integrity throughout the vascular tree is maintained by the vessel wall itself, 
as well as by a complex hemostatic mechanism with different protagonists for the 
arterial and the venous vasculature, involving blood platelets and coagulation factors. 
 
The critical need to rapidly form a stable, localized clot in response to vascular injury 
(='hemostasis') must be balanced with the need to maintain blood flow within the 
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vessels. Different antihemostatic mechanisms prevent clot formation under resting 
physiological conditions, and limit clot growth to the site of vascular injury. When 
prohemostatic tendencies proceed beyond the physiological need to maintain vascular 
integrity, a pathological thrombus may form, obstructing the normal blood flow 
(='thrombosis'). In the arterial system, thrombus formation induces oxygen-
deprivation (ischemia) of the downstream tissues, such as myocardial infarction and 
cerebral ischemia. The formation of an arterial thrombus largely depends on the 
activation of blood platelets, and is most often triggered by the rupture of an 
atherosclerotic plaque. Indeed, the chronic localized deposition of lipids into the 
arterial vessel wall (atherosclerosis) leads to the formation of plaques that can rupture 
when unstable, hereby exposing their procoagulant contents to the circulation (2). 
Hence, while often being asymptomatic in itself over many years, atherosclerosis 
formation may cumulate into an acute burst of symptomatic arterial thrombus 
formation.  
In the venous system, thrombus formation results from a decrease in blood flow, in 
conjunction with a hypercoagulable state and endothelial dysfunction (Virchow's 
triad), and most often affects the deep veins of the legs (deep vein thrombosis, DVT). 
The most serious complication of DVT is the embolisation of clot dislodgements to 
the lungs (pulmonary embolism, PE). 
 
Numerous epidemiological studies report consistent associations between exposure to 
urban air pollution and cardio-respiratory morbidity and mortality. One of the 
important discoveries of these epidemiological studies during the last decade was that 
the increased mortality associated with enhanced air pollution exposure was not due 
only to pulmonary diseases, but mainly to cardiovascular diseases. (3-13).  
The focus in the initial epidemiological research was directed towards the association 
between both short-term and long-term exposure to air pollution and arterial 
cardiovascular effects, such as myocardial infarction. These landmark studies, in the 
beginning of the 90's, were quickly followed by experimental studies in humans and 
in rodents, to unravel the underlying pathophysiological mechanisms. The number of 
publications in this field increased exponentially, so that in the middle of 2011, a 
search through PubMed using the MeSH terms 'air pollution' and 'cardiovascular 
disease' retrieved almost 1400 hits. 
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Active cigarette smoking has been established as a major independent cause of 
cardiovascular disease (14). The inhaled dose of fine particles from ambient air 
pollution, as from secondhand cigarette smoke, is extremely small compared with that 
from active cigarette smoking. Accordingly, the estimated relative risks from active 
smoking, even at relatively light smoking levels, are substantially larger than the risks 
from ambient air pollution or secondhand smoke. However, the risks induced by these 
latter 2 types of exposure are higher than would be expected from a simple linear 
extrapolation based on the amount of inhaled PM from active smoking (15), and have 
important public health implications (16). 
 
Arterial and venous thrombosis share common risk factors (17). The role of air 
pollution exposure as a risk factor for arterial events now being beyond discussion, a 
few years ago, epidemiologists started investigating a possible association with 
venous thrombotic events. Thus, in 2008, Baccarelli et al. demonstrated a link 
between chronic exposure to elevated levels of air pollution and deep vein thrombosis 
(DVT) for the first time (18).  
 
The following paragraphs will describe how air pollutants affect arterial and venous 
functionality and lead to pathophysiological manifestations. 
 
Particle triggered pathophysiological mechanisms 
Inhaled particles deposit in various segments of the human respiratory tract. While the 
larger PM10 particles impact to a large extent in the nasopharyngeal and tracheal 
region, the smaller PM2.5 particles penetrate deeper into the bronchi and bronchioli, 
whereas the UFP reach the alveolar regions. Inhaled particles are believed to affect 
the cardiovascular system through 3 different pathways: interference with the 
autonomic nervous system, direct translocation of UFP into the systemic circulation 
and pulmonary inflammation. 
 
PM inhalation deranges the autonomic nervous control of the heart (1). Numerous 
studies (e.g. (19, 20)) have shown that, by reducing the heart rate variability, PM may 
increase the risk for cardiac arrhytmias and sudden death. In addition, elevations in air 
pollution have been associated with ST-segment depression (21, 22), an impaired 
cardiac deceleration capacity (23), hypertension (24) and increased diastolic blood 
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pressure (25). The exact underlying mechanisms remain to be elucidated, but 
stimulation of irritant receptors in the airways and subsequent reflex activation of the 
nervous system as well as direct effects of pollutants on cardiac ion channels have 
been suggested (1, 26). 
 
A second mechanism of action comprises the translocation of inhaled particles into 
the systemic circulation. Direct effects may occur via UFP that readily cross the 
pulmonary epithelial barrier, along with soluble constituents released from the larger 
particles (e.g. transition metals). Systemic translocation of particles was demonstrated 
in experimental animal models (27) (28). Although evidence of systemic translocation 
from human studies is less clear, with both positive (29, 30) and negative (31) 
findings, it is likely that this pathway also exists in humans, given the deep 
penetration of UFP into the alveoli and the close apposition of the alveolar wall and 
the capillary network. Radioactivity in the systemic circulation was already detected 1 
minute after the inhalation of radioactively labelled carbon particles in humans, with 
peak radioactivity levels between 10 and 20 minutes (29). When measured in rats 
under resting conditions, only a small fraction (1.6-2.5%) of intratracheally instilled 
UFP translocated into the circulation. However, this fraction increased to 4.7% 
following pretreatment of the lungs with lipopolysaccharides, suggesting a role for 
pulmonary inflammation in enhancing the extrapulmonary translocation of particles 
(32). Different translocation mechanisms, ranging from endocytosis by alveolar type I 
and endothelial cells, over phagocytosis by macrophages to passage through widened 
tight junctions are recognized and depend on the particle surface chemistry (33). Once 
UFP have translocated to the blood circulation, they can be distributed throughout the 
body, and interact with the vascular endothelium or circulating cells, such as blood 
platelets and leukocytes. 
 
Inhaled PM executes its deleterious effects also via a third, more chronic mechanism, 
namely pulmonary inflammation and oxidative stress. Exposure to PM induces a 
proinflammatory response in human lungs (34), consistent with observations in in 
vivo animal models (35, 36) and in vitro cellular models (37, 38). The presence of 
soluble transition metals in PM enhances the inflammatory responses via increased 
oxidative stress (39). The PM-induced pulmonary inflammation is followed by the 
release of inflammatory cytokines, such as interleukin (IL)-1β, IL-6 and granulocyte 
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macrophage colony-stimulating factor (40) in the circulation, resulting in the release 
of bone-marrow derived neutrophils and monocytes (41).  
The generation of a systemic inflammatory response, mostly demonstrated by 
increases in C-reactive protein (CRP) (42, 43), is of major importance in the 
pathogenesis of cardiovascular events. Upon PM exposure, IL-6 translocates from the 
lung into the systemic circulation (44) and is directly involved in the regulation of the 
synthesis of CRP in the liver. Elevated concentrations of IL-6 are associated with an 
increased risk of cardiovascular events (45, 46) and mortality (47). Knock-out mice 
that lacked IL-6 were protected against the prothrombotic effects of PM exposure 
(48). Increasing evidence points to an extensive cross-talk between inflammation and 
hemostasis, whereby inflammation leads to activation of blood platelets and of 
coagulation, and activated blood platelets and coagulation factors also considerably 
contribute to the inflammatory action (49). 
 
In the following paragraphs, the deleterious effects of PM exposure on endothelial 
function and arterial and venous parameters will be discussed. By virtue of their 
respective protagonist roles, blood platelet activation will mainly be discussed in the 
paragraph on arterial events, while coagulation activation will mainly be discussed in 
the paragraph on venous events. Formally, arterial thrombosis, the basis for 
myocardial infarction, is the result of vessel wall injury and formation of a platelet-
rich thrombus. Venous thrombosis, the basis for VTE (venous thromboembolism) 
results from coagulation activation and formation of a fibrin-rich thrombus. It should 
be noted, however, that both blood platelet and coagulation activation intervene in 
arterial and venous thrombosis, and that both systems highly interact with each other 
(50).  
 
Endothelial function and fibrinolysis 
The effects of air pollution on the endothelial function and the fibrinolytic system 
have mainly been investigated in controlled exposure studies by 2 research groups 
who joined forces. The groups of Newby and Blomberg used exposure chambers to 
expose healthy and compromised volunteers to the diluted exhaust of an iddling diesel 
engine for several hours in randomized cross-over studies. They demonstrated an 
impaired bradykinin-induced endothelial release of tissue plasminogen activator (t-
PA) upon diesel exhaust inhalation (estimated reduction of net t-PA release of 34%) 
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(22, 51), in addition to an attenuated agonist-induced increase in blood flow at 6 hours 
post-inhalation, in the absence of inflammatory changes (51). At 24 hours post-
inhalation, endothelium-dependent vasodilation (induced by acetylcholine and 
bradykinin) remained impaired, while endothelium-independent vasodilation (using 
sodium nitroprusside and verapamil) and t-PA release were unaffected, in the 
presence of mild sytemic inflammation (52).  
These and other (53-56) studies did not demonstrate an assocation between PM 
exposure and baseline levels (not bradykinin-induced) of t-PA. 
While studies, based on controlled exposure to diluted diesel exhaust (22, 52, 57) or 
concentrated ambient particles (55), did not observe increases in the levels of 
plasminogen activator inhibitor-1 (PAI-1), some epidemiological or animal studies, 
focussing on urban PM, did: a study in 76 young healthy students demonstrated 
elevated PAI-1 concentrations in association with the mean PM2.5 or PM10 
concentration at their university's campus over 1 to 3 days (54). Likewise, urban PM 
upregulated PAI-1 levels, 24 hours after intratracheal instillation in mice (58).  
PM exposure could also impair the endothelial repair mechanisms by reducing the 
number of endothelial progenitor cells, as demonstrated by a recent report (59). 
Taken together, these studies indicate a potential deleterious effect of PM inhalation 
on the endothelial and fibrinolytic function that may aggravate the prothrombotic 
phenotype induced by blood platelet and coagulation activation. 
 
Air pollution and arterial events 
Over the last 2 decades, a vast number of epidemiological studies (reviewed in (60)) 
have provided convincing evidence to conclude that chronic exposure to PM enhances 
atherosclerosis and that acute exposure increases the thrombotic risk associated with 
atherosclerotic plaque rupture, triggering arterial thrombosis, myocardial infarction 
and cardiovascular mortality. Relative risk levels for cardiovascular disease may vary 
between different studies, due to differences in study design. Short-term effects have 
been most often studied in time-series and case-crossover studies, while long-term 
effects have been studied in case-control and cohort studies. Relative risk levels are 
generally lower in time series studies than in other epidemiological designs. 
Nevertheless, the associations between cardiovascular disease and PM exposure are 
consistent, whatever the type of method used (60). 
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An initial landmark report was that of the Harvard Six Cities study (5), in which a 
cohort of 8111 adults were followed up for 14 to 16 years. The adjusted overall 
mortality rate for the most polluted city vs. the least polluted was 1.26 (95%CI 1.08-
1.47). Cardiovascular deaths accounted for the largest single category of increased 
mortality. Each 10 µg/m3 increase in long-term levels of PM2.5 has been associated 
with a 8 to 18% increase in cardiovascular mortality (7). An association with 
mortality was also found for traffic-related air pollution and several traffic exposure 
variables, although relative risks were small (61). The effects of long-term PM 
exposure on cardiovascular mortality have been shown elegantly by the 
demonstration of a parallelism between air quality improvement and reduction in 
cardiovascular events on a population-based level (62, 63). A potential benefit in 
general mortality can be expected within 2 years after the reduction of PM exposure 
(64). 
The magnitude of these associations appeared to be more pronounced for the smaller 
PM2.5 fraction than for the larger PM10 fraction (65). Considering a large body of 
evidence, a recent updated version of the American Heart Association scientific 
statement on 'Air Pollution and Cardiovascular Disease' (66) concluded that per 10 
µg/m3 increase in long-term levels of PM2.5, all-cause mortality increased by an 
approximate 10%. The mortality risk specifically related to cardiovascular disease 
appears to be elevated to a similar, or perhaps even greater extent, ranging from 3 to 
76% over different studies. 
 
Chronic PM exposure and atherosclerosis 
What etiological agent can explain the link between chronic air pollution exposure 
and cardiovascular mortality? Künzli et al. provided the first epidemiological 
evidence for an association with atherosclerosis: living in the areas of Los Angeles 
with highest annual mean concentrations of ambient PM2.5 was associated with an 
increased intima-media thickness of the carotid artery (67).  
Distance from the residence to a major road correlated with the degree of coronary 
artery calcification, a measure for atherosclerosis (68).  
Another study in 5172 adults investigated 20-year PM exposure and found an 
association, although weaker than in the previous studies, with carotid intima media 
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thickness, but not with other measures of atherosclerosis i.e. coronary calcium and 
ankle brachial index (69).  
A recent study demonstrates that long-term PM exposure is not only related to the 
degree, but also to a faster progression rate of atherosclerosis (70). 
 
Along with this epidemiological evidence, experimental research also established a 
link between exposure to PM and the development of atherosclerosis. Repeated 
exposure to PM10 in rabbits was associated with both systemic inflammation and the 
progression of the atherosclerotic process, the extent of which correlated with the 
extent of PM10 phagocytosed by alveolar macrophages (71).  
Exposing genetically susceptible apolipoprotein E-null mice for 6 months to an 
equivalent concentration of 15.2 µg/m3 PM2.5 over a lifetime, enhanced abdominal 
aortic plaque formation as compared to mice exposed to filtered air (72). 
Interestingly, ultrafine (<0.18 µm) particle-exposed mice exhibited significantly 
larger atheroslerotic lesions than mice exposed to fine (<2.5 µm) particles or filtered 
air (73). 
 
Atherosclerosis is now considered an inflammatory disease with low density 
lipoprotein (LDL) cholesterol accumulation in the arteries as the primary risk factor 
(2). However, up to 50% of the patients who develop atherosclerosis do not have high 
cholesterol (74). Therefore, it is the relationship between the accumulated lipids and 
other harmful components of inflammation in the arterial vessel wall that is of 
concern. LDL infiltration of the arterial vessel wall is followed by oxidative 
modification to oxidized LDL (ox-LDL) in the subendothelial space and chemotaxis 
of monocytes. These monocytes differentiate into macrophages and the subsequent 
phagocytosis of ox-LDL leads to the formation of foam cells and the release of 
inflammatory mediators, inducing a vicious cycle of inflammation. Further stages 
include smooth muscle cell proliferation, formation of a fibrous cap with necrotic core 
and calcification (2). Thickening of the vessel wall and obliteration of the vascular 
lumen induces downstream ischemia of the tissues.  
 
PM exposure can induce atherosclerosis via different pathways: systemically 
translocated UFP or their chemical constituents induce activation of proatherogenic 
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molecular pathways in endothelial cells, by oxidative stress. Inflammatory mediators 
released from the lungs may promote chemotaxis of monocytes into the vessel wall. 
PM induces high-density lipoprotein (HDL) dysfunction with loss of its anti-
inflammatory properties (75). 
 
Oxidative transformation of LDL into ox-LDL is a key step in the initiation and 
progression of atherosclerosis (76), and circulating levels of ox-LDL are therefore an 
early marker, and a risk factor for the disease (77). The correlation between PM 
exposure and circulating levels of ox-LDL on an individual level was shown by 
Jacobs et al., demonstrating a dose-dependent association between this parameter and 
the carbon load of airway macrophages, a personal marker for chronic exposure to 
fossil fuel derived ultrafine particles (78). 
It has been previously shown that particles can induce oxidative stress both in vitro 
(79, 80) and in exposed animals (73, 81-83).  
In agreement with epidemiological findings (65), experimental studies suggest that 
the smaller particles are more pathogenic, as a result of their greater propensity to 
induce systemic prooxidant and proinflammatory effects (73). Indeed, ambient UFP 
trigger the induction of the antioxidant gene heme oxygenase 1 (HO-1) to a higher 
degree than ambient PM2.5 or coarse particles, both in vitro (84) and in vivo (73, 75). 
Several mechanisms contribute to the greater proatherogenic potential of UFP: 
because of their small size, particles <0.1-0.2 µm contribute very little to overall 
PM2.5 mass. However, they represent >85-90% of the total PM2.5 particle number 
(85). The high number of UFP, in conjunction with a large surface-to-mass ratio 
increases the bioavailability of the pro-oxidant chemicals (polycyclic aromatic 
hydrocarbons, transition metals etc.) present on the UFP's surface. The number of 
chemicals that are displayed on the surface of particles increases exponentially as the 
size shrinks below 100 nm (33). Deep penetration in the lung and subsequent 
translocation of UFP into the circulation make these pro-oxidant chemicals more 
bioavailable at the contact sites of the particles with cells and tissues. 
 
Acute PM exposure and arterial thrombosis 
Not only chronic, but also short-term PM exposure has been linked to cardiovascular 
mortality: Both the American NMMAPS (National Morbidity, Mortality, and Air 
Pollution Study (13)) and the European APHEA2 (Air Pollution and Health: A 
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European Approach (3, 12)) studies (approximately 50 million and 43 million persons 
included respectively) demonstrated small increases in cardiovascular mortality with 
increasing PM exposure. In an attempt to evaluate the coherence of studies across 
continents, the APHENA (A Combined European and North American Approach) 
analyzed data of these 2 aforementioned studies and Canadian studies (86). The 
combined effect on all-cause mortality ranged from 0.2% to 0.6% for a 10 µg/m3 
increase in daily levels of ambient PM10, with greater effects for the elderly (>75 
years) and the unemployed. An extensive review of studies investigating a link 
between short-term PM exposure and cardiovascular mortality is provided in (66). 
Peters et al. (87) demonstrated an increased risk of myocardial infarction in 
association with elevated concentrations of fine PM2.5, both in the previous 2-hours 
period and the day before the onset. Likewise, the onset of myocardial infarction was 
linked to participation in traffic, as soon as 1 h afterward (odds ratio 2.92, 95%CI 
2.22-3.83) (88). 
Exposure to ambient PM2.5 is associated with short-term increases in hospital 
admission rates for cerebrovascular, peripheral and cardiac ischemic disease, heart 
rhythm and heart failure, with the strongest association for heart failure (1.28 % 
95%CI 0.78-1.78% increase in risk per 10 µg/m3 increase in same-day PM2.5) (89). 
The risk of mortality from coronary heart disease related to PM exposure appears to 
be higher in women (RR 1.42, 95%CI 1.06-1.90) than in men (RR 0.90, 95%CI 0.76-
1.05 per 10 µg/m3 increase in PM2.5)(90). In a study of 65,893 postmenopausal 
women with a median follow-up of 6 years, each increase in long-term levels of PM2.5 
of 10 µg/m3, measured at the women's residence, was associated with a 24% (95%CI 
09-41%) increase in the risk of a cardiovascular event, and a 76% (95%CI 25-147%) 
increase in the risk of death of cardiovascular disease (91). 
Although the magnitude of the risk on myocardial infarction induced by short-term 
PM exposure is rather small on a personal level, it is of major importance on a 
population level, by virtue of the large number of people exposed. Taking into 
account both risk magnitude and risk prevalence by measurement of the population 
attributable fraction (PAF), Nawrot et al. showed that a short-term increase in air 
pollution exposure is an important trigger for myocardial infarction, of similar 
magnitude (PAF 5-7%) as other well accepted triggers such as physical exertion, 
alcohol and coffee (16). 
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Epidemiological studies suggest an association between short-term increases in PM 
exposure and atherosclerotic plaque rupture, causing arterial thrombosis and 
myocardial infarction. In contrast to the growing number of mechanistic studies 
investigating the role of chronic PM exposure on atherogenesis, the precise 
mechanisms explaining the role of short-term PM exposure in acute plaque rupture 
largely remain to be elucidated. However, several epidemiological and mechanistic 
studies demonstrated that, in parallel to atherosclerotic plaque rupture, direct or 
indirect activation of circulating blood platelets by PM contributes to the arterial 
thrombosis risk. Indeed, the extent to which a growing thrombus occludes the 
vascular lumen may in part depend on platelet hyperactivity. 
Under physiological circumstances, the high blood pressure generated on the arterial 
side of the circulation requires a powerful, almost instantaneous prohemostatic 
response in order to minimize blood loss from sites of vascular injury. Blood platelets 
play a critical role in this response. Upon damage of the endothelial cell layer 
covering the luminal side of blood vessels, circulating blood platelets adhere to the 
exposed subendothelial matrix through the binding of the glycoprotein (GP) Ib-IX-V 
receptor to exposed von Willebrand factor (VWF). Blood platelet adhesion is further 
enhanced by the binding of different GP receptors to other subendothelial matrix 
proteins, such as collagen and fibrin(ogen). Upon adhesion and activation of the blood 
platelets by various agonists, VWF and fibrinogen molecules cross-link different 
platelets, resulting in blood platelet aggregation and the formation of an initial platelet 
plug which covers the site of endothelial lesion. The simultaneous activation of the 
coagulation cascade leads to the formation of a network of insoluble fibrin strands 
that further stabilize the initial platelet plug.  
Air pollution exposure can induce an inappropriate activation of blood platelets 
beyond the physiological need to restore vessel damage, resulting in arterial 
thrombosis (Fig. 2). 
 
By exposing healthy volunteers to diluted diesel exhaust, Lucking et al. showed an 
association with enhanced platelet activity and thrombus formation in an ex vivo 
perfusion chamber, 2 hours and 6 hours after exposure, in conjunction with increased 
numbers of platelet-neutrophil (+52%) and platelet-monocyte (+30%) conjugates 
(92). 
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Short-term, but not long-term PM exposure was found to enhance platelet function, as 
measured ex vivo by a shortening of the closure time of the Platelet Function Analyzer 
(PFA-100, Siemens Healthcare Diagnostics), in patients with diabetes (93). In this 
study, an interquartile range (39.2 µg/m3) increase in the PM10 concentration, 
measured 2 hours before the clinical investigation at the entrance of the hospital, was 
associated with a decrease of 21.1 sec (95%CI -35.3 to -6.8) in the PFA-100 closure 
time. Platelet function was not correlated with leukocyte counts, suggesting that short-
term PM exposure may have effects on platelet function independently of systemic 
inflammation, as was also shown in experimental animal models (35).  
Ambient PM10 levels have also been associated with augmented platelet aggregation 
24 to 96 hours after exposure in healthy adults, in the absence of increased CRP or 
fibrinogen (94). In patients with coronary heart disease, mean concentrations over 24 
hours of ambient UFP, but not PM2.5 or PM10 were positively associated with the 
levels of soluble CD40 ligand, a marker for platelet activation. No assocations were 
found with longer time frames, up to 5 days (95). 
 
Figure 2: Biological pathways linking PM exposure and arterial thrombosis 
BP: blood platelet, PM: particulate matter, TF: tissue factor, UFP: ultra-fine particles 
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In experimental conditions using DEP, Nemmar et al. demonstrated a prothrombotic 
tendency and activation of circulating blood platelets (confirmed by PFA-100), as 
well as lung inflammation, which persisted up to 24 hr after intratracheal instillation 
of DEP in hamsters (35, 96).  
However, different pathophysiological mechanisms seem to be responsible for the 
observed prothrombotic risk at different time points. Pretreatment of hamsters with a 
histamine H1-receptor antagonist, an anti-inflammatory drug, abolished pulmonary 
inflammation at all time points and reduced DEP-induced thrombosis at 6 and 24 
hours post-instillation, indicating a crucial role for inflammation in thrombogenicity 
at these time points. Likewise, the administration of other anti-inflammatory drugs, 
such as dexamethasone and selective inhibitors of basophils, macrophages and 
neutrophils, also significantly reduced the PM-induced prothrombogenicity at 24 
hours (97, 98). In contrast, pretreatment with the histamine H1-receptor antagonist did 
not reduce thrombosis as soon as 1 hour after DEP exposure (35). 
Therefore, the early prothrombotic tendency appears not to result from pulmonary 
inflammation, but possibly from direct effects of systemically translocated particles 
on the blood platelets and/or the (pulmonary) vessel wall (35). The direct activating 
effect of PM on blood platelets was shown by the addition of as little as 0.5 µg/mL 
DEPs to untreated hamster blood, significantly shortenening the PAF-100 closure 
time (96), as well as by a dose-dependent (0.1-1 µg/mL) effect of PM on in vitro 
platelet aggregation in rat blood (99), although similar experiments in human blood 
were negative (94).  
In agreement with these results, 1 hour after intratracheal instillation, well-defined 
positively charged ultrafine (60 nm) polystyrene particles significantly enhanced 
platelet-rich thrombus formation, while 400 nm particles, incapable of systemic 
translocation, did not affect thrombus formation, despite similar increases in 
neutrophils, lactate dehydrogenase and histamine levels in the bronchoalveolar lavage 
fluid (100).  
Pulmonary instillation of carbon nanotubes elevated platelet-leukocyte conjugates at 6 
hours and increased the peripheral thrombotic potential at 24 hours after exposure. 
Inhibition of P-selectin abrogated these responses (101). P-selectin is found in storage 
Weibel-Palade bodies of endothelial cells and in α-granules of platelets, from where it 
can be expressed on the outer membrane upon activation. Surface expression of P-
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selectin initiates capture and rolling of circulating leukocytes over stimulated 
endothelium (102) and the formation of platelet-leukocyte conjugates (103). Increased 
levels of platelet-leukocyte conjugates have been demonstrated in Indian women who 
used biomass as cooking fuel, producing higher levels of PM, as compared to women 
cooking with a cleaner fuel (liquefied petroleum gas) (104). In a panel study of 60 
elderly subjects with coronary artery disease, Delfino et al. demonstrated associations 
between soluble P-selectin levels and the mean 1 to 5-day concentrations of ambient 
finer particles (PM0.25 and PM2.5), but not the bigger PM10 (105). Taken together, 
these studies suggest that the release of pulmonary cell-derived mediators (eg. 
histamine) and the expression of endothelial and platelet surface proteins (eg. P-
selectin) after several hours, along with the more rapid activation of circulating 
platelets by direct contact with UFP may mediate peripheral prothrombotic effects. 
 
Air pollution and venous thromboembolism 
Epidemiology 
In addition to the well-recognized PM-related adverse effects on the arterial vascular 
system, recent epidemiological evidence also suggests an association between 
exposure to PM and venous thromboembolism (VTE). Baccarelli et al. reported a 
70% increase in the risk of deep vein thrombosis (DVT) for each 10 µg/m3 increase of 
the annual mean level of PM10 in the areas of residence of the study subjects (OR 
1.70, 95%CI 1.30-2.23) (18). The observed exposure-response relationship was 
approximately linear over the observed PM10 range, so that PM10 at the higher 
concentrations within the international limits can still increase the risk of DVT, as 
compared to the lowest concentration measured. These authors found, in the same 
study subjects, that living near major traffic roads was also associated with an 
increased risk of DVT, even after controlling for the community-level PM pollution 
(106). Very recently, exposure to PM has also been associated with hospital 
admission for VTE in Chile. Both for DVT and for PE, pooled estimates of relative 
risk of hospitalization were 1.05 (95%CI 1.03-1.06) for a 20.02 µg/m3 increase in 
PM2.5 (107). 
Table 1: Associations between PM exposure and coagulatory changes according to different studies 
 
reference       exposure   coagulatory changes 
author year   type   controlled exposure type of air pollution 
exposure 
time   
significant 
changes no significant changes 
Seaton (108) 1999   NA   no ambient PM10 3 days   FVII (-), fbg (-)   
Ghio (34) 2000   healthy subjects   yes concentrated  PM2.5 2h   fbg   
Pekkanen (109) 2000   healthy subjects   no ambient PM10 1-3 days   fbg   
Ghio (55) 2003   healthy subjects   yes concentrated  PM2.5 2h   fbg D-dim, PC, VWF 
Riediker (110) 2004   healthy subjects   no in-vehicle PM2.5 9h   VWF   
Becket (111) 2005   healthy subjects   yes zinc oxide particles 2h     FVII, fbg, VWF 
Blomberg (112) 2005    COPD patients   yes diesel exhaust 1h     fbg, D-dim, VWF 
Barregard (113) 2006   healthy subjects   yes wood smoke 4h   FVIII fbg, FVII, D-dim, VWF 
Ruckerl (114) 2006   CHD patients   no ambient PM2.5 and PM10 1-5 days   FVII (-), VWF fbg, D-dim 
Baccarelli (115) 2007   healthy subjects   no ambient PM10 t0 - 30days   PT aPTT, fbg, AT, PC, PS 
Carlsten (57) 2007   healthy subjects   yes diesel exhaust 2h     D-dim, VWF 
Chuang (54) 2007   healthy students   no ambient PM2.5 and PM10 1-3 days   fbg   
Ruckerl (116) 2007   MI survivors   no ambient PM2.5 and PM10 1-4 days   fbg   
Scharrer (117) 2007   healthy subjects   yes welding fume 1h     FVIII, VWF, AT 
Brauner (118) 2008   healthy subjects   yes indoor PM2.5 and PM10 2 days     fbg, FII+VII+X 
Lucking (92) 2008   healthy subjects   yes diesel exhaust 1-2h     PT, aPTT 
Rudez (94) 2009   healthy subjects   no ambient PM10 6h - 4days     fbg,TG 
Samet (56) 2009   healthy subjects   yes concentrated ambient UFP 2h   D-dim fbg, FIX, FXII, VWF 
Bonzini (53) 2010   steel plant workers   no occupational PM10 1-3 days   PT,TG aPTT, D-dim 
Stewart (119) 2010   T2DM patients   yes carbon UFP 2h     FVII, FIX, D-dim, TF 
Thompson (120) 2010   healthy subjects   no ambient PM2.5 t0 - 7 days     fbg 
Jacobs (78) 2011   DM patients   no carbon load in alveolar Mφ NA     VWF 
COPD: chronic obstructive inflammatory disease, MI: myocardial infarction, CHD: coronary health disease, DM: diabetes mellitus, T2DM: type 2 diabetes mellitus, PM: particulate matter, UFP: 
ultra-fine particles, Mφ: macrophages, PT: prothrombin time, aPTT: activated partial prothrombin time, AT: antithrombin, PC: protein C, PS: protein S, F: factor, fbg: fibrinogen, D-dim: D-dimers, 
VWF: von Willebrand factor, TG: thrombin generation, TF: tissue factor. (-) denotes inverse correlations.  Values between brackets denote non-significant trends. NA: data not available 
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However, these initial epidemiological reports on the association between air 
pollution exposure and venous thrombosis were followed by a number of prospective 
cohort studies that failed to demonstrate an association (121, 122) (see general 
discussion).  
Hence, in contrast to the well-accepted and documented deleterious effects of air 
pollution exposure on arterial events, data are scarce and the link with venous 
thrombosis is less straightforward, prompting further epidemiological investigation. 
 
Pathophysiology 
At lower rates of shear found in the venous circulation, the contribution of blood 
platelets to clot formation is of lesser importance than in the arterial circulation, 
leaving a protagonist role for the coagulation cascade in venous hemostasis. 
Activation of the coagulation cascade is initiated by activation of coagulation factor 
VII (FVII) by binding to tissue factor (TF), expressed on subendothelial cells such as 
fibroblasts and vascular smooth muscle cells. The complex of TF and activated FVII 
(FVIIa) initiates a cascade of subsequent coagulation factor activations, resulting in 
the generation of thrombin. Thrombin (FII) is a key enzyme, converting fibrinogen 
monomers to fibrin polymers that clot into a fibrin plug, and amplifying the 
coagulation cascade through activation of FV, FVIII and FXI. 
The mechanisms underlying the observed increase in venous thrombosis in 
association with exposure to air pollution remain largely unknown, and published 
results with regard to markers of secondary hemostasis activation are conflicting. 
Although some epidemiological and controlled exposure studies demonstrated an 
association between PM exposure and shortening of the prothrombin time (PT) or 
increased levels of fibrinogen and VWF, others failed to demonstrate positive 
associations with these or other markers of coagulation, in humans (Table 1). In fact, 
disappointingly few studies reported on PM-induced coagulatory changes that could 
form the basis for the observed link between air pollution and DVT. 
 
VTE is a common disease, and aging raises the relative risk for DVT from about 
1/10,000 at the age of 40 to 1/100 at the age of 80 (123). In view of the combination 
of the comonness of air pollution exposure and an ageing population in the western 
world, research into the association between air pollution exposure and VTE has 
substantial public health relevance. 
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It was the conundrum of air pollution-associated risk of venous thrombosis in the 
absence of well-documented changes in secondary hemostasis parameters that formed 
the basis for the present thesis. 
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Development of a mouse model of PM-induced venous prothrombogenicity and 
identification of pathophysiological mechanisms. 
The short-term effects of PM exposure on primary hemostasis activation are well 
known. In contrast, whether short-term PM exposure also induces changes in 
secondary hemostasis parameters, or whether a more sustained exposure time is 
warranted, remained to be elucidated. Epidemiological studies show that the increased 
risk of VTE is associated with long-term, but not with short-term exposure to PM (1). 
Therefore, we aimed to identify changes in both inflammatory and prothrombotic 
parameters upon short-term and long-term exposure to air pollution. 
 
Acute and subacute exposure of mice to PM by intratracheal instillation  
Mice were exposed to 2 types of PM via a single ('acute') or 3 repetitive ('subacute') 
intratracheal instillations. Besides the analysis of parameters of inflammation and 
coagulation ex vivo, thrombosis experiments were also performed in vivo. (Chapter 1) 
 
Subchronic exposure of mice to PM  
Mice were subchronically exposed to traffic-related air pollution by placing them in a 
roadside tunnel for several weeks. (Chapter 4) 
 
Epidemiological analysis of the associations between air pollution exposure and 
increased risk factors for VTE 
To unravel the pathophysiological mechanisms underlying the described association 
between PM exposure and VTE in humans, we assessed several parameters of 
inflammation and coagulation in a group of patients with diabetes, and correlated the 
results with different measures of both recent and chronic exposure to air pollution. 
(Chapter 2) 
 
Interaction between risk factors 
Epidemiological research indicates that some populations are more susceptible to the 
deleterious health effects of PM exposure. Several studies suggest that susceptible 
individuals may, amongst others, include the elderly (2, 3) and patients with diabetes 
(4-6). The aforementioned epidemiological study was performed in a group of 
susceptible patients with diabetes (Chapter 2).  
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We also investigated to which extent aging affects the PM-induced procoagulant 
changes in mice subchronically exposed to PM (Chapter 4). Baseline (i.e. unexposed) 
differences in coagulation parameters and microvesicles (see below) between elderly 
and young persons were investigated in Chapter 3. 
 
Role of microvesicles 
Microvesicles, cell-derived vesicles with a diameter <1 µm, are believed to play a 
central role in the interface between inflammation and hemostasis. Some publications 
indirectly suggest a role for microvesicles in PM-induced prothrombotic changes (7, 
8), but neither the demonstration of a direct association, neither the identification of 
the pathological fraction of microvesicles in this regard has been achieved yet. By 
using both antigenic and functional assays, we aim to clarify the role of microvesicles 
in our animal model of chronic PM inhalation (Chapter 4), as well as in the human 
epidemiological study (Chapter 2).  
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Abstract 
Background: Epidemiological findings suggest an association between exposure to 
particulate matter (PM) and venous thrombo-embolism.  
Objectives: To investigate arterial vs venous thrombosis, inflammation and coagulation in 
mice, (sub)acutely exposed to 2 types of PM. 
Methods: Various doses (25, 100, 200 µg/animal) of urban particulate matter (UPM) or 
diesel exhaust particles (DEP) were intratracheally instilled in C57Bl6/n mice and several 
endpoints measured at 4, 10 and 24 hours. Mice were also repeatedly exposed to 100 
µg/animal on 3 consecutive days with endpoints measured 24 hours after the last instillation. 
Results: Exposure to 200 µg/mouse UPM enhanced arterial thrombosis, but neither UPM nor 
DEP significantly enhanced venous thrombosis. Both types of PM induced dose-dependent 
increases in broncho-alveolar lavage fluid (BALF) total cell numbers (mainly neutrophils) 
and cytokines (IL-6, KC, MCP-1, RANTES, MIP-1α), with peaks at 4 hours and overall 
higher values for UPM than for DEP. Systemic inflammation was limited to increased serum 
IL-6 levels, 4 hours after UPM. Both types of PM induced similar and dose-dependent but 
modest increases in FVII, FVIII and fibrinogen. Three repeated instillations did not or only 
modestly enhance the proinflammatory and procoagulant status. 
Conclusions: Compared to DEP, UPM induced more pronounced pulmonary inflammation, 
but both particle types triggered similar and mild short-term systemic effects. Hence, acute 
exposure to PM triggers activation of primary haemostasis in the mouse, but no substantial 
secondary haemostasis activation, resulting in arterial but not venous thrombogenicity. 
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Introduction 
Numerous epidemiological studies reported consistent associations between exposure to 
urban air pollution, especially by particulates, and cardio-respiratory morbidity and mortality 
(1-4). Over the last 2 decades, a vast number of both epidemiological and mechanistic studies 
have provided convincing evidence to conclude that chronic exposure to particulate matter 
(PM) enhances atherosclerosis and that acute exposure increases the risk of atherosclerotic 
plaque rupture and blood platelet activation, triggering arterial thrombosis and myocardial 
infarction (5-9). 
 
In addition to the well-recognized PM-related adverse effects on the arterial vascular system, 
recent epidemiological evidence also suggests an association between exposure to PM and 
venous thrombo-embolism (VTE). Baccarelli et al. reported a 70% increase in the risk of deep 
vein thrombosis (DVT) for each 10 µg/m3 increase of the annual mean level of PM with 
aerodynamic diameter ≤10 µm (PM10) in the areas of residence of the study subjects (10). 
These authors found, in the same study subjects, that living near major traffic roads was also 
associated with an increased risk of DVT, even after controlling for the community-level PM 
pollution (11). Very recently, exposure to PM has also been associated with hospital 
admission for VTE in Chile (12). The mechanisms underlying the observed increase in 
venous thrombosis remain largely unknown, and published results with regard to markers of 
secondary haemostasis activation are conflicting. Although some epidemiological and 
controlled exposure studies demonstrated an association between PM exposure and 
shortening of the prothrombin time (PT) (13, 14) and increased levels of fibrinogen (15-18), 
von Willebrand factor (19, 20) or plasminogen activator inhibitor-1 (PAI-1) (16), others failed 
to demonstrate any association with these markers (21-25). Also in the limited number of 
experimental studies in rodents, investigating the PM-induced changes in secondary 
haemostasis, results are conflicting (26-29). This discrepancy in different studies is likely to 
be attributed to differences in experimental design and in the composition of PM. Among 
other factors, animal studies differ in dosing of PM, the type of exposure, lag time between 
PM exposure and sampling, and the type of PM animals are exposed to. Both urban 
particulate matter (UPM) (26, 28, 29) and diesel exhaust particles (DEP) (27) are frequently 
used.  
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In an attempt to take into account the determining role of variable exposure parameters, we 
investigated how and whether standardized short-term experimental exposure of mice to 2 
different types of PM would affect experimental venous thrombosis and activate the 
coagulation system, the activation of which is central in VTE. Different time frames and 
doses were applied. 
 
Materials and methods 
Particle collection 
UPMs with a mean aerodynamic diameter smaller than 10 µm (PM10) were collected as 
previously described (30) using a high volume sampler (GMW Model 1200, VFC HVPM10; 
Sierra Andersen, Smyrna, GA, USA) in the industrial region of the Metropolitan Zone of 
Mexico City, in Xalostoc from November 2004 till April 2005 (Mexican Consortium for 
Particulate Matter Studies). Elemental composition is shown in table E1 (data supplement). 
DEPs were generated using a 4-cylinder Deutz BF4M1008 diesel engine and collected in a 
baghouse at the US EPA’s National Risk Management Research laboratory (RTP, NC) from 
October till November 2004 (kind gift of Dr A Farraj, National Health and Environmental 
Effects Research Laboratory, NHEERL) (31). 
LPS content of both types of PM was measured as described previously (32) and found to be 
138.4 endotoxin units (EU)/mg for UPM and smaller than 0.05 EU/mg (detection limit) for 
DEP. 
 
Intratracheal instillation of particles 
This study was approved by the Institutional Review Board of the University of Leuven, and 
experiments were performed in accordance with protocols approved by the Institutional 
Animal Care and Research Advisory Committee. 
Particles were suspended in vehicle (NaCl 0.9%, containing 0.1% Tween 80). To minimize 
aggregation, particle suspensions were always sonicated for 15 minutes and vortexed 
immediately (<1 minute) before their IT instillation in 8- to 10-week old male C57Bl6/n mice, 
previously anesthetized with sodium pentobarbital (60 mg/kg). A Becton Dickinson 22 Gauge 
cannula was inserted via the mouth into the trachea and 50 µL of PM suspension was instilled 
via a syringe, followed by an air bolus of 100 µL. Controls received vehicle only. 
The IT instillation of a bolus of particles could be considered as non-physiologic, but this 
method of delivery has been shown to be a convenient and valid, although admittedly not 
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perfect, mode of administration of foreign compounds into the airways (33) and has been used 
in numerous PM-based studies (7, 26, 27, 29). 
 
Experimental design 
Arterial and venous thrombotic occlusion times were recorded 24 hours after a single IT 
instillation of vehicle or PM (200 µg/mouse). In each experimental group, n=5-7. 
In dose-response experiments, samples were taken 24 hours after a single IT instillation of 
different doses of PM (25, 100 or 200 µg/mouse).  
In time-dependence experiments, samples were taken at 4, 10 or 24 hours after a single 
(‘acute’) instillation of 100 µg of PM/mouse, or at 24 hours after the last of 3 consecutive 
(‘subacute’) daily instillations of 100 µg of PM/mouse.  
Systemic coagulation parameters were measured at 24 hours after a single (different doses) or 
after repeated (100 µg doses) PM exposure. In each experimental group, n≥5. 
 
Blood collection and analysis 
Following anesthesia (sodium pentobarbital, 60 mg/kg, i.p.), blood was collected from the 
retroorbital sinus on citrate 0.38%. Blood cell counts and differentials were performed on a 
Cell-Dyn 3500R counter (Abbott, Diegem, Belgium). Samples were centrifuged twice 
(15,000 g x 10 min) and plasma was stored at -80°C for subsequent coagulation assays. Blood 
was also collected in a dry tube, incubated at 37°C for 1 hour, centrifuged (15,000 g x 10min) 
and serum was stored at -20°C for cytokine analysis. 
 
Thrombotic occlusion time 
Thrombotic occlusion times were measured as previously described (34). Platelets were 
fluorescently labelled in vivo by IV injection of Rhodamine 6G (3.3 mg/kg, Invitrogen, 
Merelbeke, Belgium). After opening the abdomen, mesenteric arteries and veins were 
exposed on the table of an inverted epifluorescent microscope (×10) (Nikon Diaphot 300), 
coupled to ImageJ software. Endothelial injury was induced by topical deposition of filter 
paper saturated with FeCl3 (5%) (Sigma-Aldrich, Bornem, Belgium) for 3 minutes. Platelet 
deposition and thrombus growth were then monitored in real-time until complete occlusion 
occurred in the mesenteric artery and vein. The parameter analyzed was the vessel occlusion 
time, defined as an arrest of blood flow for at least 1 min. Mean values of up to two controlled 
lesions per animal are shown. 
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To investigate to which extent both occlusion times were determined by secondary 
haemostasis parameters, non-instilled mice were pretreated with 4 mg/kg low molecular 
weight heparin (LMWH: enoxaparin, Sanofi-Aventis, Diegem, Belgium) I.V. and arterial and 
venous occlusion times were compared to the values found in separate untreated controls.  
 
Plasma assays 
Activated partial thromboplastin time (aPTT) and prothrombin (PT) clotting times were 
determined on a semi-automated coagulometer (KC10, Amelung, Germany) using 
commercially available reagents (HemsIL Synthasil, IL, Zaventem, Belgium and Innovin, 
Siemens, Brussels, Belgium). Levels of the coagulation factors FVII and FVIII were 
measured in parallel, via a 1-stage clotting assay (FVII and FVIII Deficient Plasma, IL, 
Zaventem, Belgium), sensitive to in-vivo preactivation of clotting factors, and a chromogenic 
assay (Coaset FVII, Chromogenix, Milan, Italy and FVIII chromogenic assay, Siemens, 
Brussels, Belgium), insensitive to such preactivation. A fractionated murine plasma pool of 
different strains was used to make the calibration curves for the determination of FVII and 
FVIII. Fibrinogen levels were determined by commercial anti-murine fibrinogen ELISA 
(Gentaur, Brussels, Belgium).  
 
Bronchoalvolar lavage fluid (BALF) collection and analysis 
Following blood sampling, the abdomen was opened and mice were sacrificed by transsection 
of the abdominal vessels. The trachea was exposed, cannulated with a 20 Gauge cannula and 
lungs were lavaged three times with 0.7 mL (total volume of 2.1 mL) of sterile NaCl 0.9%. 
The recovered fluid aliquots were pooled and placed on ice. No difference in the volume of 
collected fluid was observed between the different groups. Cells in fresh BALF were stained 
with Trypan Blue and counted in a Bürker hemocytometer. Cell differentials were determined 
by light microscopy on cytocentrifuge preparations fixed in methanol and stained with Diff 
Quick (Siemens, Brussels, Belgium). The remaining BALF was then centrifuged (1000 g x 10 
min.) and the supernatant stored at -20°C for cytokine analysis.  
 
Cytokine analysis 
We analyzed 6 cytokines involved in the activation of macrophages: interleukin-6 (IL-6), 
keratinocyte-derived chemokine (KC), monocyte chemoattractant protein-1 (MCP-1), 
RANTES, macrophage inflammatory protein-1a (MIP-1α) and interleukin-1b (IL-1β). 
Analysis was performed on both undiluted serum and BALF using a multiplex cytometric 
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bead assay for murine cytokines, purchased from Becton Dickinson (Erembodegem, 
Belgium). In separate experiments, the role of endotoxin (LPS) in pulmonary cytokine 
production was investigated in mice exposed to UPM, DEP, LPS or the combination of DEP 
and LPS (see data supplement). 
 
Tissue collection and analysis 
Lung and liver tissues were harvested, snap frozen in liquid nitrogen and stored at -80°C. 
RNA was extracted using chloroform extraction and isopropanol precipitation. After reverse 
transcription of RNA (1 µg) to cDNA, real-time PCR measurements of individual samples 
were performed in duplicate on the AB 7500 Fast PCR System (Applied Biosystems, 
Ottignies-Louvain-la-neuve, Belgium). FAM labeled primers were commercially obtained 
from Applied Biosystems (tissue factor: Mm00438853_m1; thrombomodulin: 
Mm00437014_s1; VCAM-1: Mm01320970_m1; ICAM-1: Mm00516023_m1; antithrombin: 
Mm00446573_m1; protein C: Mm00435966_m1; coagulation factor VII: Mm00487329_m1; 
fibrinogen beta-chain: Mm00805336_m1; GaPDH: Mm99999915_g1). GaPDH was used as 
house keeping gene for relative expression of Ct values and results are expressed as arbitrary 
units (AU). 
 
Statistical analysis 
All statistics were performed non-parametrically. Data are expressed as median with 
interquartile range. Mann-Whitney tests were used to analyze significance between 
thrombosis experiments in the presence or absence of LMWH. Statistical significance 
between groups at different time points after a single or repeated instillation of 100 µg PM or 
vehicle was analyzed by Kruskal-Wallis with Dunn's multiple comparison post-tests. Dose-
response relationships were determined by Spearman correlation. This trend analysis was 
preferred over multigroup comparisons to limit the total number of statistical tests (multiple 
testing). This approach limits, but does not eliminate the possibility of a type-1 error. 
Therefore, we can not exclude that some of the significant (defined as p<0.05) results 
observed are chance findings. However, given the relatively small number of animals per 
group, a stringent correction would compromise the possibility of finding small changes in 
the parameters analyzed. All statistical analyses were performed using GraphPad Prism 
version 4.0b and Instat version 3 (GraphPad Software, San Diego, US). 
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Results 
Pulmonary effects: white blood cells 
At 24 hours after a single instillation, pulmonary exposure to either UPM or DEP led to a 
significant dose-dependent increase in BALF total white blood cell (WBC) counts (10 fold  
increase for UPM200µg vs vehicle, p for trend <0.0001, and 4-fold increase for DEP200µg vs 
vehicle, p for trend <0.0001), mainly driven by a neutrophil influx (Table 1). Total WBC and 
neutrophil counts in the UPM group, but not in the DEP group, were significantly higher than 
in the vehicle group, as early as 4h post-instillation, and peaked at 10h (Total WBC: 8-fold 
increase for UPM100µg vs vehicle; Neutrophils: increase from 0.9 (0.7-11.7) cells/µL for 
vehicle to 432 (342-476) cells/µL for UPM100µg).  
Table 1: Dose-response values for inflammatory parameters in broncho-alveolar lavage fluid, 24 hours 
after intratracheal administration of UPM or DEP in mice 
 vehicle  UPM 25 µg UPM 100 µg UPM 200 µg  correlation coefficient r 
p for 
trend 
total WBC  
(/µL) 
50 (40-70) 
(18)  
120 (100-150) 
(11) 
380 (320-420) 
(11) 
510 (435-565) 
(10)  0.952 <0.0001 
neutrophils  
(/µL) 
0.4 (0.0-1.5) 
(18)  
82 (70-86) 
(11) 
331 (250-357) 
(11) 
434 (356-487) 
(10)  0.950 <0.0001 
macrophages  
(/µL) 
50 (40-68) 
(18)  
41 (29-53) 
(11) 
64 (52-79) 
(11) 
65 (58-77) 
 (10)  0.390 0.0051 
IL-6  
(pg/mL) 
0.6 (0.0-1.6) 
(10)  
3.1 (1.6-6.3) 
(5) 
12.0 (4.2-18.8) 
(5) 
82.7 (61.3-92.9) 
(5)  0.919 <0.0001 
KC  
(pg/mL) 
0.6 (0.0-0.9) 
(10)  
5.0 (3.7-9.1) 
(5) 
7.3 (4.4-11.6) 
(5) 
9.0 (7.2-18.8) 
(5)  0.846 <0.0001 
MIP-1α   
(pg/mL) 
0.0 (0.0-1.4) 
(10)  
3.2 (1.5-7.7) 
(5) 
10.6 (6.9-18.0) 
(5) 
24.1 (21.5-46.3) 
(5)  0.911 <0.0001 
MCP-1  
(pg/mL) 
5.3 (0.0-
17.0) 
(10) 
 0.0 (0.0-7.2) (5) 
0.0 (0.0-15.3) 
(5) 
70.3 (44.9-89.3) 
(5)  0.434 0.0302 
RANTES  
(pg/mL) 
1.3 (0.0-3.4) 
(10)  
1.2 (0.0-2.4) 
(5) 
2.0 (0.0-2.9) 
(5) 
9.1 (6.1-12.3) 
(5)  0.503 0.0104 
         
   DEP 25 µg DEP 100 µg DEP 200 µg  correlation coefficient r 
p for 
trend 
total WBC  
(/µL)   
75 (58-85) 
(6) 
115 (103-155) 
(8) 
220 (170-240) 
(9)  0.863 <0.0001 
neutrophils 
 (/µL)   
28 (5-39) 
(6) 
87 (57-113) 
(8) 
156 (142-192) 
(9)  0.920 <0.0001 
macrophages  
(/µL)   
45 (43-49) 
(6) 
39 (34-47) 
(8) 
29 (25-49) 
(9)  -0.383 0.012 
IL-6  
(pg/mL)   
3.5 (1.5-10.9) 
(7) 
25.0 (8.8-53.8 
(7) 
80.9 (63.1-91.1) 
(7)  0.898 <0.0001 
KC  
(pg/mL)   
6.8 (1.1-26.9) 
(7) 
13.7 (4.5-61.0) 
(7) 
47.1 (17.2-73.0) 
(7)  0.831 <0.0001 
MIP-1α   
(pg/mL)   
5.2 (1.7-10.6) 
(7) 
11.1 (8.0-17.4) 
(7) 
30.1 (23.3-35.3) 
(7)  0.932 <0.0001 
MCP-1  
(pg/mL)   
11.8 (8.8-13.4) 
(7) 
13.4 (5.8-14.9) 
(7) 
50.3 (26.0-53.3) 
(7)  0.651 <0.0001 
RANTES  
(pg/mL)   
3.5 (2.6-3.7) 
(7) 
3.1 (2.6-4.0) 
(7) 
3.4 (2.8-3.8) 
(7)  0.360 0.0468 
Data are expressed as median (interquartile range) (n). Significant p for trend values are highlighted in bold. 
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At all time points, cell numbers in the UPM group tended to be higher than for the DEP group 
(Fig. 1A and B). Overall, changes in macrophage numbers were modest at any dose and at 
any time-point after a single instillation (Table 1), despite obvious macrophage particle 
phagocytosis, as observed by light microscopy (Fig. 1F). When compared to a single 
instillation, repeated instillations further increased the levels of BALF macrophages after both 
UPM100µg and DEP100µg (both 2-fold increase for 3 instillations vs a single instillation, p<0.01) 
(Fig. 1C). 
 
Figure 1: White blood cells (WBC) in broncho-alveolar lavage fluid.  
WBC were measured in BALF at 4, 10 and 24 hours after a single intratracheal instillation (1 instill.), and at 24 
hours after 3 repeated instillations (3 instill.) of vehicle (white bars, left), UPM100µg (light grey bars, middle) or 
DEP100µg (dark grey bars, right). A: total WBC count. B: neutrophil count. C: macrophage count. Values are 
represented as median+interquartile range (n≥5 for each group). *:<0.05 UPM or DEP vs vehicle. **:<0.01 
UPM or DEP vs vehicle. ***:<0.001 UPM or DEP vs vehicle. °:<0.05 UPM vs DEP.  
Representative images of stained cytospin slides of WBC in BALF, 24 hours after single IT instillation of D: 
vehicle, E: UPM100µg, F: DEP100µg. Both UPM and DEP induce neutrophilic influx. Macrophagic ingestion of 
DEP is evident.  
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Pulmonary effects: cytokines 
Mean IL-1β levels in BALF were around the detection limit (1.9 pg/mL) in all groups at any 
time point or any dose (data not shown).  
 
Figure 2: Cytokines in broncho-alveolar lavage fluid (BALF) and IL-6 in serum.  
Cytokines were measured in BALF at 4, 10 and 24 hours after a single intratracheal instillation (1 instill.), and at 
24 hours after 3 repeated instillations (3 instill.) of vehicle (white bars, left), UPM100µg (light grey bars, middle) 
or DEP100µg (dark grey bars, right). A: KC in BALF. B: MIP-1α in BALF. C: MCP-1 in BALF. D: RANTES in 
BALF. E: IL-6 in BALF. Serum levels of IL-6 are shown in F. Values are represented as median+interquartile 
range (n≥5 for each group). *:<0.05 UPM or DEP vs vehicle. **:<0.01 UPM or DEP vs vehicle. ***:<0.001 
UPM or DEP vs vehicle. °:<0.05 UPM vs DEP. °°<0.01 UPM vs DEP.  
 
Marked dose-dependent increases (p for trend<0.0001) were found in the levels of IL-6, KC, 
and MIP-1α for both UPM and DEP (Table 1).  
Chapter 1  
	  
39 
Following a single instillation of UPM100µg, levels of IL-6, KC and MIP-1α peaked at 4 hours, 
exceeding several hundred-fold the levels after instillation of vehicle, and several 10-fold 
those of DEP100µg. These parameters returned to near-baseline levels at 24 hours (Fig. 
2A,B,E). Upregulation of MCP-1 levels was only modest at any timepoint after a single 
instillation of 100 µg of either UPM or DEP (Fig. 2C), but more pronounced after a single 
instillation of 200 µg of either UPM or DEP (table 1) or after repeated instillation of DEP100µg 
(Fig. 2C). Concentrations of RANTES were only upregulated 10 hours after a single, or 24 
hours after repeated instillations of UPM100µg (Fig. 2D). 
 
Pulmonary effects: mRNA expression 
A single exposure to UPM100µg induced an upregulation of both VCAM-1 and ICAM-1 at all 
time points, as compared to both vehicle and DEP, although only significantly at 4 hours for 
VCAM-1 and at 4 and 24 hours for ICAM-1. DEP100µg only upregulated ICAM-1 mRNA 
expression at 24 hours. This upregulation was no longer apparent after repeated instillations. 
A single instillation of UPM100µg, but not DEP100µg, strongly upregulated tissue factor mRNA 
expression at 4 hours. No significant differences between groups were measured in the levels 
of thrombomodulin mRNA expression at any timepoint, but an upregulation was observed for 
all groups at 4 hours, apparently related to the IT instillation itself (Fig. 3). 
 
Systemic effects: inflammation 
At 4 hours, a trend towards a rapid and transient upregulation of serum IL-6 levels was 
induced by single exposure to UPM100µg , that was not observed after DEP100µg (Fig. 2F). At 24 
hours, neither UPM100µg nor DEP100µg upregulated IL-6 levels at any dose (data supplement 
Table E1). Repeated instillations did not enhance this effect (Fig. 2F).  
No consistent changes were observed in the numbers of circulating WBC or blood platelets, 
nor in the serum concentrations of cytokines KC, MIP-1α, MCP-1 or RANTES at any dose 
(data supplement Table E1) or any time-point (on-line data supplement Fig. E1 and E2). 
Again, all values for serum IL-1β were around the detection limit (data not shown). 
 
Systemic effects: thrombotic occlusion time 
Pretreatment of non-instilled mice with LMWH lead to a considerable prolongation of 
venous, but not of arterial thrombotic occlusion time (Fig. 4A). This observation qualifies 
venous occlusion times as a valuable read-out, characteristic of venous thrombosis, i.e. 
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amongst others dependent on secondary haemostasis. In contrast, the absence of such 
prolongation in the arterial thrombosis model reflects the independence of secondary 
haemostasis parameters. Arterial thrombotic occlusion times therefore seem mainly 
determined by the vascular injury and activation of primary haemostasis. 
At 24 hours after instillation, UPM200µg induced a significant shortening of the arterial 
thrombotic occlusion time, that was more pronounced than for DEP200µg. In contrast, the 
venous thrombotic occlusion time was unaffected by both types of PM (Fig. 4B).  
 
 
Figure 3: Pulmonary mRNA expression.  
Pulmonary mRNA expression levels were measured at 4, 10 and 24 hours after a single intratracheal instillation 
(1 instill.), and at 24 hours after 3 repeated instillations (3 instill.) of vehicle (white bars, left), UPM100µg (light 
grey bars, middle) or DEP100µg (dark grey bars, right). A: VCAM-1. B: ICAM-1. C: tissue factor (TF). D: 
thrombomodulin (Thbm). Ct value of each parameter was expressed relatively to the Ct value of the house-
keeping gene GaPDH for each separate sample, and results expressed as arbitrary units (AU). Values are 
represented as median+interquartile range (n≥5 for each group). *:<0.05 UPM or DEP vs vehicle. **:<0.01 
UPM or DEP vs vehicle. °°<0.01 UPM vs DEP.  
 
Systemic effects: plasma coagulation markers 
Secondary hemostasis parameters aPTT, PT, fibrinogen, FVII and FVIII (1-stage coagulation 
and chromogenic assay) were measured at 24 hours after a single instillation (different doses) 
or after repeated instillations (100 µg doses) of PM (Table 2). 
UPM, but not DEP, induced a significant dose-dependent prolongation of the aPTT 
(r=0.5827, p for trend<0.0001). A much milder prolongation was also observed after repeated 
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instillations of UPM100µg, although not significant. No effect was seen on PT at any dose 
(Table 2). Plasma levels of fibrinogen, both a procoagulant and an acute phase protein, mildly 
increased with the dose, both for UPM and for DEP, and after repeated instillations of 
DEP100µg , by about 20%. 
 
Figure 4: Arterial and venous thrombotic occlusion times. 
Thrombotic occlusion times of arterial (artery) and venous (vein) thrombosis, upon FeCl3-induced vascular 
injury of the mouse mesenteric circulation. A: Mice were treated with low molecular weight heparin (4 mg/kg) 
as indicated (controls: -LMWH; treated: +LMWH). B: Thrombotic occlusion times were measured in the 
mesenteric arteries and veins, 24 hours after a single intratracheal instillation of vehicle, UPM200µg or DEP200µg in 
mice. Values shown are the mean values of 2 separate measurements per mouse (n=5-7). Bars represent median 
values. *:<0.05 , **:<0.01  
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Similarly, FVII, measured via one-stage clotting assay increased by 20-25% after a single 
exposure to both UPM or DEP, with r>0.4 and p<0.01 (Table 2). This trend was not observed 
for the chromogenic assay and was not pronounced enough to shorten the PT. No consequent 
increase of FVIII levels was measured for exposure to UPM or DEP. Repeated instillations of 
UPM did not alter levels of FVII and FVIII. 
 
Hepatic effects: mRNA expression 
At 24 hours after a single dose or repeated doses of 100 µg of PM, we only observed a 
significant upregulation of the mRNA expression level of protein C, after a single instillation 
of DEP100µg. Repeated exposure to either UPM or DEP did not alter mRNA expression (Table 
3). 
 
Discussion 
To initiate mechanistic studies on the relationship between exposure to particulate matter and 
VTE, we have investigated inflammation, thrombogenicity and coagulation activation after 
exposing mice acutely and subacutely to two different types of relevant PM, administered 
intratracheally. 
Both UPM and DEP dose-dependently increased WBC numbers (mainly neutrophils) and 
relevant cytokines in BALF. Overall, UPM induced a more potent pulmonary inflammatory 
response than DEP. This may be explained by the higher endotoxin content in the UPM 
sample (138.4 EU/mg of PM) than in the DEP sample (below detection limit of 0.05 EU/mg 
of PM). Previous experiments in our laboratory showed that the combined instillation of DEP 
and very low amounts of endotoxin, representative of the concentrations in UPM, resulted in 
enhanced cytokine expression in mice, with a semi-quantitative pattern highly similar to that 
observed for UPM (shown in Table E3 in the supplement). 
 
UPM undergoes airborne condensation of lipopolysaccharides, metal ions and a mix of 
organic molecules on the surface, potentially all contributing to its adverse effects (35). We 
found previously that the UPM used in this study induced an upregulation of IL-6, IL-8 
(equivalent to rodent KC) and MCP-1 in an in-vitro co-culture system mimicking the 
pulmonary cellular environment (36), and lead to elevated ICAM-1 and VCAM-1 on 
endothelial cells (37). 
 Table 2: Coagulation parameters in plasma after a single or repeated instillation of UPM or DEP in mice. 
  1 instillation   3 instillations 
  vehicle   UPM 25 µg UPM 100 µg UPM 200 µg   correlation coefficient r p for trend   vehicle   UPM 100 µg 
aPTT  
(sec) 
34.5 (33.5-36.6)  
 (18)   
37.3 (34.9-38.5) 
(11) 
36.9 (35.2-41.6) 
(11) 
40.3 (37.0-43.5) 
 (11)   0.5827 <0.0001   
35.2 (32.7-37.5) 
(12)   
36.7 (35.9-38.2) 
(7) 
PT  
(sec) 
11.7 (11.0-12.0) 
(16)   
11.1 (10.9-11.6) 
(11) 
11.5 (11.1-11.7) 
(11) 
11.4 (11.2-11.6) 
(11)   -0.0590 0.6974   
11.1 (10.5-11.4) 
(12)   
10.9 (10.7-11.6) 
(7) 
FVIIcoag  
(%) 
116 (106-130) 
(13)   
104 (97-133) 
(8) 
144 (129-154) 
(8) 
139 (120-158) 
(8)   0.4648 0.0038   
112 (104-134) 
(11)   
134 (125-154) 
(7) 
FVIIchrom  
(%) 
155 (134-174) 
(18)   
145 (142-165) 
(11) 
159 (146-174) 
 (10) 
173 (143-204) 
(11)   0.2134 0.1367   ND   ND 
FVIIIcoag  
(%) 
124 (114-132) 
(18)   
126 (114-136) 
(11) 
127 (122-138) 
(11) 
117 (114-138) 
(11)   0.09612 0.5022   
122 (108-129) 
(11)   
133 (124-145) 
(7) 
FVIIIchrom 
(%) 
118 (106-134) 
(16)   
154 (112-181) 
(11) 
151 (121-173) 
(11) 
160 (125-205) 
(10)   0.3059 0.0345   ND   ND 
Fbg  
(g/L) 
6.85 (6.00-7.70) 
(15)   
7.78 (6.20-8.65) 
(11) 
7.93 (7.18-9.22) 
(11) 
8.14 (6.44-9.41) 
(10)   0.3358 0.021   
7.02 (5.83-7.50) 
(11)   
6.44 (6.12-6.79)°  
(7) 
                          
     DEP 25 µg DEP 100 µg DEP 200 µg   correlation coefficient r p for trend      DEP 100 µg 
aPTT  
(sec)    
34.9 (31.5-36.3) 
(7) 
34.0 (32.4-35.9) 
(8) 
33.8 (31.9-35.8) 
(9)   -0.1409 0.3735      
36.1 (33.6-40.0) 
(5) 
PT  
(sec)    
11.5 (10.4-12.6) 
(7) 
11.3 (11.0-11.8) 
(8) 
11.4 (10.1-12.4) 
(9)   -0.1354 0.4048      10.6 (10.2-10.9) 
FVIIcoag  
(%)    
138 (118-174) 
(7) 
117 (107-157) 
 (8) 
141 (129-168) 
(9)   0.428 0.0082      
106 (103-128) 
(5) 
FVIIchrom  
(%)    
163 (155-165) 
(7) 
154 (140-158) 
(8) 
165 (156-174) 
(8)   0.114 0.4779      ND 
FVIIIcoag  
(%)    
138 (124-147) 
(7) 
125 (113-135) 
(8) 
132 (126-147) 
(9)   0.3176 0.0404      
126 (114-159) 
(5) 
FVIIIchrom 
(%)    
126 (91-157) 
(6) 
124 (117-144) 
(7) 
124 (115-162) 
(9)   0.1576 0.3448      ND 
Fbg  
(g/L)    
8.06 (7.12-9.32) 
(7) 
6.62 (6.02-7.39) 
(7) 
8.21 (7.49-8.80) 
(9)   0.3935 0.0145      
8.18 (7.95-9.58)**  
(5) 
Data are expressed as median (interquartile range) (n). **:<0.01 DEP vs vehicle. °:<0.05 UPM vs DEP. Values significantly different from the vehicle-treated group and significant p 
for trend values are highlighted in bold. ND: not determined. 
  
 
 
 
Table 3: Hepatic mRNA expression after a single or repeated instillation of UPM or DEP in mice. 
  1 instillation   3 instillations 
  vehicle   UPM 100 µg DEP 100 µg   vehicle   UPM 100 µg DEP 100 µg 
FVII mRNA  
(AU) 
2.25 (1.73-3.03) 
(11)   
3.05 (2.46-3.41) 
 (5) 
2.29 (2.09-2.63)  
(6)   
2.36 (2.11-2.68)  
(11)   
2.15 (1.79-2.31) 
 (6) 
2.12 (1.88-2.50)  
(5) 
Fbg β  mRNA  
(AU) 
71.46 (40.5-124.2) 
 (11)   
72.11 (71.07-
98.06)° 
 (5) 
39.82 (32.61-46.76)  
(6)   
68.61 (41.53-83.76) 
 (11)   
80.32 (73.62-93.11) 
 (6) 
38.34 (28.15-125.60) 
 (5) 
AT mRNA  
(AU) 
327.4 (279.9-345.4) 
 (11)   
304.9 (291.8-327.3) 
(5) 
343.3 (316.9-498.4) 
 (6)   
307.8 (252.8-393.7) 
 (11)   
233.0 (208.6-269.2) 
 (6) 
355.7 (245.1-399.9) 
 (5) 
ProtC mRNA  
(AU) 
23.73 (21.34-25.16) 
(11)   
24.53 (22.36-26.51) 
 (5) 
27.19 (25.67-31.87)** 
(6)   
26.93 (20.49-29.37) 
 (11)   
17.66 (16.43-23.48) 
 (6) 
26.77 (23.37-29.73) 
 (5) 
                   
Data are expressed as median (interquartile range) (n). 
For mFor mRNA expression levels, Ct value of each parameter was expressed relatively to the Ct value of the house-keeping gene GaPDH for each separate sample, and 
expressed as arbitrary units (AU)). Fbg β: fibrinogen β-chain. AT: antithrombin. ProtC: protein C. 
**:<0.01 DEP vs vehicle. °:<0.05 UPM vs DEP. Values significantly different from the vehicle-treated group are highlighted in bold.  
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Despite obvious pulmonary inflammation for both common types of particles, we 
found no substantial systemic inflammation. Published results of systemic 
inflammation after acute or chronic exposure to PM in man are conflicting. Ambient 
PM has been associated with higher levels of WBC (38), IL-6 (18) and hs-CRP (16) 
both in healthy humans and in at-risk populations, but systemic inflammation was not 
evident in all epidemiological studies (24). Likewise, although some controlled 
exposure studies showed associations between exposure to fairly high concentrations 
of PM and increased levels of circulating neutrophils (39), platelet-WBC aggregates 
(21), IL-6 and TNFα (40), others failed to observe increases in circulating WBC (15, 
41), IL-6 (41) or CRP (22, 23, 41), within 24 hours after exposure.  
 
Exposure to UPM and DEP induced mild changes in both procoagulant (tissue factor 
mRNA, FVII protein, FVIII protein and fibrinogen protein), as well as in 
anticoagulant (protein C mRNA) pathways. The rise of FVII in the UPM and DEP 
groups was observed when analyzed via one-stage clotting assay, but not with a 
chromogenic assay. This is suggestive of exposure-related FVII activation, rather than 
de novo FVII synthesis and release in the circulation. Despite increased levels of the 
acute phase proteins FVIII and fibrinogen in the UPM-treated group, a contradictory 
dose-dependent prolongation of the aPTT clotting time was observed. One possible 
explanation for this apparent discrepancy may be the recently demonstrated 
prolongation of the aPTT in human plasma upon addition of CRP, as a result of its 
binding to negatively charged phospholipids (42). In mice, CRP is not a strong acute 
phase protein, but more relevant acute phase proteins, such as serum amyloid a 
(SAA), also bind phospholipids (43) and may cause similar interference.  
In general, procoagulant changes measured were mild and were similar between UPM 
and DEP, even at the highest doses (200 µg). At the lower dose of 25 µg, which is 
more representative for daily inhaled doses in humans (i.e. comparative dose of ±35 
µg/mouse) (29) no relevant procoagulant changes were observed. 
The mild activation of secondary haemostasis is too weak to influence experimental 
venous thrombosis in mice, in contrast to the more prothrombotic effect of UPM on 
arterial thrombosis. Because arterial thrombogenicity in the model used is determined 
primarily by the intensity of the vascular lesion, platelet recruitment and aggregation 
(34), these findings are compatible with UPM-induced platelet activation. Blood 
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platelet activation was not directly measured in this study, but previously, our group 
has provided ample evidence of blood platelet activation upon short-term PM-
exposure in hamsters (6, 44), mice (7) and recently in humans (38). Thus, while short-
term increases in PM exposure affect pathways promoting arterial thrombosis, to 
trigger a risk of venous thrombosis a more chronic exposure to elevated levels of PM 
seems required, via pathways only understood in part, at the present time. This is 
corroborated by epidemiological findings in which the risk for DVT was only 
associated with the mean PM concentration over a one year period, and not with any 
shorter time-point (10). Likewise, shortenings in PT were only observed for increases 
in mean PM concentration of 1 month or more (13, 14).  
 
Surprisingly few experimental animal studies have hitherto been published on the 
association between air pollution and secondary haemostasis activation. Mutlu et al. 
reported a pronounced prothrombotic phenotype in wild type, but not in IL-6 knock-
out mice, characterized by shortenings in bleeding time, PT and aPTT, and relatively 
high increases in the levels of circulating blood platelets, FVII, FVIII, FX and 
fibrinogen, 24 hours after IT instillation of 10 µg of UPM, a dose 2.5 to 20 times 
smaller than in the present study (29). Surprisingly, the pulmonary WBC influx in 
their study almost completely consisted of macrophages, in contrast to the 
predominant neutrophil influx in our study and many others (7, 45-48). This 
remarkable difference in pulmonary WBC influx, possibly due to the type of particles 
used, may explain why the study by Mutlu et al. stands out among other studies on the 
procoagulant effects of PM in mice. Indeed, a few other experimental studies in 
rodents observed procoagulant changes in levels of fibrinogen, activated protein C, 
tissue factor pathway inhibitor (TFPI) or PAI-1, but only at doses of 100 µg or higher 
of PM per mouse (26, 27). In addition, exposure of rats to concentrated PM from New 
York City air did not alter levels of fibrinogen, FVII, PAI-1 or thrombin-antithrombin 
complexes (TAT) (28).  
 
Despite the high similarity of haemostasis between humans and mice, differences do 
exist (49). We therefore can not exclude that the modest effects observed on 
secondary haemostasis in the present work are linked to the use of a mouse model, 
which, indeed, seems less responsive to DEP than hamsters (6, 44).  
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In conclusion, UPM induced more pronounced pulmonary inflammation than DEP in 
healthy mice, likely attributable to a higher endotoxin content, but triggered weak 
systemic inflammation and mild secondary haemostatic activation only, even at high 
exposure. We therefore doubt that acute exposure studies in healthy mice will clarify 
the association in man between PM exposure and the risk of venous thrombosis. 
Chronic exposure studies in healthy and cardiovascular compromised mice, in 
conjunction with observational studies in cohorts of risk patients, are more likely to 
provide understanding of the relationship between long-term exposure to pollutant 
PM, systemic inflammation and secondary haemostasis.  
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Data supplement 
 
Materials and methods: 
The composition of the UPM used in the main article is given in Table S1.  
Measurement of circulating blood cells (Table S2 and Fig. S1) and quantitative 
cytokine analysis using multiplex bead assay (Table S2 and Fig. S2) after single or 
repeated instillations of UPM or DEP were performed as specified in the main article. 
In preliminary experiments, we aimed to investigate the contributing role of 
endotoxin (lipopolysaccharide, LPS) to PM-induced lung inflammation (Table E3). 
To this end, 8- tot 10-week old male C57Bl6/n mice were exposed via a single IT 
instillation to LPS alone (3 ng/mouse, Sigma-Aldrich, Bornem, Belgium), DEP alone 
(25 µg/mouse, National Institute for Standards and Technology, Gaithersburg, USA, 
SRM 1650b), a combination of LPS and DEP (3 ng/mouse and 25 µg/mouse, 
respectively) or UPM alone (25 µg/mouse, Mexico City, Mexico, as specified in the 
main article) resuspended in vehicle (NaCl 0.9%, containing 0.1% Tween 80). 
Controls consisted of vehicle-treated mice and sham mice. The dose of LPS (3 
ng/mouse) was chosen to be comparative to the amount of LPS present in 25 
µg/mouse of UPM. Based on the manufacturer’s information (endotoxin content of 
LPS: 500,000 EU/mg), a dose of LPS of 3 ng/mouse corresponds to 1.5 EU/mouse. 
Based on the endotoxin content of the UPM (138.4 EU/mg), a dose of UPM of 25 
µg/mouse corresponds to 3.5 EU/mouse. DEP used in this preliminary experiment 
were different from the DEP used in the main article, and results are, therefore, not 
strictly comparable. However, as for the DEP used in the main article, LPS content of 
these DEP also was below the detection limit of 0.05 EU/mg of PM.  
 
At 24 hours post-instillation, BALF was obtained as specified in the main article. 
BALF of 5 mice per experimental group was pooled for semi-quantitative analysis of 
the cytokine profile using the Proteome Profiler, Mouse Cytokine Array kit (R&D 
systems Inc, Minneapolis, USA). The obtained autoradiographs were scanned and 
analyzed using the ImageJ program (National Institute of Health, Bethesda, USA). 
The relative density of each dot was calculated in relation to the positive internal 
controls of the membranes and semi-quantitatively subcategorized. 
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Results: 
Table S1: Elemental composition and lipopolysaccharide (LPS) content of UPM (1)  
Elements  Si Ca Al Fe K S Ti Cl 
  µg/mg of PM 69 25 23 12 4 4 1.8 1 
  P Zn Mn Cr Cu Pb V Ni 
 µg/mg of PM 1 1 0.4 0.1 0.1 0.1 0.1 <0.1 
LPS EU/mg* 138.4       
* EU: endotoxin units       
 
Table S2: Dose-response values for blood cells and serum cytokines 
 vehicle  UPM 25 µg UPM 100 µg UPM 200 µg correl. coeff. r 
p for 
trend 
total WBC  
(103/µL) 
4.75 (3.73-5.60) 
(17) 
 3.34 (2.74-3.73) 
(11) 
3.04 (2.32-3.92) 
(11) 
3.94 (3.57-5.40) 
(11) 
-0.150 0.2978 
neutrophils  
(103/µL) 
1.05 (0.83-1.61) 
(17) 
 0.89 (0.63-1.05) 
(11) 
0.54 (0.48-0.90) 
(11) 
0.76 (0.59-0.91) 
(11) 
-0.393 0.0047 
monocytes  
(103/µL) 
0.04 (0.02-0.11) 
(17) 
 0.09 (0.04-0.14) 
(11) 
0.05 (0.03-0.07) 
(11) 
0.05 (0.03-0.06) 
(11) 
-0.005 0.9715 
lymphocytes  
(103/µL) 
3.27 (2.31-4.54) 
(17) 
 2.08 (1.40-2.67) 
(11) 
2.37 (1.47-2.55) 
(11) 
3.11 (2.65-3.65) 
(11) 
-0.0989 0.4945 
BP 
(103/µL) 
1205 (1113-1280) 
(17) 
 1225 (1135-1305) 
(11) 
1130 (1095-1360) 
(11) 
1305 (1225-1455) 
(11) 
0.2110 0.1414 
IL-6  
(pg/mL) 
5.0 (4.0-6.7) 
(9) 
 7.7 (4.2-10.5) 
(5) 
5.9 (3.7-7.7) 
(5) 
5.7 (3.7-6.6) 
(5) 
0.0353 0.8698 
KC  
(pg/mL) 
6.1 (5.6-7.4) 
(9) 
 12.1 (4.0-21.6) 
(5) 
11.2 (6.1-11.9) 
(5) 
8.5 (7.3-10.7) 
(5) 
0.328 0.8698 
MIP-1α   
(pg/mL) 
3.0 (1.8-4.0) 
(9) 
 2.8 (2.4-15.5) 
 (5) 
2.4 (1.8-3.9) 
(5) 
2.6 (2.2-3.0) 
(5) 
-0.173 0.4186 
MCP-1  
(pg/mL) 
25.6 (23.4-28.7) 
(9) 
 25.2 (22.4-60.2) 
(5) 
25.0 (14.5-32.1) 
(5) 
28.3 (10.4-34.2) 
(5) 
-0.049 0.8221 
RANTES  
(pg/mL) 
64.8 (48.7-117.3) 
(9) 
 141.8 (122.1-154.7) 
(5) 
166.8 (75.2-178.8) 
(5) 
104.3 (87.0-156.9) 
(5) 
0.391 0.0592 
        
   UPM 25 µg UPM 100 µg UPM 200 µg correl. coeff. r 
p for 
trend 
total WBC  
(103/µL) 
  3.30 (1.27-4.67) 
(7) 
3.27 (3.06-4.09) 
(8) 
4.14 (2.55-4.81) 
(9) 
-0.300 0.0541 
neutrophils  
(103/µL) 
  1.91 (1.60-2.30) 
(7) 
1.08 (0.96-1.65) 
(8) 
1.57 (1.22-1.77) 
(9) 
0.261 0.0996 
monocytes  
(103/µL) 
  0.11 (0.03-0.15) 
(7) 
0.05 (0.02-0.07) 
(8) 
0.02 (0.01-0.07) 
(9) 
-0.159 0.3260 
lymphocytes  
(103/µL) 
  2.92 (0.61-4.39) 
(7) 
3.06 (2.90-3.79) 
(8) 
3.64 (2.34-4.55) 
(9) 
-0.0112 0.9448 
BP 
(103/µL) 
  1355 (1220-1385) 
(7) 
1161 (1125-1350) 
(8) 
1315 (1270-1405) 
(9) 
0.0758 0.6378 
IL-6  
(pg/mL) 
  4.3 (3.7-16.1) 
(7) 
3.7 (3.2-5.1) 
(6) 
6.3 (4.7-6.7) 
(7) 
-0.0038 0.9843 
KC  
(pg/mL) 
  7.4 (5.7-9.9) 
(7) 
6.3 (5.0-9.8) 
(6) 
9.9 (6.3-10.5) 
(7) 
0.243 0.2035 
MIP-1α   
(pg/mL) 
  3.1 (2.6-4.2) 
(7) 
3.4 (2.5-5.0) 
(6) 
3.3 (2.7-4.1) 
(7) 
0.151 0.4357 
MCP-1  
(pg/mL) 
  27.8 (20.1-42.5) 
(7) 
29.9 (25.8-33.7) 
(6) 
27.8 (24.7-43.9) 
(7) 
0.210 0.274 
RANTES  
(pg/mL) 
  58.6 (46.1-70.6) 
(7) 
66.8 (52.3-73.5) 
(6) 
61.9 (47.9-67.8) 
(7) 
-0.100 0.6060 
Data are expressed as median (interquartile range) (n). 
Significant p for trend values are highlighted in bold. 
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Table S2 shows that UPM and DEP hardly induce any changes in blood inflammatory 
cells and circulating cytokines, despite important changes in BALF (see main article). 
The only remarkable finding is the drop in circulating neutrophils, which possibly 
migrate to the lung, upon UPM exposure. 
 
 
Figure S1: Circulating WBC and blood platelet numbers.  
WBC and blood platelets were measured in blood at 4, 10 and 24 hours after a single instillation (1 
instill.), and at 24 hours after 3 repeated instillations (3 instill.) of vehicle (white bars, left), UPM100mg 
(light grey bars, middle) or DEP100µg (dark grey bars, right). A: total WBC count. B: neutrophil count. 
C: lymphocyte count. D: monocyte count. E: blood platelet count. Values are represented as 
median+interquartile range (n≥5 for each group). °:<0.05 UPM vs DEP.  
No relevant significant changes in cell numbers occurred.  
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Figure S2: Inflammatory cytokines in serum.  
KC, MIP-1a, MCP-1 and RANTES were measured in blood at 4, 10 and 24 hours after a single 
instillation (1 instill.), and at 24 hours after 3 repeated instillations (3 instill.) of vehicle (white bars, 
left), UPM100µg (light grey bars, middle) or DEP100µg (dark grey bars, right). A: KC. B: MIP-1a. C: 
MCP-1. D: RANTES. Values are represented as median+interquartile range (n≥5 for each group). 
*:<0.05 UPM or DEP vs vehicle. No relevant significant changes occurred in cytokine levels.  
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Table S3: Cytokine profile in broncho-alveolar lavage fluid 
Cytokine concentrations in sham mice and in mice exposed to vehicle, UPM alone, DEP alone, LPS 
alone or the combination of DEP and LPS (n=5 per group) are expressed as a semi-quantitative fold-
increase, relative to an internal positive control on each analytical membrane. The cytokine profile in 
mice exposed to the combination of DEP and LPS is highly similar to the profile in mice exposed to 
UPM alone. 
 
 
 
Supplemental reference 
 
1. Segura-Garcia. Dano oxidante en celulas epiteliales de pulmon humano (A549), inducido por 
aeroparticulas contaminantes (PM10) de la ciudad de Mexico. Tesis de licenciatura, Universidad 
Nacional Autonoma de Mexico. Mexico 2008. 
	  
  
Sham NaCl DEP LPS LPS +DEP UPM    
BLC                
C5a                
G-CSF                
GM-CSF               
I-309               
relative  
concentration:  
Eotaxin               >80 
sICAM-1               40-80 
IFN-y               20-40 
IL-1a               5-20 
IL-1b               <5 
IL-1ra                 
IL-2                 
IL-3                 
IL-4                 
IL-5                 
IL-6                 
IL-7                 
IL-10                 
IL-13                 
IL-12 p70                 
IL-16                 
IL-17                 
IL-23                 
IL-27                 
IP-10                 
I-TAC                 
KC                 
M-CSF                 
JE                 
MCP-5                 
MIG                 
MIP-1a                 
MIP-1b                 
MIP-2                 
RANTES                 
SDF-1                 
TARC                 
TIMP-1                 
TNF-a                 
TREM-1                 
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Abstract 
Background: Epidemiological studies suggest an association between exposure to 
particulate matter (PM) in air pollution and risk of venous thromboembolism (VTE).  
Objectives: To investigate the underlying pathophysiological pathways linking PM 
exposure and VTE. 
Methods: We assessed potential associations between PM exposure and coagulation 
and inflammation parameters, including circulating microvesicles, in a group of 233 
patients with diabetes. 
Results: The numbers of circulating blood platelet-derived and annexin V-binding 
microvesicles were inversely associated with the current levels of PM2.5 or PM10, 
measured on the day of sampling. Recent past exposure to PM10, up to 1 week prior to 
blood sampling, estimated at the patients' residential addresses, was associated with 
elevated high-sensitivity C-reactive protein (CRP), leukocytes and fibrinogen, as well 
as with tissue factor-dependent procoagulant changes in thrombin generation assays. 
When longer windows of past exposure were considered, up to 1 year preceding 
blood sampling, procoagulant changes were evident from the strongly increased 
numbers of red blood cell-derived circulating microvesicles and annexin V-binding 
microvesicles, but they no longer associated with tissue factor. Past PM exposure was 
never associated with activated partial thromboplastin time (aPTT), prothrombin time 
(PT), or factor (F) VII, FVIII, FXII or D-dimers. Residential distance to a major road 
was only marginally correlated with procoagulant changes in FVIII and thrombin 
generation. 
Conclusions: Increases in the number of microvesicles and in their procoagulant 
properties, rather than increases in coagulation factors per se, seem to contribute to 
the risk of VTE, developing during prolonged exposure to air pollutants. 
Chapter 2 
	  
58 
Introduction 
Ambient environmental air pollutants include gaseous and particulate components. 
Considering a large body of evidence, the American Heart Association scientific 
statement on 'Air Pollution and Cardiovascular Disease' concluded that both short-
term and long-term exposure to the particulate component (particulate matter, PM) 
are associated with increased mortality and cardiovascular disease (1). In addition to 
the well-recognized air pollution-related adverse effects on the arterial vascular 
system (2-8), recent epidemiological evidence also suggests an association between 
PM exposure and venous thromboembolism (VTE). Thus, a higher risk for deep vein 
thrombosis (DVT) was associated with increased annual mean levels of PM with a 
mean aerodynamic diameter smaller than 10 µm (PM10) in the residential area of the 
study subjects (9). In the same study population, living near major traffic roads was 
also associated with an increased risk of DVT, even after controlling for the 
community-level PM pollution (10). These initial epidemiological findings by the 
group of Baccarelli were recently confirmed in a time-series analysis in Chile, 
demonstrating an association between PM exposure and hospital admission for VTE 
(11), although also challenged by others (12, 13). 
 
The pathophysiological mechanisms explaining the observed link between PM 
exposure and VTE remain largely unknown. Although increases in the levels of 
coagulation factors seem the most likely explanation, published data for this 
interpretation are conflicting and unconvincing. In fact, disappointingly few studies 
reported on positive associations between air pollution exposure and increased levels 
of coagulation factors, and estimated effect sizes for the reported associations are 
relatively small (14-23). Therefore, the observed increases in coagulation factors are 
unlikely to be (solely) responsible for an increased venous thrombogenicity.  
 
A potential role for microvesicles (also called microparticles, a term we prefer to 
avoid in the context of pollution by particles) has been suggested (14, 24, 25). 
Microvesicles are circulating vesicles with a mean diameter smaller than 1 µm that 
are released from stimulated or apoptotic cells in the vascular bed. Negatively charged 
phospholipids and tissue factor (TF) on their membranes create a procoagulant 
surface on which coagulation factors can bind and be activated to promote 
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coagulation (26). Elevated numbers of circulating microvesicles have been 
demonstrated in patients with VTE (27, 28). A direct link between air pollution and 
an elevation in the concentration of circulating microvesicles or their procoagulant 
potential has hitherto never been shown in humans. 
 
In the present study, we hypothesized that microvesicles, through their procoagulant 
potential, could represent a missing link between air pollution exposure and VTE. 
We, therefore, investigated associations between PM exposure and markers of 
inflammation and coagulation, with a focus on microvesicles and microvesicle-
dependent coagulation assays. We investigated these associations in an a priori 
susceptible population of patients with diabetes, because diabetic subjects are more 
sensitive to the deleterious effects of PM during air pollution (29). 
 
Materials and methods 
Study population 
Persons with either type 1 or type 2 diabetes were recruited from the diabetes 
outpatient clinic at the University Hospital Leuven, Belgium, as a new cohort of 
patients, different from the cohort of our previous studies (30, 31). These patients visit 
the diabetes clinic as part of their routine follow-up. They were included if they were 
18 years or older, current (for >6 months) non-smokers and not on anticoagulant 
therapy. Inclusion was done on different days from February 2010 through April 
2010. Of 402 patients contacted, 339 agreed to participate (84% participation rate). 
We excluded 106 patients because of current smoking (n=74), anticoagulant therapy 
(n=16), accidental lack of blood samples (n=10) or other reasons (n=6). Thus, the 
final study population consisted of 233 included patients (Fig. 1). On the study day, 
patients completed a questionnaire through a personal interview to collect information 
on age, occupation, socioeconomic status, exposure to environmental tobacco smoke, 
alcohol use, use of medication, use of oral contraception, menopausal status, place of 
residence and means of transportation to the hospital. Socioeconomic status was 
encoded and condensed into a scale with scores ranging from 1 to 3, based on 
educational level. The Ethics Review Board of the Medical Faculty of the University 
of Leuven (KULeuven) approved the study. Participants gave informed consent at 
recruitment.  
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Figure 1. Flowchart of the study population 
The study population was consecutively recruited from the diabetes outpatient clinic at the University 
Hospital Leuven. The lower right box shows the percentage of samples that were measured per group 
of analyses. HbA1c=glycated hemoglobin, FACS= flow cytometric analysis, WBC=white blood cells 
in blood. 
 
 
Exposure assessment 
Current exposure 
A portable laser-operated aerosol mass analyzer (Aerocet 531, Met One Instruments 
Inc, Grant Pass, OR, USA), previously calibrated against a local monitoring station 
(Flemish Environmental Agency, Borgerhout, Belgium) (31), was used to measure 
current PM2.5 and PM10 concentrations in the hospital waiting room, one to two hours 
before the patient’s participation in the study. In general, patients stayed in the 
waiting room and the neighboring examination room for at least one hour.  
 
Subacute, subchronic and chronic exposure 
The regional background level of PM10 at each patient's residential address was 
calculated using a kriging interpolation method. This model provides interpolated 
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PM10 values from the Belgian telemetric air quality network in 4x4 km grids (see Fig. 
2). The interpolation is based on a detrended kriging interpolation model that uses 
land cover data obtained from satellite images (Corine land cover data set, European 
Environment Agency, 2000) (32). Regional background levels of PM2.5 are not 
available in Belgium. Mean residential PM10 values were measured for different time 
windows, and classified in 3 categories of exposure: 1) subacute: mean residential 
PM10 values on the day of blood sampling ('day 0'), on the first ('day -1'), the second 
('day -2') or the third ('day-3') day before blood sampling; 2) subchronic: mean 
residential PM10 values over the preceding week ('mean 1 week') or month ('mean 1 
month'); 3) chronic: mean residential PM10 values over the preceding 3 months ('mean 
3 months'), 6 months ('mean 6 months') or 12 months ('mean 1 year'). Distances from 
the home address to major roads (N-road, a major traffic road or E-road, a 
motorway/highway) also reflect chronic PM exposure and were calculated through 
geocoding (the shortest distance being set at 10 meters). 
 
Figure 2. Location of residences of study subjects 
Map of Belgium reporting location of the study center (University hospital, Leuven, Belgium) and 
location of the residences of the study subjects. Background colors represent mean annual PM10 
concentrations for 2010 in 4x4 km grids 
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Clinical measurements 
All laboratory tests were performed without knowledge of the subject's exposure data. 
A detailed description and validation of the assays used in this study to identify and 
characterize microvesicles is given in the online data supplement. Figure S1 
schematically summarizes the physiological role of microvesicles in the coagulation 
cascade and illustrates which assays were performed in this study to evaluate 
microvesicles. In brief, microvesicle quantification was performed by flow cytometry 
(see below). To evaluate their procoagulant potential, surface expression of negatively 
charged phospholipids was evaluated by flow cytometry and surface expression of 
functional tissue factor by thrombin generation assays (TGA, see below). 
 
Blood  
All blood samples were collected in a restricted time window in the diabetes 
outpatient clinic (median hour of sampling: 01.50 p.m.), thus reducing the possibility 
of confounding by circadian rhythms of some parameters. Non-fasting blood samples 
were collected using a 21 gauge needle (Terumo, Leuven, Belgium) on EDTA, on 
sodium fluoride/oxalate, or on sodium citrate (3.8%) tubes (all BD Vacutainer, BD 
Biosciences, Erembodegem, Belgium). Analysis of blood cell counts and glucose and 
glycated hemoglobin (HbA1c) levels were performed on fresh full blood or plasma 
samples. For all other parameters, plasma was stored immediately at -80°C for future 
batch analysis. Citrated samples were centrifuged according to two different 
protocols: for biochemical analyses, tubes were centrifuged once at 3000 x g. For the 
analysis of microvesicles, both by flow cytometry and by TGA, tubes were first 
centrifuged for 10 minutes at 1900 x g, followed by a second centrifugation step of 20 
minutes at 1900 x g to obtain blood platelet-depleted but microvesicle-rich plasma. 
All plasma samples were centrifuged within one hour after collection. 
 
Blood cell counts and routine biochemical analysis 
Blood cell counts, coagulation parameters, glucose levels, glycated hemoglobin 
(HbA1c) and high-sensitivity CRP (hsCRP) were measured according to standard 
clinical procedures on automated analyzers. The following "traditional" coagulation 
parameters were measured: activated partial thromboplastin time (aPTT), prothrombin 
time (PT), factor (F) VII, FVIII, FXII, fibrinogen and D-dimers.  
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Thrombin generation assays (TGA) 
Thrombin generation was measured by means of the Calibrated Automated 
Thrombography (CAT) method using a Fluoroskan Ascent reader (Thermo 
Labsystems OY, Helsinki, Finland). Thrombinoscope software (Thrombinoscope BV, 
Maastricht, The Netherlands) was used to calculate thrombin generation curves, from 
which four parameters were derived: lag time (initiation phase of coagulation), 
endogenous thrombin potential (ETP, area under the thrombin generation curve), peak 
height (maximal reaction) and time to peak (33). In this study, only the lag time and 
the ETP are reported as representative parameters. To 80 µL of plasma sample, 20 µL 
of trigger reagent (see below) were added and thrombin generation recording was 
started upon subsequent addition of 20 µL FluCa, a mixture of calcium chloride ('Ca', 
87 mM) and thrombin substrate (Z-Gly-Gly-Arg-AMC, 2.5 mM , Bachem, Weil-am-
Rein, Germany). Three different analytical conditions were applied:  
First, a contact activator ('S', Synthasil, Instrumentation Laboratory, Zaventem, 
Belgium, final concentration 1/400) was added to trigger the intrinsic coagulation 
pathway, and 'lag time(Ca,S)' and 'ETP(Ca,S)' were recorded.   
Second, tissue factor ('TF', Innovin, Siemens, Hamburg, Germany, final concentration 
5 pM) was added to trigger primarily the extrinsic coagulation pathway and 'lag 
time(TF)' and 'ETP(TF)' were recorded. 
Third, thrombin generation was performed upon simple recalcification of 
microvesicle-rich plasma in the absence of an exogenous trigger, to investigate the 
effect of endogenous coagulation triggers in the plasma sample, including 
microvesicle-bound factors such as TF, and 'lag time(Ca)' and 'ETP(Ca)' were 
recorded. 
In TGA, especially the lag time is to a large extent determined by the amount of TF 
present in the assay (34). Hence, to functionally asses the endogenous TF in the 
plasma sample, we additionally measured 'lag time(Ca)' in the presence of 300 ng/mL 
(final concentration) tissue factor pathway inhibitor (TFPI, R&D Systems, Abingdon, 
UK). This enabled us to specifically investigate the TF-dependency of associations 
with air pollution exposure, as explained in detail in the data supplement. 
All TGA's were performed in the presence of an excess (4 µM) of exogenous 
phospholipids (phosphatidylserine 30% and phosphatidylcholine 70%, Sigma-
Aldrich, Bornem, Belgium), making thrombin generation independent of the surface 
expression on microvesicles of negatively charged phospholipids.  
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Microvesicle analysis by flow cytometry 
Microvesicles were analyzed by flow cytometry following a protocol, standardized by 
the Scientific and Standardization Subcommittee (SSC) of the International Society 
on Thrombosis and Haemostasis (ISTH)(35) with some adaptations. In brief, to 
thawed microvesicle-rich plasma, fluorescein isothiocyanate-labeled mouse anti-
CD42a (BD Biosciences, Erembodegem, Belgium), phycoerythrin-labeled mouse 
anti-glycophorin A (GPA, BD Biosciences, Erembodegem, Belgium) and 
allophycocyanin-labeled annexin V (AV, Immunotools, Friesoythe, Germany) were 
added and samples were analyzed on a FACSCantoII flow cytometer (BD 
Biosciences, Erembodegem, Belgium) to define blood platelet-derived microvesicles 
('BPµV', CD42a+), red blood cell-derived microvesicles ('RBCµV', GPA+) and 
microvesicles with a procoagulant, negatively charged phospholipid surface, binding 
annexin V ('AV+µV'). A detailed description of our microvesicle analysis by flow 
cytometry is provided in the data supplement. 
 
Tissue factor mRNA in circulating white blood cells 
TF mRNA expression measurement was performed by quantitative real-time PCR on 
the AB 7500 Fast PCR System (Applied Biosystems, Ottignies-Louvain-la-Neuve, 
Belgium) as described in the data supplement. 
 
Statistical analysis 
For database management and statistical analysis, we used SAS Software (version 
9.1, SAS Institute Inc, Cary, NC). Non-normally distributed data were log 
transformed. We investigated associations between plasma markers and recent or 
chronic exposure parameters using multiple linear regression. In all regression models 
we included the following a priori chosen covariates: gender, age, body-mass index, 
socioeconomic status, type of diabetes, physical activity, blood glucose levels, use of 
insulin, use of statins, use of antiplatelet medication and temperature and humidity on 
the day of blood sampling. Potential interactions of type of diabetes, use of statins and 
use of antiplatelet medication with the association between air pollution and all 
measured parameters were investigated. Q-Q plots of the residuals were used to test 
the assumptions of all linear models. 
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Results 
Characteristics of the study population 
Characteristics of study participants are 
shown in table 1. Of the men, 34 (32%) 
had type 1 diabetes compared to 57 (45%) 
for the women. All patients with type 1 
diabetes used insulin; among type 2 
diabetics, 126 persons (89%) used insulin 
medication. Mean values ±SD for HbA1c 
were 7.8±1.1% for type 1 diabetics and 
7.2±1.2% for type 2 diabetics. Exposure 
characteristics are shown in table 2.  
A representation of the location of the 
patients' residences and of the study center 
is shown in Fig. 2. 
 
Clinical measurements 
The value distribution of clinical 
parameters for the study population is 
shown in table S1 (data supplement). With 
the exception of FVIII, mean values for the population were within the normal 
reference ranges. Figure 3 shows the associations (adjusted for the aforementioned 
covariates) between air pollution exposure and all outcome parameters, as determined 
by the regression analysis for different time windows. The corresponding effect sizes 
for selected time windows are shown in figures 4 to 6. A stratified analysis for type of 
diabetes, statin use or antiplatelet use is shown in supplementary figures S5-7 (data 
supplement). 
 
Inflammation parameters and blood cells 
Significant positive correlations were observed between PM10 exposure at the 
patient's residence and hsCRP and WBC concentrations for PM10 exposure windows 
within 1 week (Fig. 3), with positive but only borderline significant values 
(0.05<p<0.10) for the longer time windows up to 6 months. Each 10 µg/m3 increase 
Table 1: Population characteristics 
(n=233)  Mean (SD) or 
number (%) 
Gender, men 107 (46%) 
Age, years 57.9 (17.5) 
BMI, kg/m² 28.9 (5.5) 
Type 1 diabetes 91 (39%) 
Exposure to environmental 
tobacco smoke 
34 (15%) 
Socioeconomic status  
      Low 158 (68%) 
      Middle 55 (23.5%) 
      High 17 (7.5%) 
Unknown 3 (1%) 
Antiplatelet medicationa 140 (60%) 
Statin 154 (66%) 
ACE inhibitor 129 (55%) 
Insulin 217 (93%) 
Oral antidiabetic medication 106 (46%) 
Blood glucose, mg/dL 139.2 (63.4)b,c,d 
Glycated hemoglobin, % 7.5 (1.2)e,f 
aAntiplatelet medication includes acetylsalicylic 
acid,   clopidogrel, ticlopidine or dipyridamole 
bNon-fasting values 
cData are available for 224 persons 
dReference values (fasting): 55-100 mg/dL 
eData are available for 229 persons 
fReference values: 4.0-6.0 % 
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in the mean PM10 concentration over the preceding week at the patient's residence 
increased  
the hsCRP by 23% (95%CI: 5-45) and the WBC by 7% (95%CI: 2-12) (Fig. 5A). 
 
"Traditional" coagulation parameters 
Current PM10 exposure correlated with a prolongation of the PT (Fig. 3). No 
significant correlations were found between either current, subacute, subchronic or 
chronic PM exposure and measurements of aPTT, FVII, FVIII, FXII or D-dimers 
(Fig. 3). Concentrations of fibrinogen correlated positively with PM10 at 'day-2' and 
'day-3', as well as with the mean PM10 concentration over 1 week (Fig. 3). Each 10 
µg/m3 increase in the mean concentration of PM10 over the preceding week at the 
patient's residence elevated fibrinogen levels by 4% (95%CI: 1-7) (Fig. 5A).  Each 
halving in residential distance to a major road increased FVIII by 2% (95%CI: 1-3) 
(Fig. 6).  
 
Thrombin generation 
In contrast to the paucity of relationships between PM exposure and the above 
mentioned hemostasis parameters, we found strong significant correlations with 
various parameters of thrombin generation over many different time windows of 
exposure (Fig. 3).  
 
Table 2: Exposure characteristics of included subjects (n=233). 
Type of exposure mean median range P10-P90 IQR 
Current indoor PM2.5, µg/m3 4.6 4.3 1.4-7.6 2.4-7.2 2.6 
Current indoor PM10, µg/m3 22.1 21.3 12.0-39.4 15.0-30.8 5.6 
Residential PM10, µg/m3      
   day 0 25.7 26.3 7.3-52.8 10.7-36.2 11.4 
   day -1 27.6 28.0 7.2-55.7 13.0-40.9 11.5 
   day -2 28.0 27.4 9.9-85.8 14.2-42.5 11.4 
   day -3 28.3 26.5 7.7-72.6 13.1-47.5 16.2 
   mean 1 week 25.2 25.8 11.8-44.4 14.2-37.8 16.5 
   mean 1 month 26.3 25.5 11.6-43.0 19.9-34.3 8.5 
   mean 3 months 25.9 25.7 15.0-38.3 22.9-29.2 3.08 
   mean 6 months 22.8 22.6 13.3-34.6 20.4-25.5 2.7 
   mean 1 year 22.1 21.7 12.5-33.7 19.3-25.07 2.7 
      
Residential distance to major road, m 689 410 10-5191 10-1767 755 
IQR: interquartile range, P10: percentile 10, P90: percentile 90. 
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Figure 3. Representation of significant associations between air pollution exposure and outcome 
parameters 
Regression analysis was performed to determine the associations between outcome parameters and 
current PM2.5 and PM10 concentrations measured in the diabetes outpatient clinic's waiting room, 
residential PM10 concentrations over different time windows preceding blood sampling (as indicated) 
or residential distance to a major road (N- or E-road). For significant associations, positive and 
negative slopes are denoted as '+' or '-' respectively. Significant associations that represent increases in 
inflammatory parameters or blood cells, or procoagulant changes, are highlighted in green striped 
(p<0.05) or green plain (p<0.005) boxes. Significant associations that represent decreases in 
inflammatory parameters or blood cells, or anticoagulant changes, are highlighted in red striped 
(p<0.05) or red plain (p<0.005) boxes.  
 
The strongest correlations were found for the lag time during thrombin generation 
with a contact activator ['lag time(Ca,S)'] and for both the lag time and ETP after 
simple recalcification of microvesicle-rich plasma, in the presence of standardized 
phospholipid concentrations ['lag time(Ca)' and 'ETP(Ca)']. These significant 
correlations were consistent for the subacute and subchronic time windows, with the 
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highest effect sizes measured for the mean PM10 concentration over 1 month: each 10 
µg/m3 increase in PM10 shortened the 'lag time(Ca,S)' by 6% (95%CI: 0-12, p=0.08), 
the 'lag time(Ca)' by 14% (95%CI: 4-25) and increased the 'ETP(Ca)' by 14% 
(95%CI: 5-24). Interestingly, upon the addition of a specific tissue factor inhibitor 
(TFPI) to the assay, the positive associations between PM10 and 'lag time(Ca)' 
disappeared for the subacute windows, but not for the subchronic time windows (Fig. 
3). Each halving in residential distance to a major road increased the 'ETP(Ca)' by 2% 
(95%CI: 0-4) (Fig. 6) 
 
Figure 4. Effect sizes for significant associations with current PM2.5 and PM10 concentrations  
Effect sizes (%, 95%CI) were calculated (A) for each 10 µg/m3 increase in current PM2.5 and PM10 
concentrations, measured in the diabetes outpatient clinic's waiting room in the hours preceding the 
blood sampling. Those parameters were selected that showed significant correlations in figure 3. 
hsCRP=high sensitivity CRP. WBC=white blood cells, RBC=red blood cells, BP=blood platelets, 
ETP=endogenous thrombin potential, BPµV=BP-derived microvesicles, RBCµV=RBC-derived 
microvesicles, AV+µV=annexin-V binding microvesicles. Analysis adjusted for covariates. 
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Figure 5. Effect sizes for significant associations with residential PM10 concentrations at different 
time windows before blood sampling 
Effect sizes (%, 95%CI) were calculated for each 10 µg/m3 increase in residential mean PM10 
concentrations measured over (A) 1 week, (B) 1 month or (C) 1 year preceding the blood sampling. 
Those parameters were selected that showed significant correlations in figure 3. hsCRP=high 
sensitivity CRP. WBC=white blood cells, RBC=red blood cells, BP=blood platelets, ETP=endogenous 
thrombin potential, BPµV=BP-derived microvesicles, RBCµV=RBC-derived microvesicles, 
AV+µV=annexin-V binding microvesicles. Analysis adjusted for covariates. 
Chapter 2 
	  
70 
Microvesicle analysis 
The concentrations of current PM2.5 correlated negatively with the concentrations of 
BPµV (-57%, 95%CI: -78 to -16% per 10 µg/m3 increase in PM2.5) and of AV+µV 
that express negatively charged phospholipids on their surface (-74%, 95%CI: -85 to -
56% per 10 µg/m3 increase in PM2.5), while both current PM10 and residential PM10 
on 'day -3' correlated negatively with the concentration of AV+µV (-27%, 95%CI: -39 
to -12% per 10 µg/m3 increase in current PM10) (Fig. 3 and 4). In contrast, we found 
positive correlations between mean PM10 concentrations over the chronic exposure 
windows (preceding 3 months to 1 year) and the concentrations of RBCµV and 
AV+µV with the highest effect sizes measured for the 1-year period (+77% 95%CI: 
14-176 and +60% 95%CI: 15-123 per 10 µg/m3 increase in yearly PM10, respectively) 
(Fig. 5C). Similar borderline significant results were found for the BPµV. 
 
Figure 6. Effect sizes for significant associations with residential distance to a major road 
Effect sizes (%, 95%CI) were calculated for each halving in distance from the patient's residence to the 
nearest major road (N- or E-road). Those parameters were selected that showed significant correlations 
in figure 3. hsCRP=high sensitivity CRP. WBC=white blood cells, RBC=red blood cells, BP=blood 
platelets, ETP=endogenous thrombin potential, BPµV=BP-derived microvesicles, RBCµV=RBC-
derived microvesicles, AV+µV=annexin-V binding microvesicles. Analysis adjusted for covariates.  
 
 
TF mRNA in circulating WBC 
No significant correlations were observed between air pollution exposure and levels 
of TF mRNA expression in circulating white blood cells (Fig. 3). 
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Effect-modification 
Table 1 demonstrates, for our study population of people with diabetes, the frequent 
use of different types of medication, some of which (e.g. statins) have been described 
to influence levels of TF or microvesicles. Therefore, we investigated if type of 
diabetes, use of statin medication and use of antiplatelet medication induced effect-
modification on the association between PM exposure and outcome variables. Results 
are shown in figures S5-7 of the online data supplement. 
In general, stratification for type of diabetes (Fig. S5) or medication (Fig. S6-7) did 
not considerably influence the non-stratified associations described in figure 3. For 
patients with type 1 diabetes, increased current PM exposure was associated with 
decreases in inflammatory parameters (hsCRP, fibrinogen), in thrombin generation 
['ETP(Ca,S)' and 'ETP(Ca,TF)'] and microvesicles (BPµV, RBCµV, AV+µV) that 
were not, or to a lesser extent, observed in type 2 diabetics, who rather showed 
increases in inflammatory parameters (Fig. S5), compatible with the more 
inflammatory nature of this type of diabetes. Both statins (Fig. S6) and antiplatelet use 
(Fig. S7) tended to decrease the effect size of associations between chronic (1 week-1 
year) PM exposure and inflammatory (WBC, neutrophils) or procoagulant 
['ETP(Ca,S)' and 'ETP(Ca,TF)'] changes, as compared to patients not taking these 
medications.  
 
Discussion 
Parameters of inflammation, coagulation and microvesicles were correlated with 
measures of current (at blood sampling), subacute (day 0 to day -3), subchronic 
(mean 1 week to 1 month) and chronic (mean 3 months to 1 year) PM exposure and 
with residential distance to a major road, in patients with diabetes. Especially type 2 
diabetes is a chronic inflammatory disease and circulating microvesicles seem to be 
elevated in these patients (36, 37). It was, therefore, relevant to measure inflammation 
parameters and microvesicle numbers in patients with diabetes who manifest 
increased susceptibility to air pollution (29).  
 
Current PM levels were associated with lower numbers of circulating microvesicles 
and with decreased inflammatory parameters, mainly in patients with type 1 diabetes. 
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We even found an isolated prolongation of the PT with increased levels of current 
PM10, contrasting previous observations (14, 38). However, the lower number of 
circulating microvesicles should not necessarily be interpreted as an anti-
inflammatory response to short-term PM exposure but can be explained by the 
recruitment of circulating microvesicles to the lung via enhanced expression of 
adhesive receptors, including P-selectin (39, 40) and von Willebrand factor (41), by 
acutely activated pulmonary endothelial cells.  
 
In contrast to the current PM exposure, consistent proinflammatory and procoagulant 
changes were observed for the longer PM exposure windows. 
Subacute and subchronic exposure up to 1 week were associated with a systemic 
inflammatory status, evidenced by increased hsCRP, total WBC counts and neutrophil 
counts. In agreement with other studies (15, 42, 43), and compatible with its role as an 
acute phase protein, fibrinogen concentrations increased with higher PM exposure 
levels, within 1 week. We did not measure increases in FVIII, another acute phase 
protein, but the high mean baseline value for FVIII in a diabetic study population 
(table S1 and (44)), could hinder further increase by PM exposure. 
Yet, increased fibrinogen concentrations cannot explain the strong correlations 
observed here between different thrombin generation parameters and subacute and 
subchronic PM10 exposure up to 1 month, since TGA are not influenced by 
fibrin(ogen) levels. Likewise, in the absence of procoagulant changes in any of the 
other "traditional" coagulation parameters (PT, aPTT, FVII, FVIII, FXII, D-dimers), 
other processes should be responsible for enhancing thrombin generation with higher 
levels of PM exposure so consistently. 
 
A role for microvesicles, cellular bodies released from stimulated or apoptotic cells, 
in VTE has been suggested (27, 45). We assessed the procoagulant potential of 
microvesicles through measurement of their surface expression of TF in TGA, and 
through the analysis of the number of red blood cell and blood platelet-derived 
microvesicles via flow cytometry. In addition, flow cytometric analysis of annexin V-
binding was undertaken to measure the surface expression of negatively charged 
phospholipids (mainly phosphatidylserine) (26). Specifically the latter measurement 
has one drawback, i.e. that freezing-thawing affects the expression of negatively 
charged phospholipids (46, 47), and therefore may not provide an accurate index of 
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phosphatidylserine exposure in vivo. However, the consistency of the strong 
associations of the number of AV+µV with PM exposure over the different longer 
time windows indicates that these associations are unlikely to be artificially induced 
chance findings. 
 
Both subacute and subchronic PM exposure correlated strongly (p values <0.0001) 
with thrombin generation. The most pronounced correlations were found for TGA 
performed in the absence of an external trigger of coagulation ('lag time(Ca)' and 
'ETP(Ca)'), and may therefore depend on the presence of endogenous triggers present 
in the plasma, such as contact activation or microvesicle-bound TF, the concentration 
of the latter having a pronounced effect on the lag time (34). 
In the subacute time window, associations between PM10 and lag time disappeared 
both in the presence of an excess of exogenous TF ['lag time(Ca,TF)'] and upon 
inhibition of TF by TFPI ['lag time(Ca)+TFPI']. This points towards exposure-
associated increased levels of circulating TF, most likely on microvesicles (48). The 
source of TF-bearing microvesicles is a matter of debate, yet with activated 
monocytes being the most likely candidate (49). The remarkable conincidence in the 
subacute time window of associations of PM exosure with inflammatory parameters 
and with TF-dependent changes in TGA adds to the hypothesis of inflammation-
coagulation cross-talk in the first days following exposure to air pollution. In healthy 
individuals, microvesicles derived from blood platelets and red blood cells account 
for almost all circulating microvesicles. Since WBC-derived microvesicles are 
extremely low (50), we could not quantify these microvesicles via flow cytometry. 
 
In the subchronic time window, assocations between PM exposure and thrombin 
generation were no longer dependent on TF. Associations with lag times were also 
present upon exogenous TF addition ['lag time(Ca,TF)'] and did not disappear upon 
addition of TFPI. Moreover, procoagulant changes at 1 month occured in the absence 
of those inflammatory changes mentioned above. Therefore, the enhanced thrombin 
generation associated with PM concentrations over several weeks must be explained 
by (an) other mechanism(s). A recent study in mice suggests that PM promotes early 
procoagulant changes mostly through a TF-driven extrinsic pathway of coagulation, 
whereas long lasting procoagulant effects are predominantly mediated through contact 
activation of the intrinsic pathway of coagulation by systemically translocated ultra-
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fine particles (51). Yet, we found no associations between FXII and exposure to PM. 
An alternative explanation could be offered by downregulation of the anticoagulant 
pathways, including protein C and antithrombin, but these markers were not assessed 
in the present study. 
 
In the chronic PM exposure window, procoagulant changes were no longer obvious 
from thrombin generation measurements. Yet, a procoagulant tendency was apparent 
from the higher microvesicle numbers, both blood-platelet derived and red blood cell-
derived, and increased microvesicular annexin V binding, reflecting surface 
expression of negatively charged phospholipids (mainly phosphatidylserine) (26). 
TGA in the present study was performed in the presence of an excess of exogenous 
phospholipids, and is therefore insensitive to the effects by endogenous negatively 
charged phospholipids. We found the highest effect size on microvesicle number and 
procoagulant potential for the mean PM10 measurement over 1 year. Interestingly, in 
the study by Baccarelli et al. (9), a 1-year exposure time window correlated most 
strongly with the risk of DVT, while no significant correlations were found for time 
windows shorter than 9 months. Hence, upregulation of procoagulant microvesicles 
could, at least partly, be a pathophysiological mechanism underlying the association 
between long-term PM exposure and VTE (9, 27, 28).  
 
Living near a major road has been associated with increased risk for VTE in a case-
control study (10). A recent population-based prospective cohort study (13), also 
demonstrated an, admittedly, nonsignificant 16% increase in the risk of VTE for 
subjects living within 150 m of a major traffic road. In the present study, the 
correlations with residential distance to a major road were, although following 
similar trends, fewer and weaker than for the chronic residential PM10 measurements 
by the land-use interpolation model. This is further discussed in the online data 
supplement.  
 
Our study has limitations. First, association studies do not prove causality, and our 
observations can therefore only suggest that procoagulant changes, consisting of 
enhanced thrombin generation and higher numbers of procoagulant microvesicles, are 
induced by exposure to PM. Second, the “disappearance” of associations between 
subacute PM exposure and thrombin generation in the presence of TFPI in the assays 
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demonstrates a crucial role for circulating TF, which is not necessarily all 
microvesicle-bound. Indeed, TF in plasma is primarily located on microvesicles, but it 
can also circulate as an alternatively spliced soluble protein (48). Nevertheless, 
plasma depletion of microvesicles by filtration through a 0.1 µm filter significantly 
prolonged the lag time of thrombin generation assays in previous experiments in our 
laboratory (data not shown), suggesting that microvesicles are indeed the major 
source for TF. Third, a large number of statistical analyses was performed in this 
study, increasing the possibility of rejecting the null hypothesis too readily. However, 
correction for multiple testing is not always appropriate, as discussed in larger detail 
in the online data supplement. 
 
In conclusion, this study demonstrates for the first time that increases in the number 
and the procoagulant potential of microvesicles, rather than increases in coagulation 
factors per se, may contribute to the prothrombotic risk induced by air pollution 
exposure. 
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Data supplement 
 
Supplemental Methods and Results 
Distribution of clinical parameters 
Mean values and standard deviation of clinical parameters for the study population 
are shown in table S1, together with the reference ranges for the routine clinical 
parameters. 
Table S1: distribution of clinical parameters for the whole study 
population and reference ranges 
  mean SD reference range  
hsCRP (mg/L) 2.8 3.6 <5.0 
WBC (103/µL) 7.3 2.0 3.1-8.9 
neutro (103/µL) 4.6 1.5 0.5-5.9 
mono (103/µL) 0.6 0.2 0.3-0.7 
RBC (106/µL) 4.5 0.5 m: 4.5-6.0 
    f: 3.9-5.6 
BP (103/µL) 294 85 150-450 
     
PT (sec) 8.9 1.5 7.0-9.7 
aPTT (sec) 26.2 2.5 23.3-34.5 
Fbg (g/L) 3.4 0.8 0.9-3.8 
FVII (%) 113 30 70-130 
FVIII (%) 187 52 70-150 
FXII (%) 100 18 70-150 
D-dimers (mg/L) 0.470 0.481 0.000-0.490 
     
ETP(Ca,S) (nM.min) 1436 300  
lag time(Ca,S) (min) 8.7 2.2  
ETP(Ca,TF) (nM.min) 1525 346  
lag time(Ca,S) (min) 2.6 1.4  
ETP(Ca) (nM.min) 1387 325  
lag time(Ca) (min) 25.4 12.4  
lag time(Ca)+TFPI (min) 31.4 13.8  
     
BPµV (count) 2272 1604  
RBCµV (count) 597 1076  
AV+µV (count) 1614 949  
     
TF mRNA WBC (copies/106 copies GaPDH) 1458 15129  
m: male, f: female       
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Introduction to the analysis of microvesicles 
Figure S1 gives a schematic representation of the role of microvesicles in the 
physiology of intravascular coagulation and specifies the assays used in the present 
study to measure the microvesicles' procoagulant potential. The procoagulant 
potential of microvesicles (µV) relates to the surface expression of tissue factor (TF), 
the main coagulation trigger in vivo, and of negatively charged phospholipids (PL-), to 
which different activated coagulation factors bind in a Ca2+-dependent manner to 
support the coagulation cascade, resulting in the formation of a fibrin clot. The 
quantification of blood platelet-derived and red blood cell-derived microvesicles was 
performed by flow cytometry. The procoagulant potential of microvesicles was 
evaluated through measurement of their surface expression of tissue factor (TF) by 
thrombin generation assays (TGA) in a phospholipid-independent way, and through 
measurement of their surface expression of negatively charged phospholipids (mainly 
phosphatidylserine) by a TF-independent flow cytometric analysis of annexin V 
binding.  
 
Figure S1. Microvesicles' procoagulant potential 
The left side of the figure shows a simplified scheme of the coagulation cascade. The right side of the 
figures shows the different assays used in this study to measure the microvesicles' procoagulant 
potential. TF, present on the microvesicles' surface, largely determines 'lag time(Ca)', 'endogenous 
thrombin potential ETP(Ca)', and to a lesser extent 'lag time(Ca,S)' and 'ETP(Ca,S)'. It does not 
influence extrinsic parameters, due to the addition of exogenous TF in the assay. The presence of PL- 
on the microvesicles' surface is measured through the binding of annexin V (AV) in a flow cytometric 
assay. These PL- do not influence TGA's since an excess (4 µM) of exogenous PL- is added in these 
assays. TFPI=tissue factor pathway inhibitor. 
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Thrombin generation assays 
Thrombin generation assays (TGA) were performed as described in the main article. 
In TGA, lag times are to a large extent determined by the amount of TF present in the 
assay (1). Hence, to determine the contribution to thrombin generation of endogenous 
TF, present in the plasma sample, 'lag time(Ca)' was measured as described in the 
main article, both in the presence and the absence of 300 ng/mL (final concentration) 
tissue factor pathway inhibitor (TFPI, R&D Systems, Abingdon, UK). This enabled 
us to specifically investigate the TF-dependency of associations with PM exposure.  
Figure S2A shows how increasing concentrations of TF dose-dependently shorten the 
lag time of thrombin generation. Figure S2B demonstrates how increasing 
concentrations of TF pathway inhibitor (TFPI) prolong the lag time to result in a 
complete inhibition of exogenously added TF (0.5 pM) -induced thrombin generation, 
at a concentration of 300 ng/mL TFPI. Based on these initial experiments, a dose of 
300 ng/mL was chosen to inhibit endogenous TF in our experiments. This 
concentration was deemed high enough in our patient samples, which all showed lag 
times over 10 minutes, i.e. at best contained 0.5 pM TF (Fig. S2A). 
A representative example for this analysis in a patient sample is shown in figure S2C. 
The remaining, but retarded thrombin generation in the presence of TFPI, reflects TF-
independent coagulation activation, induced by contact activation. This part can be 
inhibited in the presence of corn trypsin inhibitor (not shown). 
 
Microvesicle analysis by flow cytometry 
Microvesicles were analyzed by flow cytometry following a protocol, standardized by 
the Scientific and Standardization Subcommittee (SSC) International Society on 
Thrombosis and Haemostasis (ISTH) (2, 3) with some adaptations. Blood was 
collected on 3.8% citrate, and centrifuged twice at 1900 x g (10 min. and 20 min. 
respectively), within one hour after sampling, to obtain blood platelet-depleted and 
microvesicle-rich plasma. Subsequently, samples were immediately stored at -80°C 
for future analysis. Microvesicle-rich plasma samples were thawed for 20 minutes at 
37°C. To 20 µL of plasma, 55 µL of buffer (Hepes 10mM, NaCl 140 mM, CaCl2 2.5 
mM, pH 7.4) containing hirudin (55 µg/mL Refludan, Celgene, Braine-l'Alleud, 
Belgium), 10 µL of fluorescein isothiocyanate-labeled mouse anti-CD42a (BD 
Biosciences, Erembodegem, Belgium), 5 µL of phycoerythrin-labelled mouse anti-
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glycophorein A (GPA, BD Biosciences, Erembodegem, Belgium) and 10 µL of 
allophycocyanin-labelled annexin V (AV, Immunotools, Friesoythe, Germany) were 
added. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2: correlation between tissue factor concentration and lag time.  
(A and B) Human plasma was collected on 3.8% citrate containing corn trypsin inhibitor (CTI, final 
concentration 10 µg/mL) to prevent contact activation. Plasma was centrifuged twice at high speed to 
lower the number of microvesicles. All assays were performed in duplicate in 3 independent 
experiments in the presence of 4 µM exogenous phospholipids. (A) Exogenous tissue factor (TF, 
Innovin, Siemens) was added to human plasma at different final concentrations (0.25, 0.50, 1, 2 and 4 
pM) and the lagtime was measured upon recalcification. (B) Plasma was spiked with 0.5 pM TF and 
with different concentrations of TFPI (0, 50, 100, 300 and 500 ng/mL). No thrombin generation was 
observed for the control condition, in which no TF nor TFPI were added. (C) Representative example 
of a plasma sample from the present study with added TFPI (300 ng/mL, as indicated), in the absence 
of CTI. 
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After 20 minutes incubation at room temperature in the dark on a rocking platform, 
samples were diluted to a final volume of 500 µL with buffer (Hepes 10mM, NaCl 
140 mM, CaCl2 2.5 mM, pH 7.4). All buffers were filtered (Millex-VV 0.1 µm, 
Millipore, Brussels, Belgium) and antibodies were centrifuged (10 minutes at 
14,000g) to remove debris and aggregates.  
 
Samples (90 µL) were analyzed on a FACSCantoII flow cytometer (BD Biosciences, 
Erembodegem, Belgium) at a low flow rate (0.5 µL/sec). Events were gated according 
to size in a forward/side scatter dot plot. Subsequently, gated events were plotted on 
logarithmic scaled fluorescence channel 1, channel 2 and channel 3 dot plots. Blood 
platelet-derived microvesicles (BPµV) were identified as CD42a-positive events and 
red blood cell-derived microvesicles (RBCµV) as GPA-positive events. Microvesicles 
with a procoagulant, negatively charged phospholipid surface were identified by their 
binding to annexin V (AV+µV). Using these 3 markers, 8 different microvesicle 
populations can be defined: total BPµV, AV+ BPµV, AV- BPµV, total RBCµV, AV+ 
RBCµV, AV-RBCµV, total AV+µV and finally AV+µV that are negative for CD42a 
and for GPA. In this study, only total BPµV, total RBCµV and total AV+µV are 
reported to simplify representation of data. Measurement of microvesicles after 
filtration of platelet-poor plasma through a 0.1-µm filter (Millex-VV 0.1, Millipore, 
Brussels, Belgium) served as a negative control. Samples were run at a low flow rate 
over 3 minutes and results expressed as absolute counts.  
 
Figure S3 shows the validation of the performance of our flow cytometer according to 
the standardization protocol (2, 3) using fluorescent calibrated sub-micrometer beads 
(Megamix, BioCytex, Marseille, France). 
 
Our protocol differs from the SSC protocol on some points: first, we centrifuged the 
samples twice at 1900 x g (10 min. and 20 min. respectively), while the SSC protocol 
prescribes an intitial centrifugation for 15 min. at 1500 x g, followed by a second 
centrifugation for 2 min. at 13,000 x g. We found that our centrifugation protocol was 
more effective in eliminating blood platelets than the SSC protocol, when measured 
on a Cell Dyn 3500 automated cell counter (Abbott Diagnostics, Abbott Park, IL, 
USA) (data not shown). Second, our selection of antibodies (CD42a-FITC, GPA-PE 
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and AV-APC) differed from that of the SSC protocol (CD42a-PE and AV-FITC). 
However, these protocol differences are unlikely to influence the observed 
correlations between PM exposure and microvesicle counts by flow cytometry. 
In agreement with the SSC protocol, we did not define any size-limiting gates based 
on the forward scatter (FSC), since identification of size using FSC challenges the 
sensitivity limit of flow cytometry (3). Moreover, size-related information derived 
from plastic beads (Megamix) and that derived from biological parameters (samples) 
are not comparable (2).  
 
 
A         B 
 
 
 
 
 
 
C       D 
 
 
 
 
 
Figure S3: Validation of the BD FACSCantoII flow cytometer using Megamix beads. (A) On a 
FITC/side scatter plot, the 3 subsets of beads of differing diameters (0.5, 0.9 and 3 µm) can be 
distinguished. (B) A 'microvesicle gate' (MP, MP Megamix) was defined based on the position of the 
0.9 µm beads subset (blue) in a forward/side scatter plot. (C) This histogram, showing the FSC 
distribution of the 0.5 ('P1') and 0.9 ('P2') µm beads, validates the resolution of our flow cytometer for 
microvesicle analysis. (D) Hierarchical description of populations and gates. 
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Figure S4: Representative example of flow cytometric microvesicle analysis in a sample. (A) 
Distribution of the different microvesicle populations in a forward/side scatter plot. Colors are 
backgated from the double fluorescence plots. (B) On a CD42a-FITC/AV-APC plot, the following 
populations are defined: BPµV that bind AV ('BP uV AV+', blue), BPµV that do not bind AV ('BP uV 
AV-', green) and microvesicles that bind AV but are negative for the BP marker CD42a ('AV+ uV 
CD42-', yellow). The combination of 'BP uV AV+' and 'AV+ uV CD42-' defines all microvesicles that 
bind AV ('AV+ uV total'). (C) On a side scatter/GPA-PE plot, the population of RBC-derived 
microvesicles ('RBC uV total', red) is defined. The events localizing at the left lower of this population 
are categorized as RBC fragments, and are not counted as microvesicles. (D) Only the 'RBC uV total' 
are plotted on this GPA-PE/AV-APC plot, to define RBCµV that bind AV ('RBC uV AV+') and 
RBCµV that do not bind AV ('RBC uV AV-'). (E) Hierarchical description of populations and gates. 
 
A comparative study in 40 laboratories accounting for 59 flow cytometers, 
demonstrated that a size-limiting gate, based on e.g. the 0.9 µm beads present in the 
Megamix, is not applicable for most BD flow cytometers, since the localisation of the 
microvesicle populations can vary from being partly inside to completely outside this 
gate from one analyzer to another (2). The 'MP Megamix' gate, shown in figure S4, is 
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therefore only indicative and not restricting. Figure S4 shows a representative 
example of a sample analysis.  
 
Tissue factor mRNA in circulating white blood cells. 
Blood was collected in PAXgene Blood RNA tubes and mRNA extracted from the 
circulating white blood cells using the PAXgene Blood RNA kit (PreAnalytix, 
Hombrechtikon, Switzerland) according to the manufacturer's instructions. Taqman 
Reverse Transcription Reagents (Applied Biosystems, Ottignies-Louvain-la-neuve, 
Belgium) were used for the reverse transcription and SYBR Green PCR mastermix 
(Applied Biosystems, Ottignies-Louvain-la-Neuve, Belgium) for quantitative real-
time PCR in duplicate on the AB 7500 Fast PCR System (Applied Biosystems, 
Ottignies-Louvain-la-Neuve, Belgium) using the following primers: 
ccgaacagttaaccggaaga (TF, forward), tgcagtagctccaacagtgc (TF, reverse), 
tggtatcgtggaaggactcatgac (GaPDH, forward), atgccagtgagcttcccgttcagc (GaPDH, 
reverse). Ct values for tissue factor were expressed relatively to the Ct values for the 
house-keeping gene GaPDH. 
 
Assesment of chronic air pollution exposure 
In the present study, chronic air pollution exposure was assessed by estimation of the 
mean residential PM10 concentration over 3 months to 1 year, and by measurement of 
the residential distance to a major road. We found fewer and weaker correlations for 
clinical outcome parameters with residential distance to a major road than for the 
chronic residential PM10 measurements by the land-use interpolation model. 
Distance to a major road is a measure of exposure to traffic-related air pollution, 
consisting of both gaseous pollutants and PM, mainly diesel exhaust particles (DEP) 
with a mean aerodynamic diameter smaller than 2.5 µm (PM2.5). In contrast, the 
measurement of PM10 by the land-use interpolation model also includes the coarse 
fraction of PM (PM with a mean aerodynamic diameter between 2.5 and 10 µm) that 
derives predominantly from natural sources, especially crustal material. Important 
bioaerosols, such as endotoxin, pollen grains and fungal spores, are found mostly in 
the coarse fraction (and larger particles) (4), and might explain, at least partially, the 
differences in the results between the 2 exposure assessment techniques. As an 
alternative explanation, distance to major road as a measure for air pollution exposure 
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could be compromised by the density of the road network, the high degree of 
urbanization and industrial activity in our study area. In less populated or 
industrialized areas, distance to a major road would be the major determinant of 
individual air pollution exposure, but not so in a region with a high background level 
of PM. 
 
Effect-modification 
Potential interactions of type of diabetes and use of medication (statins and 
antiplatelet drugs) medication with the association between air pollution and all 
measured parameters were investigated. Figures S5-7 show the stratified effect sizes 
for the association between air pollution exposure and the different parameters, for 
patients with type 1 (black) vs type 2 (grey) diabetes (Fig. S5), for patients not taking 
(black) or taking (grey) statins (Fig. S6) and for patients not taking (black) or taking 
(grey) antiplatelet medication (Fig. S7). All analyses were corrected for gender, age, 
body-mass index, socioeconomic status, physical activity, blood glucose levels, use of 
insulin, temperature and humidity at the day of blood sampling, and type of diabetes 
(only S6 and S7), use of statins (only S5 and S7) and use of antiplatelet medication 
(only S5 and S6). Asteriks denote significant effect-modification (p<0.05 for 
interaction). 
 
A large number of statistical analyses was performed in this study. Adjustment for 
multiple comparisons is usually recommended to avoid rejecting null hypotheses too 
readily. The theoretical basis for advocating routine adjustment for multiple 
comparisons is that chance serves as the first order explanation for observed 
phenomena. However, this hypothesis undermines one of the basic premises of 
epidemiological research, which holds that human biology follows regular laws that 
may be studied through observation of populations or patients. Moreover, if, as in our 
current study, outcome variables such as different parameters reflecting microvesicle 
function or coagulation factors are correlated, then correction for multiple testing is 
not indicated, because each new test does not provide a completely independent 
opportunity for a type I error. Under such circumstances, adjustment for multiple 
comparisons is inappropriate.  
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Figure S5: Effect modification for type of diabetes. Effect sizes for the association between air pollution exposure at different time windows (as indicated) and different 
parameters were stratified for patients with type 1 (black) vs type 2 (grey) diabetes. Analysis adjusted for covariates. Arrows indicate significant effect modification (p<0.05). 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure S6: Effect modification for statin use. Effect sizes for the association between air pollution exposure at different time windows (as indicated) and different 
parameters were stratified for patients not taking statins (black) vs patients taking statins (grey). Analysis adjusted for covariates. Arrows indicate significant effect 
modification (p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S7: Effect modification for use of antiplatelet medication. Effect sizes for the association between air pollution exposure at different time windows (as indicated) 
and different parameters were stratified for patients not taking antiplatelet medication (black) vs patients taking antiplatelet medication (grey). Analysis adjusted for 
covariates. Arrows indicate significant effect modification (p<0.05). 
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Abstract 
Background: Aging has been associated with an increase in the risk of venous 
thrombo-embolism. Elderly persons demonstrate higher plasma concentrations of 
different coagulation factors, but whether aging is associated with changes in the 
levels of circulating procoagulant microparticles (MP) remains to be investigated. 
Materials and methods: We analyzed blood cell counts, coagulation and thrombin 
generation parameters in a cohort of young persons (n=18), and compared the results 
with those from a cohort of presumably healthy elderly persons (n=18), recruited from 
2 nursing homes. In addition, the number and the procoagulant potential of MP was 
investigated by by flow cytometry and thrombin generation assays. 
Results: Red blood cell counts and hemoglobin levels are lower in elderly persons, 
but no differences were observed in the number of total white blood cells. Higher 
levels of FVIII (about 60% increase in elderly vs young) and fibrinogen (about 50% 
increase in elderly vs young) were measured in the elderly, resulting in a shortening 
of the aPTT and an increase in peak height in thrombin generation assays. Plasma 
antigen levels of VWF almost doubled in the elderly as compared to the young.  
No age-related differences were measured in the number of red blood cell-derived or 
blood platelet-derived MP, nor in assays that are sensitive to the surface expression of 
tissue factor or negatively charged phospholipids on MP. 
Conclusion: Our findings, based on a cohort of healthy elderly persons outside a 
hospital setting, confirm that aging is associated with increases in coagulation factors, 
but does not elevate MP numbers or their procoagulant potential. 
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Introduction 
Aging has been associated with an increase in the risk of venous thrombo-embolic 
events, including deep vein thrombosis and pulmonary embolism. Advanced age 
leads to a state of hypercoagulability in the blood, raising the relative risk for deep 
vein thrombosis (DVT) from about 1/10,000 at the age of 40 to 1/100 at the age of 80 
(1). Aging may be associated with an increased prevalence of conventional risk 
factors, development of new, age-specific risk factors and accumulation of risk factors 
with age (2). Immobility, malignancy, co-morbidity, hormone replacement therapy 
and endothelial dysfunction all contribute to the prothrombotic risk in the elderly, in 
conjunction with a hypercoagulable state in the plasma (2). Elevation of the plasma 
levels of fibrinogen, homocystein, D-dimers, coagulation factors VII (FVII), FVIII 
and FIX and of plasminogen activator inhibitor 1 (PAI-1), an inhibitor of fibrinolysis, 
have been described (2-5). Since these procoagulant changes are not accompanied by 
a proportional parallel rise in natural anticoagulant factors, the haemostatic balance 
between pro- and anticoagulant pathways is shifted towards an elevated risk for DVT 
in the elderly (2). 
 
Microparticles (MP) are circulating vesicles with a mean diameter smaller than 1 µm 
that are released from stimulated or apoptotic cells in the vascular bed. They carry a 
procoagulant potential via 2 mechanisms: the expression of negatively charged 
phospholipids and/or tissue factor (TF) on their membranes creates a procoagulant 
surface on which coagulation factors can bind and be activated to promote 
coagulation (6). Elevated numbers of circulating MP have been demonstrated in 
patients with VTE (7). We aimed to investigate whether MP numbers or their 
procoagulant potential increase with age. 
 
Materials and methods 
Study population  
The study was designed as a pilot study to analyze the influence of age on circulating 
MP numbers and their procoagulant potential and was approved by the Ethics Review 
Board of the Medical Faculty of the University of Leuven (K.U.Leuven). We 
compared a cohort of young persons with a cohort of presumably healthy elderly 
persons. Participants gave informed consent at recruitment. To overcome possible 
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confounding by other risk factors such as immobilization and co-morbidity (2), 
elderly persons were not recruited from the hospital but from 2 nursing homes in the 
region of our laboratory. They were invited to participate, in writing. On the study 
day, a questionnaire was completed through a personal interview to collect 
information on general health and well-being. Medication use was registered via the 
nursing homes' medication files for the elderly, and by questionaire for the young 
persons. Exclusion criteria were immobilization, current smoking (last 6 months), use 
of anticoagulant therapy, diabetes, history of malignancy and self-reported non-well 
being at the time of blood collection (negative answer to the question 'do you feel in 
good health at this moment?'). Of the 26 elderly persons who agreed to participate, 4 
were excluded because of use of anticoagulant medication, 2 because of diabetes, 1 
because of non-well being at the time of blood collection and 1 because of difficulties 
during blood sampling. Young persons were recruited in the laboratory on the same 
days and fulfilled the same exclusion criteria. 
 
Blood sampling and blood cell count 
Non-fasting blood samples were collected using a 21 gauge needle (Terumo, Leuven, 
Belgium) on EDTA or on sodium citrate (3.8%) tubes (BD Vacutainer, BD 
Biosciences, Erembodegem, Belgium). Blood cell counts and differential leukocyte 
counts were determined using an automated cell counter with flow differential (Cell 
Dyn 3500, Abbott Diagnostics, Abbott Park, IL, USA). Citrated samples were 
centrifuged for 10 minutes at 1900 x g, followed by a second centrifugation step of 20 
minutes at 1900 x g, within one hour after collection. 
 
Coagulation 
Activated partial thromboplastin time (aPTT), prothrombin time (PT), FVII, FVIII, 
fibrinogen, antithrombin (AT) and protein C (PC) were all measured via functional 
assays on a BCS-XP coagulation analyzer according to the manufacturer's procedures, 
using the manufacturer's reagents (Siemens, Hamburg, Germany). 
 
Thrombin generation 
Thrombin generation (TG) was measured by means of the Calibrated Automated 
Thrombography method using a Fluoroskan Ascent reader (Thermo Labsystems OY, 
Helsinki, Finland). Thrombinoscope software (Thrombinoscope BV, Maastricht, The 
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Netherlands) was used to calculate thrombin generation curves, from which the lag 
time, the endogenous thrombin potential (ETP) and the peak height were derived. As 
explained in more detail in the online data supplement, TG was measured upon 
simple recalcification of plasma in the presence of an excess (4 µM) of exogenous 
phospholipids to investigate the effect of MP-contained factors on TG initiation. In 
addition, lag times were measured upon the addition of 300 ng/mL (final 
concentration) tissue factor pathway inhibitor (TFPI, R&D Systems, Abingdon, UK) 
to determine the contribution of tissue factor to thrombin generation. In TG assays, 
lag times are to a large extent determined by the amount of tissue factor (TF) present 
in the assay (8). Hence, measuring lag times in the presence and absence of TFPI 
enabled us to specifically investigate plasma tissue factor activity (see online data 
supplement).  
 
Antigen measurements 
ELISA was performed to measure antigen levels of TF (American Diagnostica, 
Stamford, USA) and von Willebrand factor (VWF, in-house). All coagulation assays 
were performed on thawed (-80°C) plasma. 
 
Microparticle analysis 
MP were analyzed by flow cytometry following a protocol, standardized by the 
Scientific and Standardization Subcommittee (SSC) of the International Society of 
Thrombosis and Haemostasis (ISTH) with some adaptations (9). To 20 µL of plasma, 
fluorescein isothiocyanate-labeled mouse anti-CD42a (BD Biosciences, 
Erembodegem, Belgium), phycoerythrin-labeled mouse anti-glycophorein A (GPA, 
BD Biosciences, Erembodegem, Belgium) and allophycocyanin-labeled annexin V 
(AV, Immunotools, Friesoythe, Germany) were added and samples were analyzed on 
a FACSCantoII flow cytometer (BD Biosciences, Erembodegem, Belgium) to define 
blood platelet-derived MP (PMP), red blood cell-derived MP (RBC-MP), and the 
procoagulant potential of these particles by measuring annexin V (AV) binding to the 
negatively charged phospholipids expressed on their surface. Samples were analyzed 
for 3 minutes at a low flow rate (0.5 µL/sec).  
To also functionally assess the surface expression of negatively charged 
phospholipids on microvesicles, additional TG assays were performed: peak height 
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was measured both before and after filtering the plasma through a 0.1 µm filter 
(Millex-VV 0.1 µm, Millipore, Brussels, Belgium), in the presence of 5 pM 
exogenous TF (Innovin, Siemens, Marburg, Germany) and of 2 IU/mL recombinant 
FVIII (Kogenate, Bayer, Diegem, Belgium), in the absence of exogenous 
phosholipids. Under these conditions, TG is independent of changes in plasma FVIII 
levels and becomes dependent on the concentration of negatively charged 
phospholipids present in the plasma (see online data supplement). Therefore, the 
difference in peak height before and after filtering plasma samples is a specific 
measure of the expression of procoagulant phospholipids on the MP's membranes 
('phospholipid-dependent TG'). Since freezing-thawing potentially affects the surface 
expression of negatively charged phospholipids on MP (10-12), all MP analyses were 
performed on fresh plasma.  
 
Statistics 
Statistical significance (defined as p<0.05) between groups was analyzed via Mann 
Whitney testing, using GraphPad Prism version 4.0b and Instat version 3 (GraphPad 
Software, San Diego, US). 
 
Results 
Table 1 compares the population characteristics and the results for blood cell count, 
coagulation parameters and for microvesicle analysis between young persons and 
elderly persons. Red blood cell (RBC) counts and hemoglobin (Hgb) levels are lower 
in elderly persons, but no differences were observed in the number of total white 
blood cells or neutrophils. In agreement with previous observations (3, 13-15), higher 
levels of FVIII (about 60% increase in elderly vs young) and fibrinogen (about 50% 
increase in elderly vs young) were measured in the elderly, resulting in a shortening 
of the aPTT and an increase in peak height in thrombin generation assays. Plasma 
antigen levels of VWF almost doubled in the elderly as compared to the young.  
 
Both in the young and in the elderly, lag times prolonged significantly upon addition 
of TFPI in the assay. This observation justifies the use of lag times in TG assays as a 
functional measure of TF activity in the plasma (8). Despite a significant increase in 
the antigen levels of TF (about 40%) in the elderly as compared to the young, no age-
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related shortening of the lag time was observed in TG assays, in the presence or 
absence of TFPI. These findings exclude upregulation of TF activity in plasma with 
aging. In plasma, MP are a major source of blood-borne TF activity. 
 
MP not only exert their procoagulant activity through surface TF expression, but also 
through the exposure of negatively charged phospholipids on their membranes. We 
assessed the surface expression of procoagulant phospholipids both via flow 
cytometric analysis of annexin V binding, and via a modified phospholipid-dependent 
TG assay where differential peak height was measured in plasma before and after 
removal of MP through filtration. Both assays (total annexin V positivity in flow 
cytometry vs. differential peak height in TG) correlated strongly (r2 0.57, p<0.0001) 
(see online data supplement). No significant changes were observed between the 
elderly and the young in the total number of PMP or RBC-MP, nor in their respective 
annexin V-binding fractions. In other words, phosholipid-dependent TG was not 
enhanced in the elderly. 
 
Discussion 
Our findings are in relative agreement with two recent reports on the association 
between MP and aging. Forest et al. demonstrated lower numbers of endothelial cell-
derived MP, but no changes in the numbers of PMP or RBC-MP or in the annexin V-
binding capacity of MP in the elderly in stable conditions. Annexin V-binding 
decreased in the elderly in septic conditions (16). 
 
We did not assess endothelial MP in the current study because of the low number in 
healthy individuals. An association between phospholipid-dependent TG and age was 
demonstrated by Owen et al. in patients with a history of venous thromboembolim 
(VTE), but not in control persons without a history of VTE. However, no association 
was found between annexin V-binding PMP and aging for either category of persons 
(17). Both latter studies were performed on frozen plasma, obtained from either 
persons who where either hospital inpatients (16) or outpatients (17). Our study is 
novel because a cohort of healthy elderly persons was recruited outside a hospital 
setting, reducing the possibility of confounding by co-morbidity. Moreover, in order 
to minimize potential bias that can be introduced by freezing and thawing MP (10-
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12), we chose to assay only fresh plasma to assess phospholipid-dependent 
procoagulant activity of MP.  
 
In brief, our findings, based on a cohort of healthy elderly persons outside a hospital 
setting, confirm that aging is associated with increases in coagulation factors, but does 
not elevate MP numbers or their procoagulant potential. 
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 Table 1   YOUNG   ELDERLY     
    Median (P25-P75)         or (%)   Median 
(P25-P75)       
or (%)   p-value 
Population characteristics                 
n   18     18       
Age (years)   29 (26.0-32.0)   85 (83.5-88.0)     
Gender (male)   10 (56%)   7 (39%)     
BMI (kg/m2)   22.6 (19.7-25.4)   25.2 (23.3-27.5)     
Medication:                 
   Statins   0 (0%)   3 (17%)     
   Antiplatelet    0 (0%)   7 (39%)     
   Antihypertensive   0 (0%)   11 (61%)     
                  
Blood cell count                 
WBC (103/µl)   6 (4.8-7.1)   6.3 (5.6-7.1)   ns 
neutrophils (103/µl)   3 (2.1-4.2)   3.9 3.4-4.7   ns 
RBC (106/µl)   5.1 (4.6-5.2)   4.4 (4.2-4.9)   0.0188 
HGB (g/dl)   15.3 (14.0-15.5)   13.8 (12.9-14.7)   0.0096 
BP (103/µl)   261 (219-300)   258 (199-337)   ns 
                  
Coagulation                 
aPTT (sec)   28.1 (26.6-31.4)   26.1 (25.1-27.9)   0.0397 
PT (sec)   8.4 (7.8-8.7)   8.4 (7.8-8.8)   ns 
Fbg (g/L)   2.2 (1.83-2.98)   3.4 (2.40-3.50)   0.0174 
FVII (%)   133 (117-178)   124 (111-140)   ns 
FVIII (%)   90 (77-101)   151 (138-169)   <0.0001 
AT (%)   115 (108-121)   115 (99-119)   ns 
PC (%)   123 (116-141)   129 (109-133)   ns 
TF ag (pg/mL)   189 (147-287)   263 (220-305)   0.0398 
VWF ag (ng/mL)   6097 (5006-8316)   11898 (9558-14771)   <0.0001 
TG lag time (min.)   26.2 (21.8-42.0)   22.8 (18.1-60.0)   ns 
TG ETP (nM)   829 (670-1417)   1299 (1078-1504)   ns 
TG peak (nM)   129 (108-213)   249 (188-317)   0.0148 
TG lag time +TFPI (min.)   60 (56.2-60.0)   57.5 (40.1-60.0)   ns 
                  
Microparticles                 
BP derived (CD42+)                 
   total (count)   3488 (2309-6142)   3619 (2128-4462)   ns 
   AV- (count)   3178 (2133-5546)   3328 (1945-4231)   ns 
   AV+ (count)   184 (157-282)   255 (156-339)   ns 
RBC derived (GPA+)                 
   total (count)   281 (194-1507)   305 (243-600)   ns 
   AV- (count)   75 (41-119)   117 (73-165)   ns 
   AV+ (count)   174 (108-268)   198 (139-360)   ns 
phospholipid-dependent TG   26.6 (16.1-46.2)   22.8 (12.7-36.3)   ns 
 
P25: 25% percentile, P75: 75% percentile, BMI: body mass index, WBC: white blood cells, RBC: red blood 
cells, Hgb: hemoglobin, BP: blood platelets, aPTT: activated partial thromboplastin time, PT: prothrombin 
time, Fbg: fibrinogen, F: factor, AT: antithrombin, PC: protein C, TFag: tissue factor antigen, VWFag: von 
Willebrand factor antigen, TG: thrombin generation, ETP: endogenous thrombin potential, TFPI: tissue factor 
pathway inhibitor, AV: annexin V, GPA: glycophorin A, ns: not significant. Statistics were perfomend using 
Mann Whitney analysis. 
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Data supplement 
 
Supplemental methods and results 
Thrombin generation assays 
Thrombin generation (TG) was measured by means of the Calibrated Automated 
Thrombography method using a Fluoroskan Ascent reader (Thermo Labsystems OY, 
Helsinki, Finland). Thrombinoscope software (Thrombinoscope BV, Maastricht, The 
Netherlands) was used to calculate thrombin generation curves, from which different 
parameters were derived: 
Lag time: the time in minutes from the start of the assay to the intial generation of 
thrombin (the moment at which 10 nM thrombin is formed). 
Endogenous thrombin potential (ETP): area under the thrombin generation curve 
(AUC), expressed in nM x min. 
Peak height: Value for the maximum thrombin generation, expressed in nM. 
 
Thrombin generation (TG) assays were performed in 2 different ways.   
 
1) To measure endogenous triggers of coagulation. 
TG was measured upon simple recalcification of thawed plasma in the presence of an 
excess (4 µM) of exogenous phospholipids. Under these conditions, TG is initiated by 
triggers contained in the plasma, such as contact activators and/or functional tissue 
factor. Lag time, endogenous thrombin potential (ETP) and peak height were derived 
from the thrombin generation curves. Coefficients of variation for within run and 
between run precision were smaller than 11% for all 3 parameters. 
 
To evaluate the contribution of TF to TG more specifically, additional TG 
measurements were performed, including the addition of 300 ng/mL (final 
concentration) tissue factor pathway inhibitor (TFPI, R&D Systems, Abingdon, UK). 
Hence, while lag times, measured in the absence of TFPI, are to a large extent 
determined by the amount of tissue factor (TF) present in the assay (1), lag times, 
measured in the presence of TFPI are independent of plasma TF concentrations. Fig. 
S1 demonstrates how lag times shorten with increasing doses of TF and prolong upon 
addition of TFPI. 
Chapter 3 Data supplement 
 
103 
 
Figure S1: correlation between lag times in thrombin generation assays and tissue factor 
concentrations and inhibition by TFPI. 
(A) Blood was collected on sodium citrate (3.8%) and corn trypsin inhibitor (CTI, 10 µg/mL blood) to 
block contact activation.  Thrombin generation (TG) was measured in plasma at increasing 
concentrations (as indicated) of exogenously added tissue factor (TF, Innovin, Siemens, Marburg, 
Germany) in the presence of 4 µM of exogenous phospholipids (colored TG curves). A dose-dependent 
shortening of the lag times is observed. 
The addition of tissue factor pathway inhibitor (TFPI, 300 ng/mL) is shown here in combination with 2 
pM TF (black dotted line): TG is almost completely inhibited. At lower concentrations of TF, TG was 
completely inhibited by TFPI (not shown).  
(B) TG was measured upon simple recalcification of the plasma, in the presence of 4 µM of exogenous 
phospholipids and in the presence (blue) or absence (black) of TFPI (representative example of the 
analyses performed in the present study). Plasma samples of study subjects in the present study were 
not collected on CTI. Correspondingly, TFPI (300 ng/mL) inhibits TG partially, with a clear 
prolongation of the lag time (arrows) in the filtered vs the non-filtered plasma. 
 
 
2) To measure procoagulant phospholipids 
Microparticles are cell-derived vesicles with a mean diameter between 0.1 and 1 µm.  
Through the expression of negatively charged phospholipids on their membranes, 
they create a procoagulant surface on which coagulation factors can bind to promote 
coagulation (2). 
We adopted TG to functionally measure the surface expression of negatively charged 
phospholipids on the microparticles' surface. TG was triggered with 5 pM exogenous 
TF (Innovin, Siemens, Marburg, Germany) in the absence of exogenous 
phospholipids. Under these conditions, TG is dependent on the negatively charged 
phospholipids present in the plasma. Plasma was assessed both before and after 
removal of microparticles (Fig. S2) by filtering the plasma through a 0.1 µm filter 
(Millex-VV 0.1 µm, Millipore, Brussels, Belgium). The difference in TG peak height 
(delta peak height) between the filtered and the non-filtered plasma was used as a 
measure of microparticle-contained negatively charged phospholipids (called 
'phospholipid-dependent TG'). 
0 20 40 60
0
50
100
150
200 TF 4 pM
TF 2 pM
TF 1 pM
TF 0.5 pM
TF 0.25 pM
TF 0.125 pM
TF 2 pM 
+TFPI 300 ng/mL 
time (min.)
TG
 (n
M
)
0 20 40 60
0
50
100
150
200
-TFPI
+TFPI
14.5
36.2 
time (min.)
TG
 (n
M
)
A      B
Chapter 3 Data supplement 
 
104 
 
 
 
Figure S2. Removal of microparticles by filtering, as evidenced by flow cytometry. 
Plasma was collected and handled as described in the main article.  Both blood platelet-derived 
microparticles (BP-MP) and red blood cell-derived microparticles (RBC-MP) can be detected in the 
plasma before filtering (left panel). All MP populations disappear upon filtering of the plasma through 
a 0.1 µm filter (right panel). A: forward scatter (FSC-H) - side scatter (SSC-H) plot, indicating the MP 
gate defined by fluorescent calibrated sub-micrometer beads (Megamix, BioCytex, Marseille, France), 
as proposed by the standardization protocol of the International Society on Thrombosis and 
Haemostasis (3). B: plot showing positivity for the FITC-labelled BP marker anti-CD42a vs APC-
labelled annexin V (AV). C: plot showing positivity for the PE-labelled marker glycophorin A (GPA) 
vs side scatter (SSC-A). A separate gate defines the position of RBC fragments. D: plot showing 
positivity for the PE-labelled marker glycophorin A (GPA) vs APC-labelled annexin V (AV). Only 
events appearing in the 'RBC-MP total' gate in plot C are shown in plot D. 
Analysis performed on thawed plasma. 
 
Since the filtering procedure also partially removes FVIII from the plasma samples 
(by about 50%, without altering other coagulation factor levels, data not shown), in 
conjunction with partial removal of von Willebrand factor, 2 IU/mL of recombinant 
human FVIII (Kogenate, Bayer, Diegem, Belgium) was added to both in the filtered 
and in the non-filtered sample, eliminating FVIII dependence (Fig. S3). 
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Figure S3: effect of filtering and addition of rFVIII on thrombin generation. 
Thrombin generation (TG) in plasma was triggered with 5 pM tissue factor (Innovin, Siemens, 
Marburg, Germany), in the absence of exogenous phospholipids (A) or in the presence of 10 µM 
exogenous phospholipids (B). In both conditions, TG was assessed in plasma with or without filtering 
through a 0.1 µm filter to remove microparticles, and with or without the addition of recombinant 
human FVIII (rFVIII), as indicated. 
In the absence of exogenous phospholipids (A), the differencee in peak height observed between the 
filtered (orange) and the non-filtered (red) plasma can be attributed to lower concentrations of both 
FVIII and endogenous phospholipids in the filtered sample.  Therefore, an excess of rFVIII was added 
to both the non-filtered (black) and the filtered (grey) plasma to make the assay more phospholipid-
specific. 
We define the 'phospholipid-dependent TG' as the difference in peak height (delta peak) between the 2 
latter conditions (arrow). 
Panel (B) demonstrates how differences in peak height between the non-filtered (black) and the filtered 
(grey) condition disappear in the presence of an excess of both exogenous phospholipids (10 µM) and 
rFVIII (2 IU/mL). 
 
 
The surface expression of negatively charged phospholids on microparicles was also 
assessed by measuring binding to annexin V by flow cytometry (see main article). We 
found a strong correlation between the 'phospholipid-dependent TG assay' and the 
flow cytometric measurement of annexin V binding (p<0.0001, r2 0.57) for the 
samples in the present study (Fig. S4). 
Freezing-thawing potentially affects the surface expression of negatively charged 
phospholipids on MP (4-6), therefore, all MP analyses were performed on fresh 
plasma. 
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Figure S4. Correlation between annexin V binding and phospholipid-dependent thrombin 
generation. 
Binding of annexin V (AV) to the negatively charged phospholipids on the microparticles' surface was 
measured by flow cytometry (Y-axis), and correlated to the results of the functional measurement in 
the phospholipid-dependent thrombin generation (TG) assay (based on the difference in peak height 
(delta peak height, X-axis) between filtered and non-filtered plasma). 
Data shown are obtained from fresh plasma of all study subjects in the present study. 
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Abstract  
Objective: Elderly subjects are particularly susceptible to the cardiovascular effects 
of air pollution. We investigated if traffic-related air pollution exposure alters 
hemostatic parameters differently in young and old mice. 
Methods and results: Young (10 weeks) and old (20 months) mice were placed in an 
urban roadside tunnel or in a clean environment for 25 or 26 days. 
Tunnel mice showed an elevated carbon load and endothelial von Willebrand factor 
(VWF) expression in the lung, but no pulmonary or systemic inflammation. Traffic-
related air pollution raised red blood cell and blood platelet numbers in young and old 
mice, but raised numbers of procoagulant blood platelet-derived microvesicles only in 
old mice. 
Baseline levels of plasma soluble P-selectin (sP-sel) and VWF were higher in old 
mice and did not further increase with exposure. In young mice, sP-sel increased with 
exposure and correlated strongly with soluble E-selectin and VWF. 
Changes in coagulation factors and thrombin generation were mild or absent. 
Conclusion: Traffic-related air pollution does not trigger overt lung inflammation, 
but triggers endothelial cell and platelet activation. The high absolute numbers 
reached in the aged exposed mice for blood platelets, microvesicles, sP-sel and VWF 
indicate higher thrombogenicity in old mice, subchronically exposed to polluted air. 
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Introduction 
Over the last two decades, a large body of epidemiological research has consistently 
demonstrated an association between exposure to air pollution and cardiovascular 
disease and mortality (1-7).  Both gaseous (carbon monoxide, nitrogen oxides, sulfur 
dioxide, ozone) and particulate components (particulate matter, PM) are implicated in 
air pollution, but the larger body of evidence points towards the deleterious effects of 
the particulates. Both acute and chronic cardiovascular health effects are described. 
Thus, exposure to PM for as little as 2 h suffices to trigger myocardial infarction (8). 
More chronic exposure, such as living near a major road, has been associated with 
increased coronary artery calcification, a measure for atherosclerosis (9), and with an 
enhanced risk for venous thrombosis (10). In view of the commonness of exposure in 
modern society, traffic-related air pollution likely poses a major public health burden 
(11).  
 
Because of a gradual decline in physiological processes and a higher prevalence of 
pre-existing cardiovascular and respiratory diseases, elderly persons (>65 years of 
age) are believed to be more susceptible to deleterious cardiovascular effects of air 
pollution than young persons (12). PM exposure-related relative risk estimates appear 
to be higher in elderly, both for mortality (1, 5, 13) and hospitalization for 
cardiovascular disease (14, 15). Similarly, the relative risk for cardiovascular disease 
associated with gaseous pollutants is increased in the very elderly (≥ 75 years of age) 
(16). Even though an association between age and increased relative risk for air 
pollution-related cardiovascular disease was not found in all studies, the attributable 
risk, an estimate depending both on the strength of the association between risk factor 
and disease and its prevalence, was highest among the elderly, due to their greater 
baseline risk (16). Indeed, the elderly not only have a higher baseline risk for 
developing myocardial infarction (17), but they also show a strongly upregulated 
tendency for venous thrombogenicity, linked to elevation of several coagulation 
factors (18). Yet, despite growing epidemiological evidence of raised cardiovascular 
risk associations with air pollution exposure in the elderly, it is not known if air 
pollution affects blood hemostasis parameters differently with age. 
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In the current study, we investigated the effects of exposure to traffic-related air 
pollution on hemostasis in young vs old mice. In mice, a short-term experimental 
exposure via intratracheal instillation of PM was found to be inadequate to induce 
changes in secondary hemostasis parameters (19). Therefore, presently, we placed 
young and old mice in an urban roadside tunnel for 25 or 26 days, and analyzed 
hemostasis thoroughly, in comparison to partial and non-exposed groups. In addition 
to a detailed analysis of parameters of primary hemostasis, plasma was analyzed for 
microvesicles (also called microparticles, a term we prefer to avoid in the context of 
pollution by particles), since negatively charged phospholipids and tissue factor (TF) 
on their membranes manifest procoagulant properties, via binding of coagulation 
factors (20).  
 
Materials and methods 
Mice 
This study was approved by the Institutional Review Board of the University of 
Leuven, and experiments were performed in accordance with protocols approved by 
the Institutional Animal Care and Research Advisory Committee. 
Male C57Bl6/j mice aged 10 weeks ('young') or 20 months ('old') were purchased 
from Janvier (Le Genest St Isle, France). 
 
Experimental design 
Mice were randomly allocated to 1 of 3 groups: a first group ('clean') remained in the 
animal facility of the University of Leuven during the whole period of the experiment. 
They were kept in micro-isolation cages covered by a conventional filter top 
(Tecniplast, Buggiate, Italy) in a light-controlled (14/10-h day/night cycle) room with 
continuous air filtration. The second ('tunnel filtered') and third ('tunnel exposed') 
groups were stationed in an urban roadside tunnel (Craeybeckx tunnel, Antwerp, 
Belgium) at 57 km from the University of Leuven. This tunnel is a major motorway 
of car and truck traffic entering Antwerp. It is 1600 m long and consists of separate 
pipes for each direction, each comprising 4 lanes.  Mice were placed in an alcove 
inside the tunnel, close to the end of one of the pipes and at 4 m distance of the 
bypassing traffic. Preliminary measurements demonstrated that PM concentrations 
were highest at this location of the tunnel (data not shown). Mean daily counts for 
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vehicle traffic in 2010 for this pipe were 49,780 non-trucks and 6,545 trucks (source: 
Department Mobility and Public Works - Division Traffic Centre of the Flemish 
government, unpublished data). Mice allocated to the 'tunnel filtered' group were 
placed in micro-isolation cages covered with two layers of highly efficient flexible 
filter material (Pads F7, Camfil Farr, Zaventem, Belgium, minimum life efficiency on 
0.4 µm: ≥35%), separated by about 5 cm of air. Mice allocated to the 'tunnel exposed' 
group were placed in the same location in micro-isolation cages without filter tops. 
For all 3 groups, mice had access to food and water ad libitum and cages were cleaned 
once a week (n=7-8 per group). The total study period was 25 to 26 days. 
 
Exposure measurements 
PM measurements were performed every 30 minutes during the entire exposure 
period, using a portable laser-operated aerosol mass analyzer (Aerocet 531, Met One 
Instruments Inc, Grant Pass, OR, USA) inside empty cages, placed among the mice-
containing cages, in the tunnel and control sites. 
PM concentrations were also assessed on a single occasion by sampling PM on a 
glass microfibre filter (Whatman, Kent, UK) by using a sampling pump (SP350, TSI, 
Shoreview, USA) at 2 L/min over 10 hours.  
Data on the tunnel traffic during the study period were collected through courtesy of 
the Department Mobility and Public Works - Division Traffic Centre of the Flemish 
government in Belgium. 
 
Blood collection 
At the end of the exposure period (25-26 days), mice were anesthetized (sodium 
pentobarbital, 60 mg/kg, i.p.) and blood was collected from the retroorbital sinus on 
citrate 0.38% or on EDTA. Blood cell counts and differentials were performed on a 
Cell-Dyn 3500R counter (Abbott, Diegem, Belgium).  Citrated samples were 
centrifuged twice (1,500 g x 15 min) and plasma was snap frozen in liquid nitrogen 
and stored at -80°C for subsequent coagulation and microvesicle assays.  EDTA-
anticoagulated blood was centrifuged once (15,000 g x 10min) and plasma was stored 
at -20°C for antigen measurements. 
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Bronchoalveolar lavage and lung tissue collection 
Following blood sampling, the mouse abdomen and thorax were opened. The left 
bronchus was ligated and the trachea exposed and cannulated with a 20 Gauge 
cannula to lavage the right lung three times with 0.4 mL (total volume of 1.2 mL) of 
sterile NaCl 0.9%.  The recovered bronchoalveolar lavage fluid (BALF) aliquots were 
pooled and placed on ice.  No difference in the volume of collected fluid was 
observed between groups.  Cells in fresh BALF were stained with Trypan Blue and 
counted in a Bürker hemocytometer.  Cell differentials were determined by light 
microscopy on cytocentrifuge preparations fixed in methanol and stained with Diff 
Quick (Siemens, Brussels, Belgium).  The remaining BALF was then centrifuged 
(1000 g x 10 min.) and the supernatant stored at -20°C for cytokine analysis.   
Upon bronchoalveolar lavage, the left lung was filled with 0.4 mL parafomaldehyde 
4% (PFA), isolated and immersed in PFA 4% for fixation. 
 
Carbon load 
Airway macrophages were visualized by light microscopy (AxioPlan 2 Imaging, 
Zeiss, Zaventem, Belgium) and pictures were taken with Axiovision Rel. 4.6. (Zeiss). 
ImageJ software (version 1.440, National Institutes of Health, USA) was used to 
calculate the carbon load of airway macrophages via surface analysis, as described 
previously (21, 22). First, the nucleus was removed from the image of each 
macrophage. Then carbon load was defined as the median area (µm2) occupied by 
carbon, in at least 20 randomly selected macrophages per mouse.  
 
Histology 
Lung tissues of 3 randomly chosen mice per group were embedded in paraffin and 8 
µm cross-sections were stained with hematoxylin and eosin (H&E) or von Willebrand 
factor (VWF) using rabbit anti-human VWF antibody and a biotinylated secondary 
goat anti-rabbit antibody (both Dako, Heverlee, Belgium). All slides were stained at 
the same time and for an identical reaction time. Stainings were analyzed with a Zeiss 
AxioPlan 2 Imaging microscope (Zeiss, Jena, Germany) and pictures were taken with 
Axiovision Rel. 4.6. (Zeiss). Per mouse, the intensity of the VWF staining was 
manually scored by 3 independent and blinded observers, via a simple graded score of 
1, 2 or 3, corresponding to light, moderate or intense staining, respectively, for each 
section. 
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Coagulation assays 
All coagulation assays were performed on the BCS-XP coagulation analyzer 
(Siemens, Hamburg, Germany) using the manufacturer's reagents and adapted 
procedures for murine coagulation testing (23). Coagulation factor (F) VII and FVIII 
activity were determined by one-stage coagulation assays, calibrated with pooled 
murine plasma. Fibrinogen concentrations were determined by the functional Clauss 
method, calibrated with Standard Human Plasma (Siemens, Hamburg, Germany). 
 
Thrombin generation assays (TGA) 
Thrombin generation was measured in diluted plasma (1/4) by means of the 
Calibrated Automated Thrombography (CAT) method using a Fluoroskan Ascent 
reader (Thermo Labsystems OY, Helsinki, Finland). Thrombinoscope software 
(Thrombinoscope BV, Maastricht, The Netherlands) was used to calculate thrombin 
generation curves, from which the lag times, endogenous thrombin potential (ETP) 
and peak height were derived. TGA were performed in two ways: first, in the 
presence of 10 µM phospholipids and in the absence of exogenously added tissue 
factor (TF) (condition called '+PL-TF'), and second, in the presence of both 10 µM 
phospholipids and 0.3 pM exogenously added TF (Innovin, Siemens, Marburg, 
Germany) (condition called '+PL+TF'). 
 
Flow cytometric microvesicle analysis 
Plasma was thawed at 37°C, labeled with fluorescein isothiocyanate-labeled anti-
CD41/61 (Emfret, Eibelstadt, Germany), phycoerythrin-labeled anti-Ter119  (BD 
Biosciences, Erembodegem, Belgium) and allophycocyanin-labeled annexin V (AV, 
Immunotools, Friesoythe, Germany) and analyzed on a FACSCantoII flow cytometer 
(BD Biosciences, Erembodegem, Belgium) to define blood platelet-derived 
microvesicles ('BP-µV') and red blood cell-derived microvesicles ('RBC-µV'). 
Surface expression of negatively charged phospholipids was assessed by measuring 
annexin V binding ('AV').  
 
Antigen measurements 
Von Willebrand factor antigen (VWFag) levels were measured by in-house ELISA on 
citrated plasma using rabbit anti-human VWF (Dako, Heverlee, Belgium).  
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Commercial ELISA's were used to determine the concentrations of soluble P-selectin 
(sP-sel), soluble E-selectin (sE-sel), platelet factor 4 (PF4)  (all R&D Systems, 
Abingdon, UK) and interleukin-6 (IL-6, eBioscience, Vienna, Austria) oin EDTA 
plasma. 
 
Statistical analysis 
We used non-parametrical Kruskal-Wallis tests with Dunn's multiple comparison 
post-tests to analyze significance between the different exposure groups within each 
age class, and Mann-Whitney tests to analyze significance between both age classes 
for mice placed in the 'clean' environment. All statistical analyses were performed 
using GraphPad Prism version 4.0b (GraphPad Software, San Diego, US). 
 
Results 
Exposure characteristics 
Figure 1 shows the measurements for PM10 (PM with a mean diameter smaller than 
10 µm) and for PM2.5 (PM with a mean diameter smaller than 2.5 µm) at both 
locations, together with the hourly vehicle transit through the tunnel. 
In general, PM measurements parallelled vehicle transit data, with higher values on 
week days as compared to weekend days, and higher values during the morning rush 
hours. Mean levels of PM10, averaged over the entire study period, were 59% lower 
inside the filtered cages in the tunnel ('tunnel filtered', 38.6 µg/m3) and 97% lower 
inside the cages in the clean environment ('clean', 2.9 µg/m3), compared with the 
unfiltered cages in the tunnel ('tunnel exposed', 93.8 µg/m3).  For PM2.5, values were 
32.3% lower for the 'tunnel filtered' group (16.8 µg/m3) and 95.5% lower for the 
'clean' group (1.1 µg/m3), compared to the 'tunnel exposed' group (24.9 µg/m3). 
Correspondingly, the collection filter was considerably blacker upon sampling of 
unfiltered tunnel air than upon sampling of filtered tunnel air, while hardly any 
particulate material was sampled on the filter in the clean environment (Fig. 1). 
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Figure 1: Exposure characteristics 
Levels of PM10 (upper graph, left Y-axis) and PM2.5 (lower graph, left Y-axis) were measured inside 
cages placed in both locations (as indicated), during the entire study period (days in X-axis). Dotted 
line represents total vehicle traffic transit through the roadside tunnel, calculated per hour (right Y-
axis). The bottom panel shows glass microfibre filters on which PM was sampled in (from left to right) 
a cage in the clean environment, a filtered cage inside the roadside tunnel and an unfiltered cage inside 
the tunnel. 
 
Bronchoalveolar lavage cells and IL-6 
Baseline values (defined as the value for the 'clean group') of BALF WBC 
concentrations were higher in old mice than in young mice (Table 1). Almost all 
BALF cells were monocytes/macrophages. Exposure to traffic-related air pollution 
did not influence WBC counts or differentiation in either age category (Table 1 and 
Fig. 2), despite the high carbon load in alveolar macrophages of the tunnel mice, 
which tended to be higher for the 'tunnel exposed' than for the 'tunnel filtered' group 
(Fig. 2D). Concentrations of IL-6 in BALF were below the detection limit for all but 2 
mice (in different groups).  
  
 
 
 Table 1 YOUNG   OLD 
  clean tunnel filtered tunnel exposed   clean tunnel filtered tunnel exposed 
Final body weight (g) 27.8 (26.9-28.0) 28.7 (27.8-29.8) 29.0 (28.2-29.5)   30.3 (29.7-33.8)¶ 33.4 (32.2-34.1) 31.1 (29.5-32.6) 
                
BALF cell count               
WBC (/µL) 45.0 (25.0-50.0) 50.0 (42.5-57.5) 50.0 (32.5-60.0)   77.5 (70.0-90.0)¶¶ 80.0 (40.0-80.0) 60.0 (42.5-85.0) 
Neutrophils (%) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.8)   0.0 (0.0-0.0) 0.0 (0.0-0.0) 0.0 (0.0-0.0) 
Monocytes (%) 100 (99.3-100.0) 99.5 (97.5-100.0) 100.0 (99.0-100.0)   99.5 (97.5-100.0) 99.0 (96.0-100.0) 98.5 (98.0-100.0) 
                
Coagulation               
Fibrinogen (mg/dL) 199 (172-221) 188 (181-207) 196 (173-226)   191 (178-207) 181 (171-201) 192 (182-201) 
FVII (%) 115 (107-125) 116 (112-137) 122 (114-127)   117 (108-127) 120 (114-140) 115 (107-129) 
FVIII (%) 95 (93-112) 106 (86-119) 107 (103-125)   134 (112-144)¶¶ 111 (103-128) 120 (111-129) 
                
TG (+PL-TF) lagtime (min.) 9.0 (5.8-14.7) 10.7 (10.0-13.3) 14.7 (7.1-14.8)   17.3 (10.3-60.0) 13.5 (7.7-17.8) 14.3 (11.7-60.0) 
TG (+PL-TF) ETP (nM.min) 102 (76-139) 123 (108-208) 105 (70-161)   67 (0-162) 61 (39-89) 143 (0-193) 
TG (+PL-TF) peak (nM) 9.6 (7.0-10.5) 9.6 (7.4-18.7) 8.3 (5.0-11.5)   4.9 (0.0-11.5) 5.7 (2.9-7.9) 9.5 (0.0-20.8) 
                
TG (+PL+TF) lagtime (min.) 2.8 (2.4-3.2) 2.9 (2.4-3.1) 3.0 (2.3-3.1)   3.5 (2.8-3.7) 3.0 (2.7-3.3) 3.5 (2.7-3.8) 
TG (+PL+TF) ETP (nM.min) 296 (279-320) 375 (350-422)** 317 (301-353)   330 (255-412) 365 (274-442) 312 (282-365) 
TG (+PL+TF) peak (nM) 42.1 (37.7-48.8) 39.3 (38.1-42.1) 37.5 (35.8-40.2)   44.4 (40.1-52.9) 45.4 (35.7-48.6) 38.0 (34.7-45.6) 
                
All data are represented as median (percentile 25 - percentile 75) 
** p<0.01 vs 'young clean' (Kruskal Wallis),  ¶ p<0.05 vs 'young clean', ¶¶ p<0.01 vs 'young clean' (Mann-Whitney)  
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Figure 2: Microscopic images of BALF cells and carbon load 
A-C: Microscopic image of cytospins of bronchoalveolar lavage fluid (BALF) cells from young mice 
placed in a cage in the clean environment (A), a filtered cage inside the roadside tunnel (B) and an 
unfiltered cage inside the tunnel (C). Carbon particles are obvious in macrophages for both tunnel 
groups. D: measurement of carbon load in alveolar macrophages from young (left) and old (right) 
mice, placed in a clean environment ('clean', white dots), in filtered cages inside the tunnel ('tunnel 
filtered', grey dots) or in unfiltered cages inside the tunnel ('tunnel exposed', black dots). Data are 
represented as a scatter dot plot with median values. Dotted line represents baseline median value 
(=value for the 'clean' group) for the young mice. * p<0.05, *** p<0.001. 
 
Lung histology 
No morphological differences were noted between groups on H&E stained lung 
sections (data not shown). Immunohistochemical staining for VWF was suggestive of 
higher expression, especially in the smaller pulmonary blood vessels for the 'tunnel 
exposed' [mean (SD) score for young mice: 2.2 (0.8), old mice: 1.8 (0.2)] and the 
'tunnel filtered' groups [mean (SD) score for young mice: 2.7 (0.3), old mice: 2.4 
(0.4)], as compared to the 'clean' group [mean (SD) score for young mice: 1.6 (0.7), 
old mice: 1.4 (0.2)] (Fig. 3). 
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Figure 3: immunohistochemical staining for VWF in lung tissue 
Representative images (left: low magnification, right: high magnification) of immunohistochemical 
staining for VWF in lung tissues from young mice placed in a clean environment ('clean'), in filtered 
cages inside the tunnel ('tunnel filtered') or in unfiltered cages inside the tunnel ('tunnel exposed'). 
While large blood vessels stained positive in all 3 groups, the majority of smaller blood vessels did not 
stain in the 'clean' group, but stained moderately to strongly positive in both tunnel groups. Arrows 
indicate alveolar macrophages. AW= large airways. 
 
Hematological parameters and IL-6 
Results for blood cell counts are shown in figure 4. Higher baseline values in old vs 
young mice were observed for WBC, RBC, hemoglobin and blood platelet levels. 
WBC concentrations were not affected by exposure to traffic-related air pollution.  In 
contrast, values for RBC and hemoglobin increased significantly for the 'tunnel 
filtered' and 'tunnel exposed group' as compared to the 'clean' group, both in young 
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and old mice. BP numbers also increased in all 'tunnel' groups, with a trend to even 
higher values in the 'tunnel exposed' group for the old mice. Concentrations of IL-6 in 
plasma were below the detection limit for all but 3 mice (in different groups). 
 
Figure 4: Blood cell parameters 
(A) White blood cells (WBC), (B) red blood cells (RBC), (C) hemoglobin (Hgb) and (D) blood 
platelets (BP) in blood from young (left) and old (right) mice, placed in a clean environment ('clean', 
white dots), in filtered cages inside the tunnel ('tunnel filtered', grey dots) or in unfiltered cages inside 
the tunnel ('tunnel exposed', black dots). Data are represented as a scatter dot plot with median values. 
Dotted line represents baseline median value (=value for the 'clean' group) for the young mice.* 
p<0.05, ** p<0.01, *** p<0.001. 
 
Markers of BP and endothelial activation 
Baseline values for sP-sel and VWF were higher in old vs young mice.  Exposure to 
traffic-related air pollution upregulated concentrations of sP-sel in young mice, with 
trends towards similar elevations in the concentrations of sE-sel and VWF. No 
differences were observed between 'tunnel filtered' and 'tunnel exposed' groups.  
Values in old mice were unaltered by air pollution exposure (Fig. 5). Both in young 
and old mice, levels of the specific endothelial marker sE-sel correlated with levels of 
sP-sel (p<0.0001, r2: 0.605 and p=0.0035, r2: 0.386 respectively) and of VWF 
(p=0.02, r2: 0.312 and p=0.05, r2: 0.200 respectively). 
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Figure 5: Markers of endothelial and blood platelet function 
(A) soluble P-selectin (sP-sel), (B) soluble E-selectin (sE-sel), (C) platelet factor 4 (PF4) and (D) von 
Willebrand factor antigen (VWFag) levels in plasma from young (left) and old (right) mice, placed in a 
clean environment ('clean', white dots), in filtered cages inside the tunnel ('tunnel filtered', grey dots) or 
in unfiltered cages inside the tunnel ('tunnel exposed', black dots). Data are represented as a scatter dot 
plot with median values. Dotted line represents baseline median value (=value for the 'clean' group) for 
the young mice.* p<0.05, ** p<0.01. 
 
Microvesicles 
Baseline values for all investigated microvesicle populations were similar between 
old and young mice. The majority of microvesicles bound annexin V, a measure for 
their surface exposure of procoagulant negatively charged phospholipids. In contrast 
to the young mice, a trend towards increased levels of BP-µV (total, AV- and AV+) 
was observed for the old mice in the tunnel, with the highest values for the 'exposed' 
group (Fig. 6). Total BP-µV numbers correlated with circulating BP numbers in 
young mice (p=0.01, r2: 0.279) and to a lesser extent in old mice (p=0.07, r2: 0.171).  
No correlations were found between RBC-µV and circulating RBC. 
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Figure 6: Microvesicle numbers 
(A) blood platetelet-derived microvesicles (BP-µV), (B) red blood cell-derived microvesicles (RBC-
µV), (C) BP-µV that do no bind annexin V (BP-µV AV-), (D) RBC-µV that do no bind annexin V 
(RBC-µV AV-), (E) BP-µV that bind annexin V (BP-µV AV+) and (F) RBC-µV that bind annexin V 
(RBC-µV AV+), measured by flow cytometry, in plasma from young (left) and old (right) mice, placed 
in a clean environment ('clean', white dots), in filtered cages inside the tunnel ('tunnel filtered', grey 
dots) or in unfiltered cages inside the tunnel ('tunnel exposed', black dots). Data are represented as a 
scatter dot plot with median values. Dotted line represents baseline median value (=value for the 'clean' 
group) for the young mice. 
 
Coagulation 
Baseline values were higher in old vs young mice for FVIII, but not for FVII or 
fibrinogen, or for any of the thrombin generation (TG) parameters. ETP in the 'tunnel 
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filtered' group was significantly higher than in the 'clean' group for young mice, when 
TG was measured upon addition of both phospholipids and TF. No air pollution-
induced changes were observed in any of the other coagulation parameters (table 1). 
 
Discussion 
Young and old mice were placed in an urban roadside tunnel where they were 
exposed to traffic-related air pollution for more than 3 weeks.  Mice were put in either 
unfiltered or filtered cages, and results were compared to those from mice placed in a 
clean environment outside the tunnel. Different hemostatic responses were observed 
in young and old mice.  
 
A striking and unexpected observations in this study was that subchronic air pollution 
exposure raised both RBC and BP numbers, over an interval as short as 25 days, both 
in young and old mice. In the absence of identical controls with low exposure to PM, 
and due to the lack of similar data in the literature, it is difficult to correctly interpret 
whether this finding is related to exposure to PM, raising oxidative stress in the lungs 
and bone marrow, resulting in enhanced hematopoiesis (24), to exposure to gaseous 
pollutants such as carbon monoxide or sulfur dioxide (25, 26) or to stress (e.g. caused 
by noise) inducing upregulation of growth factors (27, 28). Yet, a correlation between 
chronic air pollution exposure and BP numbers has recently also been shown in 
humans (22).  
 
Air pollution-induced increases in the concentrations of sP-sel, sE-sel and circulating 
VWF were only observed in young mice. While sE-sel is a specific marker for 
endothelial activation, sP-sel and VWF can be released by both activated endothelial 
cells and blood platelets. The strong correlation between these three markers in the 
present study suggests endothelial cell activation.  This interpretation is corroborated 
by the demonstration of higher VWF expression in pulmonary endothelium for the 
tunnel mice, by semi-quantitative immunohistochemical analysis of lung sections. An 
altered endothelial function has been demonstrated in humans exposed to diluted 
diesel exhaust (29, 30). Moreover, platelet-endothelial interactions in vivo can 
account for a series of events in which platelets are activated, upon exposure of E-sel, 
P-sel and VWF by activated endothelium (31). We showed before that P-sel is 
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implicated in arterial thrombogenicity upon intratracheal instillation of carbon 
nanotubes in mice (32). Subsequent secretion by activated plateletes will further raise 
sPsel and VWF in the plasma. The already elevated levels of sP-sel in old mice were 
not upregulated upon air pollution exposure.  However, a panel study of 60 elderly 
subjects with coronary artery disease demonstrated an association between sP-sel 
levels and the mean ambient 1 to 5-day concentrations of PM2.5, but not PM10 (33).  
 
A potential role for microvesicles in the induction of air pollution-induced 
prothrombotic changes has been suggested (34-36). Although not significant, we 
observed here a trend towards higher levels of total BP-µV for the old mice located 
inside the tunnel, with the highest median values for the 'exposed' group. As opposed 
to the findings for the BP activation markers, no changes were observed in 
microvesicle numbers in the young mice. Microvesicles can promote coagulation 
through the surface expression of TF and negatively charged phospholipids (20), and 
elevated numbers of circulating microvesicles have been demonstrated in patients 
with VTE (37). They accumulate on stimulated vascular surfaces that express P-
selectin to form a continuous supply of procoagulant factors on a growing thrombus 
(38). As the majority of BP-µV in the present study bound annexin V, a measure for 
the surface expression of negatively charged phospholipids, such as phosphatidyl 
serine, the air pollution-induced increase in their number reflects a procoagulant risk 
factor in the old mice, which was not observed in the young. 
 
All thrombin generation measurements were performed in the presence of an excess 
of exogenously added phospholipids. Therefore, these assays are insensitive to the 
phospholipid-dependent procoagulant state observed in the old mice exposed to air 
pollution. Moreover, in the absence of changes in any of the measured coagulation 
factors, no enhancement of the thrombin generation was observed under any 
condition, except for a small increase in ETP for the 'tunnel filtered' group of the 
young mice.  The increased ETP in this group could result from decreases in 
anticoagulant factors, such as antithrombin or protein C, markers that were not 
assessed in the present study. 
The paucity of changes in secondary hemostasis parameters is in agreement with 
previous findings of our group (19), and might be explained by the absence of an 
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inflammatory reaction. Mutlu et al. linked pronounced procoagulant changes upon 
PM exposure in mice to increased IL-6 production in alveolar macrophages (39, 40). 
In the present study, we did not observe increased IL-6 levels in either BALF or 
plasma. Kilinç et al. exposed mice via intratracheal instillation to ultra-fine particles 
that were collected near a roadside tunnel and observed a TF-driven increase in 
thrombin generation at 4 hours, and a contact activation-driven increase at 20 hours 
(41). Differences in administration route, exposure period and composition and dose 
of the particles could account for the discrepancy between these results and those of 
the present study. 
Overall, physiological outcome parameters for the 'tunnel filtered' group were 
unexpectedly close to those of the 'tunnel exposed' group. Several explanations may 
apply: first, filtering reduced the exposure of mice considerably, but not completely. 
Furthermore, PM2.5 was filtered less efficently (-32%) compared to PM10 (-59%). In 
view of the major impact of ultrafine particles on cardiovascular status (11), it is not 
surprising that the unfiltered and filtered groups responded similarly, but differently 
from the non-exposed groups. 
Second, we cannot exclude that differences observed between the 'clean' group and 
both 'tunnel' groups might, at least partially, result from other variables such as 
gaseous components in air pollution, noise, environmental conditions (lighting) and 
stress, each of which can have independent and potentially synergistic or antagonistic 
effects with each other and with PM. These variables were identical for both groups 
inside the tunnel. 
 
In summary, this study shows that subchronic inhalation of traffic-related polluted air 
does not trigger overt lung inflammation, but triggers platelet and endothelial cell 
activation, indicating a higher risk for arterial thrombosis. It also demonstrates that 
hemostatic changes upon exposure to traffic-related air pollution differ between 
young and old mice. Old mice, with higher baseline values of the corresponding 
activation markers, show a weaker proportional rise upon exposure. However, the 
high absolute concentrations of these markers reached in exposed old mice, in 
conjunction with upregulated blood platelet and blood platelet-derived microvesicle 
numbers are indicative of a higher overall thrombogenicity in old mice, 
subchronically exposed to traffic-polluted air. 
 
Chapter 4 
 
125 
Acknowledgements 
The authors would like to thank Peter De Leenheir, Guido Cole and Stefaan 
Hoornaert from the Department Mobility and Public Works of the Flemmish 
Government for practical assistance in the tunnel and for providing the tunnel transit 
data, respectively.  JE is holder of a grant from the Institute for the Promotion of 
Innovation through Science and Technology in Flanders (IWT-Vlaanderen, project 
81045). For part of this work, JE received the CSL Behring Heimburger Award in 
2011. J.A.J Vanoirbeek en V. De Vooght are post-doctoral fellows of the FWO 
Flanders. B. Nemery is holder of a FWO grant (G.0905.11). The CMVB is supported 
by the “Programmafinanciering KULeuven” (PF/10/014). 
 
Chapter 4 
 
126 
References 
1. Samoli E, Peng R, Ramsay T, Pipikou M, Touloumi G, Dominici F, et al. Acute effects of 
ambient particulate matter on mortality in Europe and North America: results from the APHENA 
study. Environ Health Perspect. 2008 Nov;116(11):1480-6. 
2. Samet JM, Rappold A, Graff D, Cascio WE, Berntsen JH, Huang YC, et al. Concentrated 
ambient ultrafine particle exposure induces cardiac changes in young healthy volunteers. Am J Respir 
Crit Care Med. 2009 Jun 1;179(11):1034-42. 
3. Pope CA, 3rd, Burnett RT, Thurston GD, Thun MJ, Calle EE, Krewski D, et al. 
Cardiovascular mortality and long-term exposure to particulate air pollution: epidemiological evidence 
of general pathophysiological pathways of disease. Circulation. 2004 Jan 6;109(1):71-7. 
4. Hoek G, Brunekreef B, Goldbohm S, Fischer P, van den Brandt PA. Association between 
mortality and indicators of traffic-related air pollution in the Netherlands: a cohort study. Lancet. 2002 
Oct 19;360(9341):1203-9. 
5. Katsouyanni K, Touloumi G, Samoli E, Gryparis A, Le Tertre A, Monopolis Y, et al. 
Confounding and effect modification in the short-term effects of ambient particles on total mortality: 
results from 29 European cities within the APHEA2 project. Epidemiology. 2001 Sep;12(5):521-31. 
6. Dominici F, McDermott A, Daniels M, Zeger SL, Samet JM. Mortality among residents of 90 
cities. In Revised Analyses of Time-Series Studies of Air Pollution and Health. Boston, MA: Health 
Effects Institute. 2003:9-24. 
7. Baccarelli A, Martinelli I, Zanobetti A, Grillo P, Hou LF, Bertazzi PA, et al. Exposure to 
particulate air pollution and risk of deep vein thrombosis. Arch Intern Med. 2008 May 12;168(9):920-
7. 
8. Peters A, Dockery DW, Muller JE, Mittleman MA. Increased particulate air pollution and the 
triggering of myocardial infarction. Circulation. 2001 Jun 12;103(23):2810-5. 
9. Hoffmann B, Moebus S, Mohlenkamp S, Stang A, Lehmann N, Dragano N, et al. Residential 
exposure to traffic is associated with coronary atherosclerosis. Circulation. 2007 Jul 31;116(5):489-96. 
10. Baccarelli A, Martinelli I, Pegoraro V, Melly S, Grillo P, Zanobetti A, et al. Living near major 
traffic roads and risk of deep vein thrombosis. Circulation. 2009 Jun 23;119(24):3118-24. 
11. Brook RD, Rajagopalan S, Pope CA, 3rd, Brook JR, Bhatnagar A, Diez-Roux AV, et al. 
Particulate matter air pollution and cardiovascular disease: An update to the scientific statement from 
the American Heart Association. Circulation. 2010 Jun 1;121(21):2331-78. 
12. Sacks JD, Stanek LW, Luben TJ, Johns DO, Buckley BJ, Brown JS, et al. Particulate matter-
induced health effects: who is susceptible? Environ Health Perspect. 2011 Apr;119(4):446-54. 
13. Goldberg MS, Burnett RT, Bailar JC, 3rd, Brook J, Bonvalot Y, Tamblyn R, et al. The 
association between daily mortality and ambient air particle pollution in Montreal, Quebec. 2. Cause-
specific mortality. Environ Res. 2001 May;86(1):26-36. 
14. Pope CA, 3rd, Renlund DG, Kfoury AG, May HT, Horne BD. Relation of heart failure 
hospitalization to exposure to fine particulate air pollution. Am J Cardiol. 2008 Nov 1;102(9):1230-4. 
15. Larrieu S, Jusot JF, Blanchard M, Prouvost H, Declercq C, Fabre P, et al. Short term effects of 
air pollution on hospitalizations for cardiovascular diseases in eight French cities: the PSAS program. 
Sci Total Environ. 2007 Nov 15;387(1-3):105-12. 
16. Anderson HR, Atkinson RW, Bremner SA, Marston L. Particulate air pollution and hospital 
admissions for cardiorespiratory diseases: are the elderly at greater risk? Eur Respir J Suppl. 2003 
May;40:39s-46s. 
17. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart 
disease. Lancet. 1999 Jan 9;353(9147):89-92. 
18. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. 
Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost. 2007 
Apr;5(4):692-9. 
19. Emmerechts J, Alfaro-Moreno E, Vanaudenaerde BM, Nemery B, Hoylaerts MF. Short-term 
exposure to particulate matter induces arterial but not venous thrombosis in healthy mice. J Thromb 
Haemost. 2010 Dec;8(12):2651-61. 
20. Morel O, Toti F, Hugel B, Bakouboula B, Camoin-Jau L, Dignat-George F, et al. 
Procoagulant microparticles: disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc 
Biol. 2006 Dec;26(12):2594-604. 
21. Kulkarni NS, Prudon B, Panditi SL, Abebe Y, Grigg J. Carbon loading of alveolar 
macrophages in adults and children exposed to biomass smoke particles. Sci Total Environ. 2005 Jun 
1;345(1-3):23-30. 
Chapter 4 
 
127 
22. Jacobs L, Emmerechts J, Mathieu C, Hoylaerts MF, Fierens F, Hoet PH, et al. Air pollution 
related prothrombotic changes in persons with diabetes. Environ Health Perspect. 2010 
Feb;118(2):191-6. 
23. Peters LL, Cheever EM, Ellis HR, Magnani PA, Svenson KL, Von Smith R, et al. Large-
scale, high-throughput screening for coagulation and hematologic phenotypes in mice. Physiol 
Genomics. 2002 Dec 3;11(3):185-93. 
24. Motohashi H, Kimura M, Fujita R, Inoue A, Pan X, Takayama M, et al. NF-E2 domination 
over Nrf2 promotes ROS accumulation and megakaryocytic maturation. Blood. 2010 Jan 
21;115(3):677-86. 
25. Baskurt OK, Levi E, Caglayan S, Dikmenoglu N, Kutman MN. Hematological and 
hemorheological effects of air pollution. Arch Environ Health. 1990 Jul-Aug;45(4):224-8. 
26. Chen KC, Lee EW, McGrath JJ. Effect of intermittent carbon monoxide inhalation on 
erythropoiesis and organ weights in rats. J Appl Toxicol. 1984 Jun;4(3):145-9. 
27. Goldberg ED, Dygai AM, Zakharova O, Shakhov VP. The modulating influence of 
enkephalins on the bone marrow haemopoiesis in stress. Folia Biol (Praha). 1990;36(6):319-31. 
28. Ratajczak MZ, Kuczynski WI, Onodera K, Moore J, Ratajczak J, Kregenow DA, et al. A 
reappraisal of the role of insulin-like growth factor I in the regulation of human hematopoiesis. J Clin 
Invest. 1994 Jul;94(1):320-7. 
29. Mills NL, Tornqvist H, Robinson SD, Gonzalez M, Darnley K, MacNee W, et al. Diesel 
exhaust inhalation causes vascular dysfunction and impaired endogenous fibrinolysis. Circulation. 
2005 Dec 20;112(25):3930-6. 
30. Tornqvist H, Mills NL, Gonzalez M, Miller MR, Robinson SD, Megson IL, et al. Persistent 
endothelial dysfunction in humans after diesel exhaust inhalation. Am J Respir Crit Care Med. 2007 
Aug 15;176(4):395-400. 
31. Theilmeier G, Michiels C, Spaepen E, Vreys I, Collen D, Vermylen J, et al. Endothelial von 
Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. 
Blood. 2002 Jun 15;99(12):4486-93. 
32. Nemmar A, Hoet PH, Vandervoort P, Dinsdale D, Nemery B, Hoylaerts MF. Enhanced 
peripheral thrombogenicity after lung inflammation is mediated by platelet-leukocyte activation: role 
of P-selectin. J Thromb Haemost. 2007 Jun;5(6):1217-26. 
33. Delfino RJ, Staimer N, Tjoa T, Gillen DL, Polidori A, Arhami M, et al. Air pollution 
exposures and circulating biomarkers of effect in a susceptible population: clues to potential causal 
component mixtures and mechanisms. Environ Health Perspect. 2009 Aug;117(8):1232-8. 
34. Brook RD. Air pollution: what is bad for the arteries might be bad for the veins. Arch Intern 
Med. 2008 May 12;168(9):909-11. 
35. Vermylen J, Hoylaerts MF. The procoagulant effects of air pollution. J Thromb Haemost. 
2007 Feb;5(2):250-1. 
36. Bonzini M, Tripodi A, Artoni A, Tarantini L, Marinelli B, Bertazzi PA, et al. Effects of 
inhalable particulate matter on blood coagulation. J Thromb Haemost. 2010 Apr;8(4):662-8. 
37. Chirinos JA, Heresi GA, Velasquez H, Jy W, Jimenez JJ, Ahn E, et al. Elevation of 
endothelial microparticles, platelets, and leukocyte activation in patients with venous 
thromboembolism. J Am Coll Cardiol. 2005 May 3;45(9):1467-71. 
38. Polgar J, Matuskova J, Wagner DD. The P-selectin, tissue factor, coagulation triad. J Thromb 
Haemost. 2005 Aug;3(8):1590-6. 
39. Mutlu GM, Green D, Bellmeyer A, Baker CM, Burgess Z, Rajamannan N, et al. Ambient 
particulate matter accelerates coagulation via an IL-6-dependent pathway. J Clin Invest. 2007 
Oct;117(10):2952-61. 
40. Budinger GR, McKell JL, Urich D, Foiles N, Weiss I, Chiarella SE, et al. Particulate matter-
induced lung inflammation increases systemic levels of PAI-1 and activates coagulation through 
distinct mechanisms. PLoS One. 2011;6(4):e18525. 
41. Kilinc E, Van Oerle R, Borissoff JI, Oschatz C, Gerlofs-Nijland ME, Janssen NA, et al. Factor 
XII activation is essential to sustain the procoagulant effects of particulate matter. J Thromb Haemost. 
2011 Jul;9(7):1359-67. 
 
 
  
 
 
 
 
GENERAL DISCUSSION 
 
 
 
Adapted from  
 
Emmerechts	   J,	   Jacobs	  L	  &	  Hoylaerts	  MF.	  Air	  pollution	  and	  cardiovascular	  disease.	  
In: Khallaf (ed). The impact of air pollution on health, economy, environment and 
agricultural sources. Rijeka: Croatia, InTech 2011; 69-92.   
 
and 
 
Emmerechts J & Hoylaerts MF. The effect of air pollution on hemostasis. 
Hamostaseologie 2011; 32, DOI: http://dx.doi.org/10.5482/ha-1179, epub ahead of 
print 
 
General discussion 129	  
Dealing with the conundrum of PM-associated DVT in the absence of changes in 
coagulatory changes 
Recent epidemiological evidence suggests an increased risk of venous thrombosis in 
association with exposure to air pollution (1-3). The underlying mechanisms, however 
remain largely unknown, and published results with regard to markers of secondary 
hemostasis activation are conflicting. In this thesis, we aimed to unravel how this 
conundrum of PM-associated DVT in the absence of a classical procoagulant 
phenotype can be explained. Four possible explanations can be advanced: 
 
1) Lack of association between air pollution exposure and DVT 
Initial epidemiological reports on the existence of an association between air pollution 
exposure and venous thrombosis were soon followed by a number of prospective 
cohort studies that failed to demonstrate an association: 26,450 post-menopausal 
women, enrolled in the Women's Health Initiative (WHI) Hormone Therapy trials, 
were randomized to treatment with either hormone therapy or placebo. Regardless of 
the treatment category, no evidence was found for an association between short-term 
or long-term (up to 1 year) PM exposure and VTE (4). Another prospective study in 
13,134 middle-aged persons, including men and women, also provided evidence 
against an association between VTE and long-term air pollution exposure, as assessed 
by residential distance to a major road (5). It needs to be emphasized, however, that 
both studies were not originally designed to examine air pollution.  
The aforementioned study of Baccarelli et al. also observed a lower PM-associated 
risk of VTE among women compared to men (1). Furthermore, what is most 
surprising from the results of Baccarelli et al. is not that air pollutants are associated 
with VTE, but the very large magnitude of the reported risk (odds ratio 1.7 per 10 
µg/m3 elevation in PM10). According to this estimate, high concentrations of air 
pollutants would increase the risk for VTE by an even greater magnitude than several 
of the major established risk factors, such as estrogens, cancer, hospitalization and 
heterozygous factor FV Leiden. Against this knowledge, the large effect size of the 
reported association appears somewhat questionable (6). 
However, taking into consideration that arterial and venous thrombosis share common 
risk factors (7), the well-established association of air pollution exposure with arterial 
thrombosis (8) enhances the plausibility of an association with venous thrombosis. 
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Our results in mice (chapter 1) showed that although acute exposure to PM promotes 
arterial thrombogenicity, it does not induce venous thrombosis and only marginally 
raises classical risk factors of venous thrombogenicity. Subchronic exposure for 25 
days to traffic pollution in a road tunnel (chapter 4) did not elevate the classical 
coagulation parameters either. 
 
2) Role of the exposure duration 
Another explanation for the lack of positive associations between PM exposure and 
classical parameters of coagulation might be found in the short duration of exposure 
investigated, varying from a few hours to a few days, in most experimental studies 
(see table 1 in the introduction). While short-term PM exposure unequivocally 
enhances blood platelet activation, a more chronically sustained exposure appears to 
be necessary to induce significant changes in the coagulation cascade.  
This hypothesis is corroborated by epidemiological findings in which the risk for 
DVT was only associated with the mean PM concentration over a one year period, 
and not with any shorter time-point (1). This interpretation is compatible with our first 
animal study in which exposure of healthy mice to a single intratracheal instillation of 
DEP or UPM enhanced arterial, but not venous thrombosis (chapter 1). Indeed, 
although some studies suggest a short-term effect by directly translocated UFP 
through the activation of the coagulation cascade via contact activation (9, 10), 
evidence seems to favor a more prominent role for inflammatory changes upon 
chronic PM exposure. In this context, it is of interest that the only coagulation factor 
for which the associations with air pollution are consistent over different studies in 
humans is fibrinogen (see table 1 in the introduction), an acute phase protein 
upregulated during inflammatory processes. 
Accordingly, no proinflammatory or consistent procoagulant associations with 
'current PM' were found in our epidemiological study in patients with diabetes 
(chapter 2), but subacute and subchronic PM exposure was associated with hsCRP 
and procoagulant changes in thrombin generation assays, and chronic PM exposure 
with elevated numbers of procoagulant microvesicles. Increased microvesicle 
numbers were also found by exposing mice subchronically to traffic-related air 
pollution, in parallel with raised markers of arterial thrombogenicity (chapter 4). 
However, whether these specific procoagulant changes, found upon long-term PM 
exposure, measured in ex vivo coagulation assays, also confer a prothrombotic risk for 
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DVT in vivo was not investigated in the present thesis; this remains to be 
demonstrated in studies of venous thrombogenicity in mice exposed to PM  for even 
more prolonged periods. 
 
3) Role of microvesicles 
Coagulation factors other than fibrinogen are only marginally associated with air 
pollution exposure (see table 1 in the introduction). We only measured increased 
levels of FVII and FVIII upon intratracheal instillation of unphysiologically high 
concentrations (100 and 200 µg/mouse) of UPM or DEP (chapter 1), and even then, 
increases were mild. Hence, at 25 µg/mouse, a dose representative for the daily 
human exposure under very polluted conditions (11), no changes were observed in 
any of the measured coagulation parameters. In fact, the absence of changes in 
'classical' coagulation parameters (coagulation factors, aPTT, PT, D-dimers) is a 
consistent finding throughout this thesis, in both humans (chapter 2) and animals 
(chapter 1 and 4), irrespective of the exposure period.  
Even under rather extreme conditions such as exposure of mice to traffic-related air 
pollution inside a roadside tunnel for more than 3 weeks (chapter 4), inhaled PM 
doses were insufficient to induce coagulatory changes: assuming a pulmonary minute 
ventilation of 40 mL/min for a mouse at rest, the total volume of inhaled air over the 
25-day study period would have been 1440 L. Taking into account a mean 
concentration for PM10 of 94 µg/m3 (see chapter 4), exposed mice inhaled about 135 
µg of PM10 over the whole study period, of which about 70 µg reached the alveoli, 
assuming 50% alveolar deposition. 
Taken together, these findings indicate that exposure-induced changes in coagulation 
factors, if any, are unlikely to be solely or primarily responsible for the PM-induced 
increased risk of DVT. 
 
Through the expression of procoagulant proteins and lipids on their surface, 
microvesicles could represent an alternative risk factor for venous thrombosis. The 
role of microvesicles in inflammation and coagulation is depicted in figure 1. This 
figure illustrates the central role of the interaction between P-selectin and PSGL-1 in 
the delivery of monocyte-derived microvesicles, carrying membrane-bound TF. In 
addition, these microvesicles, as well as microvesicles derived from blood platelets, 
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red blood cells and endothelial cells, expose a procoagulant phospholipid surface to 
which coagulation factors can bind (12). Elevated numbers of circulating 
microvesicles have been demonstrated in patients with VTE (13, 14). In a recently 
published case-control study comprising 186 VTE patients and 418 healthy controls, 
individuals with microvesicle concentrations above the 90th percentile of the controls' 
distribution had a 5-fold increased riskof having had a previous VTE, as compared to 
those with microvesicle concentrations below the 10th percentile (14). 
 
 
Figure 1. Role of microvesicles in coagulation. 
(A) After vessel wall injury, limited to a few cells or stimulation of endothelial cells (left), 
subendothelial TF or TF expressed on endothelial cells initiates clotting. Platelets adhering to the site 
of injury with deposited fibrin promptly seal vessel wall TF from the blood stream. TF activity required 
for thrombus growth and stabilization is provided from blood-borne TF (orange). When large-scale 
damage to the vessel wall occurs (right), a significant amount of subendothelial TF enters the blood 
stream, lessening the importance of blood-borne TF. (B) P-selectin (P) on activated platelets and 
endothelial cells and P-selectin shed from these cells (sP) binds to P-selectin glycoprotein ligand 1 
(PSGL-1, V) on monocytes and this induces TF-positive microvesicle generation. P-selectin on 
activated platelets in thrombi helps the recruitment of these microvesicles to the growing thrombus. 
This ultimately leads to increased thrombin generation at the site of injury (from (15) with permission). 
 
A role for microvesicles in the induction of an exposure-associated procoagulant 
phenotype has been suggested by Bonzini et al., who investigated blood samples 
collected in steel-production plant workers. Besides shortening the PT, elevated PM 
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exposure also enhanced thrombin generation, but only when measured in an assay 
without the exogenous addition of a coagulation trigger or negatively charged 
phospholipids (16). These findings suggest that PM exposure may induce, as part of a 
systemic inflammatory response, the release of small amounts of endogenous TF (by 
circulating monocytes) and/or negatively charged phospholipids that may function as 
triggers of thrombin generation in the assay system. Circulating microvesicles might 
well be the source of these triggers. This hypothesis is corroborated by animal studies 
demonstrating elevated numbers of procoagulant microvesicles, 24 hours after 
intratracheal instillation of carbon nanotubes in mice (17). Likewise, when stimulated 
ex vivo, blood platelets from mice exposed to concentrated ambient PM for 2 weeks 
released more microvesicles relative to platelets from ambient air-exposed control 
animals (18). 
 
Our epidemiological study in patients with diabetes (chapter 2) is the first to directly 
demonstrate upregulation of the number of microvesicles with prolonged air pollution 
exposure in humans. In agreement with the results of Bonzini et al. (16), enhanced 
thrombin generation without addition of an exogenous trigger was associated with 
higher subacute and subchronic levels of PM10. Exposure at longer time windows, up 
to 1 year, elevated the numbers of microvesicles expressing procoagulant lipids.  
We confirmed these findings in our last animal study, by demonstrating higher 
concentrations of procoagulant blood platelet-derived microvesicles in old mice 
subchronically exposed to traffic-related air pollution (chapter 4). 
 
We did not investigate the exact mechanism by which contact with polluted air 
induces microvesicle production.  However, based on our findings and those of 
others, we can make the following assumptions: (subclinical) pulmonary 
inflammation (chapter 1) and oxidative stress (19, 20) induced by inhaled PM, and 
possibly other constituants of air pollution, activate the pulmonary endothelium via 
cytokine-mediated cellular cross-talk (21). The large pulmonary endothelial bed 
expresses P-selectin and E-selectin on its surface, and sheds both proteins into the 
circulation (chapter 4). Through the expression of these and other adhesion molecules, 
such as ICAM-1 and VCAM-1 (chapter 1), WBC are recruited to the pulmonary 
vessel wall, are activated and migrate into the lung (chapter 1). P-selectin and VWF 
expression also support platelet rolling and adhesion to the lung, followed by platelet 
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sensitization (22, 23). Cross-talk between WBC and blood platelets favours further 
mutual activation, as evidenced by experimental studies in mice, exposed to carbon 
nanotubes via intratracheal instillation (17). Externalization of phosphatidylserine 
upon cell activation modifies the neutral membrane charge with loss of phospholipid 
assymetry, leading to a cascade of events which disrupt the interactions between 
membrane and cytoskeleton proteins, eventually resulting in the release of 
procoagulant microvesicles in the circulation (chapter 2 and 4). In this regard, it is 
striking that the association of subacute and subchronic (up to 1 month) PM exposure 
with the release of TF-bearing microvesicles, most likely fom monocytic origin (24), 
coincides with proinflammatory changes, evidenced by increased levels of CRP and 
fibrinogen (chapter 2).  
More chronic exposure then further elevates microvesicles expressing procoagulant 
lipids from other sources (chapter 2), via not yet well-understood processes.  Indeed, 
the upregulation of annexin V-binding microvesicles, associated with chronic air 
pollution up to 1 year, occured in the absence of increased levels of WBC, fibrinogen 
or CRP (chapter 2). Whether this upregulation results from direct contact with 
translocated particles, from oxidative stress, from direct cell-cell interactions or from 
other pathophysiological mechanisms remains to be investigated. 
 
It needs to be emphasized that not all 'blood platelet-derived microvesicles' are really 
derived from blood platelets.  In fact, throughout this thesis, we have defined 'blood 
platelet-derived microvesicles' as the microvesicles that are positive for the surface 
marker CD42a in the case of human microvesicles or CD41/61 in the case of murine 
microvesicles. However, in view of the large number of CD42a positive (chapter 3) or 
CD41/61 positive (chapter 4) microvesicles in healthy young individuals, it is 
unlikely that these are all derived from activated blood platelets. An alternative 
posibility is that microvesicles expressing platelet-specific markers are continuously 
derived from megakaryocytes, the precursor cells of platelets. According to this 
hypothesis, CD41+ or CD42+ microparticles consist of two populations, those 
derived from platelets following activation (by agonists, shear stress, storage or by 
exposure to complement proteins) or apoptosis, and those derived from 
megakaryocytes (25). The dynamic nature of megakaryocyte-derived microparticle 
formation was demonstrated by live cell microscopy (26). Inhibition of actin 
polymerization and stimulation of actin depolymerization augmented microvesicle 
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production and blebbing from megakaryocytes (26), confirming that cytoskeleton-
based forces are involved in the process. 
Studies that distinguish platelet-derived and megakaryocyte-derived microvesicles, 
based on the measurement of surface P-selectin (CD62P) expression (which is only 
positive on platelet-derived microvesicles), demonstrate that most (about 95%) 
CD41+ microvesicles in plasma are CD62P-, indicating a megakaryocytic origin (26, 
27). Interestingly, these studies also demonstrated that only the CD62P+ population 
correlated with a history of myocardial infarction or peripheral vascular disease (27), 
while total CD41+ microvesicle numbers were not higher compared to healthy 
controls. We did not assess microvesiclular CD62P expression in the present studies. 
It is, therefore, difficult to conclude whether the air pollution-associated increase in 
platelet-derived microvesicles in mice (chapter 4) reflects enhanced blood platelet 
activation or results from an upregulated megakaryopoiesis. While the elevated sP-sel 
levels found in the tunnel exposed mice could comprise a microvesicular-derived 
component and therefore plead in favour of a platelet origin of CD41/CD61+ 
microvesicles, the strongly upregulated thrombopoiesis pleads in favour of a 
megakaryocytic origin (chapter 4). 
 
Figure 2: Biological pathways linking PM exposure and venous thrombosis 
BP: blood platelet, F: factor, fbg: fibrinogen, PM: particulate matter, TF: tissue factor, UFP: ultra-fine 
particles, WBC: white blood cell 
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It is unclear how RBC are stimulated to release annexin V-binding microvesicles 
during these processes, but oxidative stress and shear stress, possibly induced by 
blood platelets bound to activated endothelial cells in the pulmonary 
microvasculature, have been suggested (28). A hypercoagulable state associated with 
enhanced RBC-derived microvesicles has been observed in a variety of diseases, such 
as sickle cell anemia (29), paroxysmal nocturnal haemoglobinuria (30) and 
transfusion complications (31). Therefore, the association between chronic (up to 1 
year) air pollution exposure and RBC-derived microvesicles (chapter 2) might be of 
relevance to explain the link between mean annual levels of PM exposure and DVT 
(1). Of note, these exposure-related increased levels of RBC-derived microvesicles 
occurred independently of inflammatory changes (chapter 2). 
Figure 2 summarizes the different pathophysiological pathways linking PM exposure 
to venous thrombogenicity. 
 
4) Role of the anticoagulant pathways 
If the induction of a venous prothrombotic phenotype upon air pollution exposure 
does not result from an upregulation of coagulation factors, it could also result from a 
downregulation of anticoagulatory factors such as antithrombin (AT), protein C (PC) 
or protein S (PS). Indeed, during inflammation, levels of anticoagulant factors 
decrease as the result of consumption (by ongoing thrombin generation), impaired 
synthesis (as a result of a negative acute phase response), degradation by elastase 
from activated neutrophils and endothelial dysfunction (32).  
We cannot exclude that the increased thrombin generation associated with subacute 
and subchronic PM exposure in patients with diabetes (chapter 2) does not, at least 
partially, result from decreased levels of AT or activated PC (APC), because these 
factors were not measured in the present study. However, in a preceding pilot study 
conducted in 80 patients with diabetes, we did not observe any association between 
PM exposure and the circulating levels of AT or PC (data not shown). Likewise, 
intratracheal PM instillation in mice did not influence pulmonary thrombomodulin 
mRNA expression and even increased hepatic PC mRNA expression (chapter 1). The 
few other studies that investigated the anticoagulant pathways in humans as a function 
of air pollution exposure (see table 1 in the introduction) also failed to demonstrate 
any changes. However, the absence of changes in the circulating levels of 
anticoagulant proteins does not exclude more localized procoagulant changes at the 
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endothelial surface, such as altered expression of thrombomodulin or the endothelial 
protein C receptor (EPCR). Future studies should focus on the role of the endothelium 
and its anti/procoagulant status, in the lung and in the peripheral vasculature, in areas 
prone to development of DVT. 
 
The elderly as a susceptible population 
Elderly persons (>65 years of age) are believed to be more susceptible to deleterious 
cardiovascular effects of air pollution than younger persons (33). The excess in daily 
mortality per increment in ambient PM concentration is higher in the elderly than in 
the young (34-36). Hospitalization for heart failure was significantly associated with 
previous 14-day PM2.5, and this effect was stronger in elderly (37). Also PM10 was 
most strongly associated with daily hospitalization for cardiovascular disease in 
persons >65 years old (38).  
 
Why the elderly are more at risk than young persons is still not fully understood, but it 
is important to consider the concept of ‘attributable risk’. 
The 'attributable risk' represents an estimate that depends both on the strength of the 
association between risk factor and disease and its prevalence, and is therefore 
defined by both baseline risk and relative risk. 
The elderly have a greater baseline risk for developing VTE than young people: while 
the risk for deep vein thrombosis (DVT) is about 1/10,000 at the age of 40, it raises up 
to 1/100 at the age of 80 (39, 40) (Fig. 3).  
 
The higher risk for VTE with ageing results from an increased prevalence of 
conventional risk factors, development of new, age-specific risk factors and 
accumulation of risk factors with age, such as immobility, malignancy, co-morbidity, 
hormone replacement therapy, endothelial dysfunction  and a hypercoagulable state in 
the plasma (42). Elevation of the plasma levels of fibrinogen, homocystein, D-dimers, 
coagulation factors VII (FVII), FVIII and FIX and of plasminogen activator inhibitor 
1 (PAI-1), have been advocated (42-45). 
 
We confirmed these findings by demonstrating higher baseline values for FVIII, 
fibrinogen, VWF and TF antigen, and enhanced thrombin generation and a shortened 
aPTT in healthy elderly persons (chapter 3). Likewise, baseline levels of FVIII and 
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VWF antigen were higher in old than in young mice (chapter 4). In contrast, neither in 
healthy persons (chapter 3) nor in healthy mice (chapter 4) did we observe age-related 
differences in microvesicle numbers or their procoagulant potential. 
 
 
 
Figure 3. Annual incidence of VTE among participants of the Worcester DVT study, by age and 
sex (from (41) with permission). 
 
 
We assessed the relative risk related to air pollution exposure in young and old mice 
(chapter 4). Exposure upregulated sP-sel and VWF levels in young, but not in old 
mice.  However, the increased values for these markers in young mice did not exceed 
the already higher baseline values in old mice. 
While baseline values for microvesicle numbers were equal between young and old, 
only old mice demonstrated an exposure-related relative increase in the number of 
procoagulant blood platelet-derived mcirovesicles. 
Taken together, these results indicate a higher attributable risk in elderly, both 
because of a higher baseline risk (coagulation factors, blood platelet and endothelial 
markers) and a higher relative risk (microvesicles). Whether these procoagulant 
changes also confer an enhanced prothrombotic risk for DVT remains to be elucidated 
in experimental studies, investigating venous thrombogenicity after subchronic and 
chronic PM exposure in young vs old mice. 
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General conclusion 
A large array of epidemiological and experimental studies have provided persuasive 
evidence that air pollutants, the PM fraction in particular, contribute to cardiovascular 
morbidity and mortality. By virtue of the heterogeneity both in study design and the 
composition of the PM considered in these studies, it is not surprising that all findings 
are not totally consistent. Although evidence linking PM exposure with venous 
thromboembolic events is less established than for arterial events and warrants further 
investigation, our findings suggest that chronic air pollution exposure induces 
selective procoagulant changes that could elevate the risk for venous thrombosis. 
Inflammatory changes, along with the generation of circulating procoagulant 
microvesicles, seem to be more important than coagulation factor upregulation. 
Both higher baseline values and pollution-associated upregulation of selected 
hemostasis parameters are pathophysiological mechanisms that may explain the 
epidemiological finding of an enhanced susceptibility to air pollution in the elderly.  
Air pollution exposure may not be the highest risk factor for arterial or venous 
thrombosis on an individual level. However, because of the large number of persons 
exposed, on a global scale it is a major, and more importantly, a modifiable risk factor 
for cardiovascular disease and mortality. 
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Ambient environmental air pollutants include gaseous (carbon monoxide, nitrogen 
oxides, sulfur dioxide, ozone) and particulate components. Numerous epidemiological 
studies report consistent associations between exposure to air pollution, mainly the 
particulate component called 'particulate matter' (PM), and cardiovascular morbidity 
and mortality. Until recently, most epidemiological and experimental research has 
been directed towards the association between both short-term and long-term 
exposure to air pollution and arterial cardiovascular effects, such as myocardial 
infarction and atherosclerosis. Arterial and venous thrombosis share common risk 
factors. Therefore, it is not surprising that more recently, a link between chronic 
exposure to air pollution and venous thrombosis was reported. 
 
In contrast to the well-accepted and documented deleterious effects of air pollution 
exposure on arterial events, data on venous events are scarce. Moreover, the 
mechanisms underlying the increased venous thrombogenicity remain largely 
unknown, and published results with regard to markers of secondary hemostasis 
activation are conflicting. In fact, disappointingly few studies found coagulatory 
changes that could constitute the basis for the observed link between air pollution and 
deep vein thrombosis (DVT). 
In other words, the scientific community faced a conundrum of an air pollution-
associated risk of venous thrombosis in the absence of well-documented changes in 
secondary hemostasis parameters. This formed the basis for the present thesis. 
 
In chapter 1, we report findings of a study in mice, exposed to either urban PM 
(UPM) or diesel exhaust particles (DEP) via intratracheal instillation. Despite major 
pulmonary inflammation, which was more pronounced for UPM than for DEP, 
systemic inflammation was limited to increased serum IL-6 levels, 4 hours after 
UPM. At high concentrations, both types of PM induced similar but modest increases 
in FVII, FVIII and fibrinogen. Three repeated instillations did not substantially 
enhance the proinflammatory and procoagulant status. A single instillation of UPM 
enhanced experimental arterial thrombogenicity, but neither UPM nor DEP 
significantly enhanced venous thrombosis. Thus, a more chronic exposure seems 
required to increase venous thrombogenicity. 
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The determining role of varying time frames of exposure was assessed in chapter 2. 
We investigated potential associations between PM exposure, coagulation and 
inflammation parameters, including circulating microvesicles, in a study of 233 
patients with diabetes.  
Subacute and subchronic exposure to PM, estimated at the patients' residential 
addresses, was associated with elevated C-reactive protein (CRP), leukocytes and 
fibrinogen, as well as with tissue factor-dependent procoagulant changes in thrombin 
generation assays. When longer windows of past exposure were considered, up to 1 
year preceding blood sampling, procoagulant changes were evident from the strongly 
increased numbers of red blood cell-derived circulating microvesicles and annexin V-
binding microvesicles, but they were no longer associated with tissue factor or with 
inflammatory parameters. PM exposure was never associated with procoagulant 
changes in aPTT, PT, FVII, FVIII, FXII or D-dimers. Residential distance to a major 
road was only marginally correlated with increased FVIII and thrombin generation. 
We conclude from these findings that increases in the number of microvesicles and in 
their procoagulant properties, rather than increases in coagulation factors per se, may 
contribute to the risk of pollution-associated VTE. 
 
The role of microvesicles in the induction of a procoagulant phenotype, related to air 
pollution exposure, was further assessed in chapter 4. Subchronic (25 days) exposure 
to traffic-related air pollution in a roadside tunnel led to upregulated markers of 
endothelial and blood platelet activation (soluble P-selectin, von Willebrand factor) in 
young, but not in old mice. However, the increased values for these markers in young 
mice did not exceed the already higher baseline values in old mice. Moreover, while 
baseline values for microvesicle numbers were equal between young and old, only old 
mice demonstrated an exposure-related relative increase in the number of 
procoagulant blood platelet-derived microvesicles. 
Higher baseline values for FVIII, fibrinogen, von Willebrand factor and tissue factor 
antigen, but not microvesicles, were also found in healthy elderly humans, as 
compared to young (chapter 3). 
Taken together, these results indicate a higher attributable risk in elderly, both 
because of a higher baseline risk (coagulation factors, blood platelet and endothelial 
markers) and a higher relative risk (microvesicles), that could help to explain why 
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elderly are more susceptible to the deleterious cardiovascular health effects of air 
pollution, as observed in epidemiological studies.  
 
Although evidence linking PM exposure with venous thromboembolic events is less 
well established than with arterial events and warrants further investigation, our 
findings suggest that (sub)chronic air pollution exposure induces selective 
procoagulant changes that could contribute to a higher risk for venous thrombosis. 
Inflammatory changes, along with the generation of circulating procoagulant 
microvesicles, seem to be more important than coagulation factor upregulation. 
Both higher baseline values and pollution-associated upregulation of selected 
hemostasis parameters are pathophysiological mechanisms that may underly the 
epidemiological finding of an enhanced  
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Luchtvervuiling bestaat uit een complex mengsel van gassen (carbon monoxide, 
stikstof oxiden, zwavel dioxide, ozon) en vaste deeltjes. Talrijke epidemiologische 
studies toonden op consistente wijze associaties aan tussen luchtvervuiling en 
cardiovasculaire morbiditeit en mortaliteit.  Vooral de vaste deeltjes (het 'fijn stof', in 
het engels: 'particulate matter', PM) blijken een belangrijke impact op de menselijke 
gezondheid te hebben. De focus van de vroegere epidemiologische en experimentele 
studies lag op het verband tussen zowel korte termijn als lange termijn blootstelling 
aan fijn stof en arteriële aandoeningen, zoals acuut myocardinfarct en atherosclerose. 
Aangezien arteriële en veneuze trombose gemeenschappelijke risicofactoren delen, is 
het niet verwonderlijk dat recent een associatie tussen chronische blootstelling aan 
fijn stof en veneuze trombose werd aangetoond. 
  
In tegenstelling tot de algemeen aanvaarde en goed gedocumenteerde nadelige 
effecten van blootstelling aan luchtvervuiling op arteriële aandoeningen, zijn data 
over het verband met veneuze aandoeningen veel zeldzamer.  Bovendien is weinig 
geweten over de onderliggende pathofysiologische mechanismen, en spreken de 
studies die merkers van secundaire hemostaseactivatie onderzochten elkaar tegen. Het 
is in dit kader opmerkelijk hoe weinig studies procoagulante veranderingen konden 
aantonen die een basis zouden kunnen vormen voor de link tussen luchtvervuiling en 
diepe veneuze trombose (DVT). 
 
Het uitgangspunt van deze thesis werd gevormd uit de schijnbare tegenstelling tussen 
een door blootstelling aan fijn stof verhoogd veneus tromboserisico enerzijds, en de 
afwezigheid van duidelijke veranderingen in parameters van secundaire hemostase 
anderzijds.  
 
In hoofdstuk 1 worden de resultaten weergegeven van een studie waarbij muizen via 
intratracheale instillatie werden blootgesteld aan stedelijk stof (urban PM, UPM) of 
aan dieseluitlaatdeeltjes (diesel exhaust particles, DEP). Ondanks duidelijke 
longinflammatie, die meer uitgesproken was voor UPM dan voor DEP, bleef de 
systemische inflammatie beperkt tot een stijging in de serumconcentraties van IL-6, 4 
uur na UPM. Aan hoge concentraties induceerden beide types van PM gelijkaardige 
maar milde stijgingen in FVII, FVIII en fibrinogeen.  Drie repetitieve instillaties 
leidden niet tot een verdere opregulatie van de inflammatoire of de procoagulante 
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status, of slechts in beperkte mate.  Hoewel de experimenteel geïnduceerde arteriële 
tromboseneiging werd verhoogd door een éénmalige blootstelling aan UPM, 
verhoogden noch UPM, noch DEP de veneuze stollingsneiging. Een meer chronische 
blootstelling lijkt dus vereist om een veneuze stollingsneiging te bevorderen. 
 
De cruciale rol van verschillende tijdsvensters van blootstelling werd uitgewerkt in 
hoofdstuk 2. Mogelijke associaties tussen blootstelling aan fijn stof enerzijds, en 
stollings- en inflammatieparameters, waaronder ook circulerende microvesikels, 
anderzijds, werden onderzocht in een groep van 233 diabetespatiënten. 
Subacute en subchronische blootstelling aan fijn stof, gemeten op het residentiële 
adres van alle patiënten, bleek geassociëerd met stijgingen in de concentraties van C-
reactief proteïne (CRP), circulerende witte bloedcellen en fibrinogeen, en met 
weefselfactorafhankelijke procoagulante veranderingen in trombinegeneratie assays. 
Wanneer langere tijdsvensters, tot 1 jaar, in beschouwing werden genomen, konden 
procoagulante veranderingen waargenomen worden onder vorm van sterke stijgingen 
in de concentraties van circulerende rode bloedcelafgeleide en annexine V-bindende 
microvesikels. Op dit tijdspunt konden associaties met weefselfactor of met 
inflammatoire parameters echter niet langer aangetoond worden.  Blootstelling aan 
fijn stof was op geen enkel tijdspunt geasscociëerd met procoagulante veranderingen 
in aPTT, PT, FVII, FVIII, FXII of D-dimeren. De afstand tussen het residentiële adres 
en de meest nabije grote weg correleerde slechts matig met gestegen FVIII of 
trombinegeneratie.  Op basis van deze resultaten kan besloten worden dat stijgingen 
in het aantal en de procoagulante eigenschappen van microvesikels, eerder dan 
stijgingen in stollingsfactoren, kunnen bijdragen aan het veneuze tromboserisico, 
geassociëerd met subacute tot chronische blootstelling aan luchtvervuiling. 
 
In hoofdstuk 4 werd de rol die microvesikels spelen in het induceren van een 
procoagulant fenotype ten gevolge van blootstelling aan luchtvervuiling verder 
onderzocht. Subchronische (25 dagen) blootstelling aan vervuilde lucht in een 
verkeerstunnel leidde tot stijgingen van merkers van endotheliale en 
bloedplaatsjesactivatie (plasma P-selectine, von Willebrand factor) in jonge, maar niet 
in oude muizen. De waarden voor deze merkers in jonge muizen stegen echter niet uit 
boven de reeds verhoogde basiswaarden in de oude muizen. Bovendien werden na 
blootstelling enkel voor de oude muizen hogere waarden gemeten voor 
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bloedplaatjesafgeleide procoagulante microvesikels, ondanks gelijke basiswaarden 
voor jong en oud. 
In vergelijking met jonge gezonde vrijwilligers, werden bij gezonde ouderen ook 
hogere basiswaarden gemeten voor FVIII, fibrinogeen, von Willebrand factor, 
weefselfactor antigen, maar niet voor microvesikels (hoofdstuk 3). 
Deze resultaten wijzen op een verhoging van het absoluut risico in ouderen, te wijten 
aan zowel een verhoogd basisrisico (stollingsfactoren, bloedplaatjes- en endotheliale 
merkers) als een verhoogd relatief risico (microvesikels). Dit kan helpen verklaren 
waarom ouderen volgens epidemiologische studies gevoeliger zijn aan de nadelige 
cardiovasculaire gezondheidseffecten van blootstelling aan luchtvervuiling. 
 
Hoewel het verband tussen blootstelling aan fijn stof en veneuze trombose minder 
goed gedocumenteerd is dan de link met arteriële trombose, suggereren onze 
resultaten dat (sub)chronische blootstelling aan luchtvervuiling selectieve 
procoagulante veranderingen induceert die de basis kunnen vormen voor het 
verhoogde veneuze tromboserisico. Inflammatoire veranderingen en procoagulante 
microvesikels blijken een belangrijker rol te spelen dan stijgingen in stollingsfactoren. 
Zowel hogere basiswaarden als blootstellingsgerelateerde stijgingen in geselecteerde 
hemostaseparameters kunnen helpen verklaren waarom ouderen gevoeliger zijn aan 
luchtvervuiling.  
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